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Summary
Despite the advent of antimicrobials, tuberculosis (TB) caused the greatest amounts of deaths due
to an infectious disease in 2018, accounting for 1.2 million deaths alone and an additional 0.3 mil-
lion deaths due to TB-HIV co-infections. Current TB treatment regimens may impose substantial
economic and logistical burdens for patients and health care systems, as even treatment against drug-
susceptible strains ofMycobacterium tuberculosis (Mtb), the aetological agent of TB, requires daily
doses of antimicrobials for 6 to 9 months. Further complications arise when patients are infected with
multidrug-resistant strains ofMtb, which increases treatment duration to 9 to 24 months. Treatment
success rates are also reduced from approximately 85% for drug-susceptible cases down to almost 50%
formultidrug-resistant cases of TB. Therefore, substantial efforts by the medical and research commu-
nities are currently underway to develop new treatment regimens that are both more efficacious and
can reduce treatment duration against both drug-susceptible and multidrug-resistant strains ofMtb.
Fluoroquinolones (FQs) form a vital component in established and experimental TB treatment
regimens. Older generations of FQs have been used to treat multidrug-resistant forms of TB, while
newer andmore potent FQs are being tested in experimental regimens that aim to reduceTB treatment
duration. Extensive biochemical work has shown that FQs targetDNA gyrase, the sole type II topoiso-
merase inMtb. Molecular epidemiological studies demonstrate that clinically-relevant FQ-resistance
(FQ-R) mutations are restricted to a limited set of chromosomal mutations in the genes encoding
DNA gyrase: gyrA and gyrB. However, little work has been done on exploring the evolution of FQ-R
in populations ofMtb. Investigating how differentMtb populations evolve under FQs pressure, and
how FQ-Rmutations affect the continued evolution ofMtb populations, may aid in maintaining the
potency and potential use of FQs.
Treatment regimens for TB generally use standardized, empirical dosing, including when using
FQs. Previous work has shown that differentMtb genetic variants can associate with different frequen-
cies of drug-resistance (DR), even when using standardized treatment regimen. Bacterial genetics have
also been shown to modulate the phenotypes that DR mutations confer. Whether the genetic varia-
tion present in natural populations ofMtb would also modulate the frequency of FQ-R emergence,
or the phenotypes that FQ-Rmutations confer, is currently not known. It is also unclear how FQ-R
mutations themselves affect the continued evolution ofMtb populations.
In this Thesis, we explored how FQ-R evolves inMtb. Specifically, we used extensive in vitro ex-
periments coupled with analysis of publicly availableMtb genomic sequences isolated from clinical
strains to test whether the genetic variation inMtbmodulated the frequency and phenotypes of FQ-R
mutations.We then used amathematical modeling framework and in silico simulations to test the rela-
tive contributions of bacterial factors hypothesized to be relevant in DR evolution in determining the
frequency of FQ-R. Lastly, we used further in vitro assays andMtb genomic sequences from clinical
vii
strains to test the impact of FQ-Rmutations on the continued evolution ofMtb populations.
This Thesis consists of 6 main chapters. The first chapter provides a general introduction into TB
and the rationale for this Thesis, while the second chapter states the main Aims andObjectives. Three
chapters then present the results of our researchwork, with one chapter dedicated per statedObjective.
The last chapter provides a synopsis of ourmain findings, states general limitations, highlights the con-
tribution of this Thesis to theMtb and antimicrobial resistance research communities, and highlights
potential future directions that can build upon this Thesis work.
In Chapter 1, we introduce the global burden of TB and treatment regimens for TB. We then
highlight theproblemof antimicrobial resistance,and thepotential use ofmorepotentFQs in reducing
TB treatment times. Lastly, we introduce evolutionary concepts in DR evolution, highlight the role
of bacterial genetics in DR evolution, and state the rationale for this Thesis.
In Chapter 2, we state the Main Aim and Objectives of this Thesis.
In Chapter 3, we use the Luria-Delbrück fluctuation analysis, further in vitro assays, and genomic
sequences analysis to test whether the genetic variation present in natural populations ofMtbmodu-
lates the frequency and phenotypes of FQ-R mutations. We show that theMtb genetic background
can lead to differences in FQ-R that spans two orders of magnitude. Furthermore, we find that the
Mtb genetic background modulates the phenotypes conferred by FQ-R mutations in vitro, and the
observed types and relative frequencies of FQ-Rmutations both in vitro and in the clinic.
In Chapter 4, we adapt a mathematical modeling framework developed by Ford et al., 2013 to
simulate the frequency of FQ-R in order to test the relative contributions of different bacterial factors
in FQ-R evolution. Our results suggest that not all relevant bacterial factors have been accounted for
in the model, and that a new model of DR evolution is required forMtb.
In Chapter 5, we again use the Luria-Delbrück fluctuation analysis coupled with analysis ofMtb
genomes to test whether FQ-Rmutations can affect the continued evolution ofMtb populations. We
observe that FQ-Rmutations can increase the frequency of acquiring further DRmutations inMtb
in vitro. However, genomic analysis demonstrate that FQ-R mutations do not necessarily associate
with increased genetic diversity in natural populations ofMtb.
InChapter 6, we highlight the key findings of this Thesis. We then state the limitations, discuss the
implications of our results, and propose future directions in the study of FQ-R evolution inMtb.
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1 General Introduction
1.1 Global Burden of Tuberculosis
For millennia, tuberculosis (TB) has been a scourge on humanity. Morphological and molecular
evidence suggests that TB was present in people that lived during prehistoric Eastern Mediterranean
(Hershkovitz et al., 2008), prehistoric East Asia (Suzuki et al., 2008), in ancient Egypt (Nerlich et al.,
1997), and in Pre-Columbian South America (Bos et al., 2014). Today, TB remains a global burden on
human health and mortality, with approximately 10 million incident cases in 2018 (WHO, 2019a).
TB is a communicable disease. Transmission of TB occurs through the inhalation of aerosols
infected with bacterial species belonging to the Mycobacterium tuberculosis complex (MTBC), the
etiological agents of TB, which includes the human-adapted species M. tuberculosis (Mtb) and M.
africanum (Koch, 1882; Gagneux, 2018). Once infected,most individuals control the infection, do not
develop active disease, and are classified as having latent TB infection (LTBI) (O’Garra et al., 2013; Lin
et al., 2018). However, individuals with LTBI have a 5-15% of progressing to active and symptomatic
disease within 2 years of infection (O’Garra et al., 2013; Lin et al., 2018). Individuals who progress
from initial infection or LTBI to active TB disease develop fevers, heavy night sweats, and weight loss
(O’Garra et al., 2013; Lin et al., 2018); these patients also begin to cough out infected aerosols, thereby
beginning the infection cycle anew (O’Garra et al., 2013; Lin et al., 2018). While multiple immuno-
logical mechanisms are hypothesized to determine whether and how individuals progress to active TB
disease, immunosuppression, such as through HIV co-infection, is a strong risk factor (Ernst, 2012;
O’Garra et al., 2013; Lin et al., 2018).
The burden of TB is not spread equally across the world (Figures 1.1 & 1.2). This is due to TB
primarily being a disease of poverty. Poor living conditions, under-nutrition, overcrowding, poor sani-
tation, and poor indoor air quality are somewell-known risk factors forTB (Oxlade et al., 2012; Dheda
et al., 2016). People from developing nations are therefore at higher risk of being infected withMTBC,
developing active TB, and then further transmitting MTBC. Indeed, while Europe and the Americas
each accounted for approximately 3% of TB cases in 2018, South-East Asia accounted for 44%, Africa
for 24%, and the Western Pacific for 18% (WHO, 2019a). Furthermore, eight countries (India, China,
Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa) accounted for approxi-
mately two-thirds of all TB cases (WHO, 2019a).
Because of the massive burden TB imposes, TB remains one of the top ten causes of death in
humans (WHO, 2019a). In 2018, around 1.2million deaths were due to TB alone, with approximately
0.25 million additional deaths due to TB-HIV co-infections (WHO, 2019a). Since 2007, TB has been
the leading cause of deaths in humans due to a single infectious agent, surpassingHIV (WHO, 2019a).
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Figure 1.1: Estimated TB Incidence Rates in 2018.
From the Global Tuberculosis Report 2019, World Health Organization (WHO) (WHO, 2019a).
Figure 1.2: List of high-burden countries forTB, forTB/HIV co-infections,MDR-TB, and their over-
laps for the period 2016-2020, as defined by theWHO.
From the Global Tuberculosis Report 2019, World Health Organization (WHO) (WHO, 2019a).
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1.2 Treatment of Tuberculosis
TB-relatedmortalitywould likely even be higher if not for the advent of antimicrobials.WhileMtb
was discovered by Robert Koch in 1882 (Koch, 1882), the first antibiotic drugs with anti-TB activity,
streptomycin and para-aminosalicylic acid, would only be discovered in 1944 and 1946, respectively
(Schatz et al., 1944; Lehmann, 1946). Themodern age ofTB treatment regimenwas then ushered in by
the discovery of isoniazid (INH) in 1952 (Robitzek et al., 1952), rifampicin (RIF) in 1966 (Maggi et al.,
1966), and their first combined use in 1977 (Dickinson et al., 1977). Today, INH and RIF continue to
be used in combinationwith pyrazinamide (discovered in 1948;McKenzie et al., 1948) and ethambutol
(discovered in 1961; Thomas et al., 1961) as the first-line treatment regimen against drug-susceptible
Mtb (WHO, 2017; WHO, 2019a). This first-line regimen uses standardized, empirical dosing and has
high efficiency in the clinic, with an approximately 85% treatment success rate (Farah et al., 2005; Bao
et al., 2007; Gebrezgabiher et al., 2016; Tiberi et al., 2018).
However, the first-line regimen requires patients taking daily doses of antibiotics for at least 6
months (WHO, 2017). This substantial pill burden can lower patient adherence, and can impose large
economic burdens onpatients andhealth care systems (Munro et al., 2007; Barter et al., 2012; Alipanah
et al., 2018; Ruru et al., 2018). Therefore, current research and development of new TB treatment
regimens focus on developing newdrugs or drug combinations that both improve treatment outcomes
and reduce treatment duration and pill burdens (Tiberi et al., 2018; Vjecha et al., 2018).
1.3 Antimicrobial Resistance in Tuberculosis
The rise of antimicrobial resistance (AMR) further complicates TB treatment efforts. In general,
AMRinpathogens represents a globalhealth crisis as it increases treatment failures, treatmentduration,
treatment costs, and likelihood of adverse side effects from treatment (MacGowan, 2008; Winston et
al., 2012; Laxminarayan et al., 2013; Kibret et al., 2017; Zhang et al., 2018). The prevalence of AMR is
determined by the complex interaction betweenmultiple behavioural, socioeconomic, health systems,
and biological factors (Laxminarayan et al., 2013). For instance, poverty (Laxminarayan et al., 2013;
Alvarez-Uria et al., 2016; Stosic et al., 2018), patient non-adherence (Laxminarayan et al., 2013; Stosic
et al., 2018), improper or inadequate use of antibiotics (Laxminarayan et al., 2013; Shah et al., 2017;
Alipanah et al., 2018), and lack of patient support (Laxminarayan et al., 2013; Alipanah et al., 2018)
have all been positively associated with AMR prevalence.
AMR in TB is of particular importance; it represents the single largest cause of mortality due to
AMR in pathogens, accounting for approximately 200,000 out of the nearly 700,000 AMR-related
deaths in 2014 (O’Neill, 2016). The biggest risk factor for AMR in TB is history of previous treatment
(Dalton et al., 2012; Zhao et al., 2012; Dean et al., 2017). Armed conflict and the collapse of established
health systems have also been implicated in increased AMR prevalence in TB (Eldholm et al., 2016).
In 2018, there was an estimated half a million cases of multidrug-resistant TB (MDR-TB), defined
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Figure 1.3: Estimated percentage of new TB cases that were MDR-TB or RIF-R TB in 2018.
From the Global Tuberculosis Report 2019, World Health Organization (WHO). (WHO, 2019a)
as an infection with anMTBC strain that is resistant to at least RIF and INH (Figures 1.3, 1.4, & 1.5;
WHO, 2019a). Treatment forMDR-TB presents a medical, economic, and logistical challenge. While
patients with fully drug-susceptible MTBC strains require 6 to 9 months of treatment, patients with
MDR-TB require 9 to 24 months. Furthermore, treatment success rates for MDR-TB are generally
lower compared to drug-susceptible TB, withMDR-TB treatment success rates ranging from 79.8%
in randomized and controlled clinical trials (Nunn et al., 2019) down to approximately 50.0% in obser-
vational studies (Kibret et al., 2017; Parmar et al., 2018; Zhang et al., 2018; WHO, 2019a). Thus, there
is a need to develop new drugs or drug combinations that both improve treatment success rates and
reduce treatment duration for drug-susceptible and drug-resistant cases of TB.
1.4 Use of Fluoroquinolones for Tuberculosis Treatment
New types of fluoroquinolones (FQs) are being tested in experimental treatment regimens against
both drug-susceptible and drug-resistant cases of TB (Imperial et al., 2018; Vjecha et al., 2018). FQs
are broad-spectrum antibiotics that have been and continue to be used for TB treatment (Aldred
et al., 2014; WHO, 2019b). Previous MDR-TB treatment regimens used the second-generation FQs
ciprofloxacin or ofloxacin, or the third-generation FQ levofloxacin (Yew et al., 2003; Chan et al., 2004;
Takiff et al., 2011); today, current MDR-TB treatment regimens use the third-generation FQs mox-
ifloxacin or gatifloxacin (Van Deun et al., 2010; Nunn et al., 2019; WHO, 2019b). However, mox-
ifloxacin and gatifloxacin are also being considered as part of new treatment regimens that aim to
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Figure 1.4: Estimated percentage of previously treated TB cases that were MDR-TB or RIF-R TB in
2018.
From the Global Tuberculosis Report 2019, World Health Organization (WHO) (WHO, 2019a).
Figure 1.5: Estimated incidence of MDR-TB or RIF-R TB in 2018, for countries with at least 1000
incident cases.
From the Global Tuberculosis Report 2019, World Health Organization (WHO) (WHO, 2019a).
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improve treatment success rates and reduce treatment duration for drug-susceptible cases of TB (Gille-
spie et al., 2014; Jindani et al., 2014; Merle et al., 2014; Imperial et al., 2018; Vjecha et al., 2018) and
for MDR-TB (Van Deun et al., 2010; Nunn et al., 2019). These newer generations of FQs are more
potent than their older counterparts (Ji et al., 1995; Ji et al., 1998; Yu et al., 2016), have been associated
with greater treatment success rates in bothMtb-infectedmice and humans (Nuermberger et al., 2004;
Ahmad et al., 2018), and may even be used against MTBC strains that are resistant to the previous
generations of FQs (Chien et al., 2016; Maitre et al., 2017; Pranger et al., 2019).
Population-based studies have shown regional and drug-specific differences in FQ-resistance (FQ-
R) prevalence, with a range of 1.0–16.6% of all TB cases being ofloxacin-resistant, 0.5–12.4% being
levofloxacin-resistant, and 0.9-14.6% being moxifloxacin-resistant (Zignol et al., 2016). Due to treat-
ment practices, current FQ-R prevalence generally occurs in the context of MDR-TB (WHO, 2019a).
Extensively drug-resistant TB (XDR-TB), defined as cases of MDR-TB that have additional FQ-R
and resistance to an injectable aminoglycoside, represents one of the biggest challenge in TB treat-
ment, with treatment success rates being approximately 30% (Leimane et al., 2010; Alene et al., 2017;
WHO,2019a). Thus,mitigating further increases in FQ-Rprevalence is important to save patient lives,
as well as to sustain the current and potential use of FQs. Understanding how FQ-R is acquired and
maintained in natural populations of MTBC may provide insights in the development of new tools
or strategies that restrict further increases in FQ-R prevalence.
In bacteria, FQs target the type II topoisomerasesDNAgyrase and topoisomerase IV (Aldred et al.,
2014; Mayer et al., 2014). Type II topoisomerases introduces negative supercoils in the bacterial chro-
mosome through an ATP-dependent process that first creates a double-stranded DNA break (DSB)
in the chromosome, loops another intact segment of the chromosome through the DSB, and then re-
ligates the DSB (Gellert et al., 1976; Levine et al., 1998). Type II topoisomerases are therefore essential
in regulating DNA topology, DNA replication, and transcription (Levine et al., 1998). DNA gyrase
is the only type II topoisomerase present in MTBC, and is therefore the sole target of FQs inMTBC
(Cole et al., 1998; Mayer et al., 2014). Specifically, FQs bind to the active site of DNA gyrase, with the
region designated as the "Quinolone-binding pocket" (QBP) (Piton et al., 2010; Aldred et al., 2016;
Blower et al., 2016). Clinically-relevant FQ-R mutations in MTBC are restricted to a small subset of
chromosomal mutations in the "quinolone-resistance-determining region" (QRDR) of the two genes
that encode DNA gyrase: gyrA and gyrB (Takiff et al., 1994; Maruri et al., 2012; Wollenberg et al.,
2017). Structural characterizations have shown that amino acid residues in the QRDR share the same
physical space as the QBP, showing a direct relationship between FQ-DNA gyrase binding and FQ-R
mutations (Piton et al., 2010; Aldred et al., 2016; Blower et al., 2016). Further, QRDRmutations have
been shown to change the structure and interaction potential of DNA gyrase, including a disruption
of the DNA gyrase-FQs interaction that effectively leads to the FQ-R phenotype (Piton et al., 2010;
Aldred et al., 2016; Blower et al., 2016; Pandey et al., 2018).
While plenty of literature exists on the relevant biochemical mechanisms for FQ-R in MTBC,
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the evolutionary dynamics of FQ-R in MTBC has been less studied. Indeed, although multiple fac-
tors contribute to the prevalence of AMR in general (Laxminarayan et al., 2013), the emergence of
AMRwithin any given pathogen population is ultimately an evolutionary process (Wiesch et al., 2011;
Hughes et al., 2017). Understanding how MTBC populations evolve under FQ pressure, as well as
howMTBC populations continue in their evolution once they are FQ-resistant, may provide insights
into how to mitigate further increases in FQ-R prevalence.
1.5 Population Biology Factors that modulate Antimicrobial Resistance Evolution
In general, the evolution of AMR in pathogens is modulated by the interaction between multiple
biological factors. Firstly, the emergence of AMR mutations is positively associated with the rate of
genetic diversity production (Wiesch et al., 2011; Hughes et al., 2017). Production of genetic diversity
can be achieved through DNA replication errors (Reha-Krantz, 2010) or DNA repair mechanism-
inducedmutagenesis (Ysern et al., 1990; Gong et al., 2005; Baharoglu et al., 2014; Chapman et al., 2012),
which together make up the DNAmutation rate (Wiesch et al., 2011; Hughes et al., 2017). Increased
DNAmutation rates are positively associatedwith increasedAMRprevalence in in vitro and in natural
populations of multiple bacterial species (Oliver et al., 2000; Chopra et al., 2003; Örlén et al., 2006;
Oliver et al., 2010; Torres-Barceló et al., 2013; Wielgoss et al., 2013; Wang et al., 2013; Couce et al.,
2016). Horizontal gene transfer presents another avenue for increasing genetic diversity in bacterial
populations, as different bacterial strains or even species can exchange unique geneticmaterial (Hughes
et al., 2017; Sun et al., 2019). Because these unique genetic material can contain AMRmutations, the
rate of HGT has been positively associated with increased AMR prevalence (Hughes et al., 2017; Sun
et al., 2019). However, unique genetic material must first be produced throughDNAmutations; thus,
the impact of HGT on AMR prevalence is also modulated by the DNA mutation rate (Sun et al.,
2019).
Genetic diversity is positively associatedwithpopulation size, as there is simply a greaterprobability
of mutational events in a larger populations compared to smaller populations (Hughes et al., 2017;
Frenoy et al., 2018); thus, population sizes are also hypothesized to be positively associated with AMR
prevalence (Hughes et al., 2017; Frenoy et al., 2018).
The number of potentialmutations that can confer theAMRphenotype, also known as theAMR
mutational target size, may modulate AMR prevalence (Hughes et al., 2017). The AMRmutational
target size is itself modulated by the drug type and drug concentration that the pathogen population
is exposed to (Takiff et al., 2011; McGrath et al., 2014; Hughes et al., 2017). For instance, high drug
concentrations would generally lead to a smaller mutational target size, as less AMRmutations would
be capable of providing the high level of resistance required tomaintain growthunder these conditions
(Lindsey et al., 2013; Ford et al., 2013; McGrath et al., 2014; Huseby et al., 2017; Hughes et al., 2017).
Furthermore, different drugs or drug types may have differences in biochemical interactions with the
target biomolecule, or have different target biomolecules altogether, which may lead to differences in
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AMR mutational target sizes (Zhou et al., 2000; Takiff et al., 2011; Ford et al., 2013; McGrath et al.,
2014; Hughes et al., 2017). Conditions that lead to large AMRmutational target sizes, such as the use
of low drug concentration or drugs that have multiple biomolecule targets, are positively associated
with AMR prevalence (Ford et al., 2013; McGrath et al., 2014; Gygli et al., 2017; Hughes et al., 2017).
While the AMRmutational target size determines the number of potential mutations thatmay be
acquired, the fitness effect of the AMRmutations determines their relative frequencies and transmis-
sion potential (Wiesch et al., 2011; Hughes et al., 2017). Because antibiotics generally target essential
and evolutionary conserved biomolecules or pathways, AMRmutations generally confer a fitness cost
(Andersson et al., 2010; Hughes et al., 2017). However, some AMR mutations have been shown to
confer little or no fitness costs in in vitro assays, and these AMR mutations are generally the most
prevalent in the clinic (Gagneux et al., 2006c; Andersson et al., 2010; Gygli et al., 2017; Huseby et al.,
2017; Wollenberg et al., 2017). The fitness effect of AMRmutations is thus hypothesized to modulate
the clinical prevalence of AMR as well (Andersson et al., 2010; Hughes et al., 2017).
Non-heritable phenotypicmutationsmay alsomodulate AMRprevalence. Phenotypicmutations
that alter protein structure and function occur due to protein promiscuity, or due to errors in tran-
scription, translation, or epigenetic modification (Loftfield et al., 1972; Ozbudak et al., 2002; Payne
et al., 2019b). Phenotypic mutations can lead to antimicrobial tolerance, antimicrobial persistence, or
protein expression changes, which themselves have been positively associated with AMR prevalence
(Balaban et al., 2004; Javid et al., 2014; Gygli et al., 2017; Levin-Reisman et al., 2017; Chaudhuri et al.,
2018; Hicks et al., 2018).
In natural populations ofMTBC,AMR evolution is driven primarily by the emergence andmain-
tenance of chromosomalmutations (Gygli et al., 2017). Specifically,HGT- or plasmid-based resistance
have not been documented inMTBC (Boritsch et al., 2016; Gygli et al., 2017). Furthermore, while the
upregulation of efflux pumps have been observed in vitro, their relevance in the clinic is under debate
(Gygli et al., 2017). Lastly, antimicrobial persistence and tolerance may potentiate the acquisition of
AMRmutations in in vitro and inmice-infecting populations ofMTBC (Javid et al., 2014; Chaudhuri
et al., 2018); however, the only antimicrobial persistence and tolerance mechanisms that have been
shown to associate with the clinical prevalence of AMRwere themselves conferred by chromosomal
mutations (Hicks et al., 2018). Therefore, from an evolutionary perspective, studying AMR evolution
inMTBC, and FQ-R evolution specifically, provides a unique setting to investigate the emergence and
maintenance of clinically-relevant chromosomal mutations that confer or lead to AMR.
1.6 Role of Bacterial Genetics in Antimicrobial Resistance Evolution
To study aspects in MTBC evolution, the genetic diversity present in natural populations of
MTBCmust be taken into account. AlthoughMTBC genetic diversity is small compared to other bac-
terial pathogens, the global population of human-adaptedMTBC species (i.e.Mtb andM. africanum)
can be grouped into seven distinct genetic groups (Figure 1.6A; Comas et al., 2010; Gagneux, 2018);
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these genetic groups, named Lineages 1 through 7, have non-random phylogeographic distributions
(Figure 1.6B; Gagneux et al., 2006b; Gagneux, 2018). For example, while strains belonging to Lineage
1 are generally found along the rim of the Indian Ocean and in Southeast Asia (Douglas et al., 2003;
Wan et al., 2017; Gagneux, 2018), Lineage 2 and Lineage 4 strains are found throughout the world,
with Lineage 4 strains being the most prevalent globally (Gagneux et al., 2006b; Stucki et al., 2016;
Gagneux, 2018). Different lineages have also been associated with differences in phenotypes, includ-
ing differences in growth rates (Sarkar et al., 2012; Gehre et al., 2013), gene expression profiles (Rose
et al., 2013), progression to active disease (Jong et al., 2008; Baya et al., 2019), and the induction of host
immune cell responses (Portevin et al., 2011; Reiling et al., 2013).
Bacterial genetics may also play role in the evolution of FQ-R inMTBC. Indeed, bacterial genetics
have been shown to modulate AMR evolution in general in MTBC (Gagneux, 2018). For instance,
Lineage 2 strains have repeatedly been associated with MDR-TB in the clinic (Borrell et al., 2009;
Casali et al., 2014; Merker et al., 2015; Eldholm et al., 2016); this association has been hypothesized
to be due to Lineage 2 strains having much higher mutation rates, or a "hypermutator" phenotype,
which consequently leads to a higher rate of AMR emergence in Lineage 2 strains compared to strains
from other lineages (Rad et al., 2003; Ford et al., 2013). Bacterial genetics have also been shown to
modulate the mutational target size for both INH-R (Gagneux et al., 2006a; Fenner et al., 2012) and
RIF-R (Zaczek et al., 2009; Ford et al., 2013) in MTBC. Lastly, the MTBC genetic background has
also been shown to modulate the fitness effects of RIF-Rmutations (Gagneux et al., 2006c). Whether
bacterial genetics modulate the rate of FQ-R emergence, the mutational target size for FQ-R, or the
fitness effect of FQ-Rmutations in MTBC have yet to be determined.
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Figure 1.6: Phylogeny and Global Distribution of theMycobacterium tuberculosis Complex.
(A) Phylogeny of theM. tuberculosis Complex (MTBC) based on genomic data previously published
by Bos et al., 2014; phylogeny is rooted using theM. canettii genome. Branches of the seven human-
adapted lineages (in colour, named Lineages 1 through 7) and of the animal-adapted lineages (in grey)
are represented as collapsed triangles for clarity. Lineage (L)1, L2, L3, L4 and L7 are the genetic groups
belonging toM. tuberculosis sensu stricto, while L5 and L6 are the genetic groups belonging toM.
africanum. TBD1 represents the shared genomic deletion between L2, L3, and L4, while shared dele-
tions in the region of difference 7 (RD7), RD8, RD9, and RD10 are indicated under their respective
branches. Dashed line connecting theM. mungi,M. suricattae, and dassie bacillus represents most
likely phylogenetic relationship to the rest of the MTBC based on genetic data published in Dippe-
naar et al., 2015 and Alexander et al., 2016. Dagger on "Ancient Peruvian human remains" denotes an
approximately 1,000-year-old MTBC DNA isolated from archaelogical human remains in Peru and
genome sequenced by Bos et al., 2014. Scale bar represents number of nucleotide substitutions per
year. Bootstrap confidence intervals are stated where applicable. (B) Global phylogeographic distribu-
tion of the seven human-adapted bacterial lineages of MTBC, with colours denoting lineage. Figure
from Gagneux, 2018.
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1.7 Rationale
For this Thesis, we investigated whether bacterial genetics can modulate the rate of FQ-R emer-
gence, the mutational target size for FQ-R, and the fitness effect of FQ-R mutations in MTBC. We
focused our exploration on whether the genetic background ofMtb sensu stricto could modulate FQ-
R evolution; this is because genetic groups inMtb includeLineages 1, 2, and4,makingMtb responsible
for the greatest TB disease burden amongst the MTBC (Comas et al., 2010; Gagneux, 2018). Under-
standing how FQ-R evolves inMTBCmay provide insights in designing new treatment regimens that
restricts the emergence and continued transmission of FQ-R in the clinic.
As mentioned previously, FQ-R mutations may lead to structural changes in DNA gyrase, an
evolutionary-conserved enzyme that produces and religates DSBs to achieve its function of regulating
DNA topology (Levine et al., 1998; Piton et al., 2010; Aldred et al., 2016; Blower et al., 2016). We
hypothesize that FQ-Rmutations-induced structural changes inDNAgyrasemay reduce the efficiency
of its DSB religation function, leading to increased expression of error-proneDNA repairmechanisms.
Therefore,we also exploredwhether FQ-Rmutations themselves can affect the evolutionary trajectory
of MTBC populations by modulating DNAmutation rates and, consequently, modulating the levels
of genetic diversity present.
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2 Aims and Objectives
2.1 Aims
The main aim of this Thesis was to investigate the evolution of fluoroquinolone-resistance inM.
tuberculosis. Specifically, this Thesis used in vitro experimentalwork, amathematicalmodeling coupled
with an in silico simulations framework, and analysis of whole-genome sequencing data isolated from
clinical strains to explore whether the genetic variation present in naturalM. tuberculosis populations
modulates fluoroquinolone-resistance evolution. Furthermore, thisThesis testedwhether the presence
of fluoroquinolone-resistance mutations themselves can modulate the evolutionary potential ofM.
tuberculosis populations.
2.2 Objectives
2.2.1 Objective 1
Determine whether the genetic variation present in natural populations ofM. tuberculosis influ-
ences the evolution of flouroquinolone-resistance (Chapter 3).
2.2.2 Objective 2
Use a mathematical model to explore the relative contributions of bacterial factors hypothesized
to modulate the evolution of fluoroquinolone-resistance inM. tuberculosis (Chapter 4).
2.2.3 Objective 3
Investigate whether fluoroquinolone-resistance mutations associate with increased genetic diver-
sity inM. tuberculosis populations (Chapter 5).
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3.1 Abstract
Fluoroquinolones (FQ) form the backbone in experimental treatment regimens against drug-
susceptible tuberculosis. However, little is known on whether the genetic variation present in natural
populations ofMycobacterium tuberculosis affects the evolution of FQ-resistance (FQ-R). To investi-
gate this question, we used nine genetically distinct drug susceptible clinical isolates ofMtb and mea-
sured their frequency of resistance to the FQ ofloxacin (OFX) in vitro. We found that theMtb genetic
background led to differences in the frequency of OFX-resistance (OFX-R) that spanned two orders
of magnitude and substantially modulated the observed mutational profiles for OFX-R. Further, in
vitro assays showed that the genetic background also influenced the minimum inhibitory concentra-
tion and the fitness effect conferred by a given OFX-Rmutation. To test the clinical relevance of our
in vitro work, we surveyed the mutational profile for FQ-R in publicly available genomic sequences
from clinicalMtb isolates, and found substantialMtb lineage dependent variability. Comparison of
the clinical and the in vitromutational profiles for FQ-R showed that 51% and 39%of the variability in
the clinical frequency of FQ-R gyrA mutation events in Lineage 2 and Lineage 4 strains, respectively,
can be attributed to howMtb evolves FQ-R in vitro. As theMtb genetic background strongly influ-
enced the evolution of FQ-R in vitro, we conclude that the genetic background ofMtb also impacts
the evolution of FQ-R in the clinic.
Key words:Mycobacterium tuberculosis, antimicrobial resistance, evolution, fluoroquinolones, epis-
tasis, mycobacteria, fitness.
3.2 Introduction
Antimicrobial resistance (AMR)poses amajor threat to our ability to treat infectious diseases (Mac-
Gowan, 2008; Winston et al., 2012). The rise of AMR is a complex phenomenon with a broad range
of contributing socioeconomic and behavioral factors (Dalton et al., 2012;Merker et al., 2015; Alvarez-
Uria et al., 2016; Eldholm et al., 2016; Shah et al., 2017). However, the emergence of AMRwithin any
pathogen population is ultimately an evolutionary process (Wiesch et al., 2011; Hughes et al., 2017).
This evolutionary process is influenced by multiple factors, including drug pressure and pathogen ge-
netics. Firstly, the drug type and drug concentration can affect the nature and relative frequencies of
AMRmutations observed in a given pathogen population (also known as the mutational profile for
AMR) (Zhou et al., 2000; Ford et al., 2013; Lindsey et al., 2013; McGrath et al., 2014; Hughes et al.,
2017; Huseby et al., 2017). Secondly, pathogen populations comprise genetically distinct strains, and
this genetic variation may also influence AMR evolution (Fenner et al., 2012; Vogwill et al., 2014; Vog-
will et al., 2016; Gagneux, 2018). Different pathogen genetic backgrounds can have different baseline
susceptibilities to a given drug (Ängeby et al., 2010; Coeck et al., 2016), which can consequently affect
patient treatment outcomes (Colangeli et al., 2018). The genetic background has also been shown to
modulate the acquisition and prevalence of AMR (Borrell et al., 2009; Fenner et al., 2012; Ford et al.,
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2013; Wollenberg et al., 2017), the mutational profile for AMR (Fenner et al., 2012; Ford et al., 2013;
Vogwill et al., 2014; Oppong et al., 2019), and the phenotypic effects of AMR mutations (Gagneux
et al., 2006c; Decuypere et al., 2012; Angst et al., 2013; Vogwill et al., 2016). Studying the interplay
between pathogen genetics and drug pressure is therefore important in understanding how to restrict
the emergence of AMR in pathogen populations.
AMR inMycobacterium tuberculosis (Mtb), the etiological agent of human tuberculosis (TB), is
of particular importance. Mtb infections globally cause the highest rate of mortality due to a single
infectious agent both in general, and due to AMR specifically (WHO, 2018). Although the genetic
variation inMtb is small comparedwith other bacterial pathogens (Comas et al., 2010; Gagneux, 2018),
several studies have shown that this limited genetic variation influences AMR phenotypes and preva-
lence (Gagneux et al., 2006c; Zaczek et al., 2009; Fenner et al., 2012; Gagneux, 2018). The global genetic
diversity ofMtb comprises seven phylogenetic lineages (Comas et al., 2010; Gagneux, 2018), andMtb
strains belonging to the Lineage 2 Beijing/W genetic background have repeatedly been associatedwith
multidrug-resistant TB (MDR-TB; defined as an infection from anMtb strain that is resistant to at
least isoniazid and rifampicin) both in vitro and in clinical settings (Borrell et al., 2009; Fenner et al.,
2012; Ford et al., 2013; Merker et al., 2015; Wollenberg et al., 2017).
One strategy to reduce the emergence ofAMRinMtb is the developmentofnew,shorter treatment
regimens (Imperial et al., 2018; Vjecha et al., 2018). Many such experimental regimens use third- or
fourth-generation fluoroquinolones (FQ) against drug-susceptibleMtb (Gillespie et al., 2014; Jindani
et al., 2014; Merle et al., 2014; Imperial et al., 2018; Vjecha et al., 2018). However, FQs have long been
integral to treatingMDR-TB (Takiff et al., 2011), and the previous use of FQs has led to the emergence
of FQ-resistance (FQ-R) in clinical strains ofMtb (Takiff et al., 1994; Maruri et al., 2012; Shah et al.,
2017). FQ-R is one of the defining properties of extensively drug-resistant TB (XDR-TB), and XDR-
TB accounts for 8.5% of MDR-TB cases (WHO, 2018). Understanding how FQ-R is acquired in
natural populations ofMtbmay allow for the development of tools or strategies to mitigate further
increases in FQ-R prevalence.
InMtb, the sole target of FQ isDNAgyrase (Takiff et al., 1994; Zhou et al., 2000; Piton et al., 2010;
Aldred et al., 2016; Blower et al., 2016). Consequently, clinically relevant FQ-R in Mtb is primarily
due to a limited set of chromosomal mutations located within the “quinolone-resistance-determining
region” (QRDR) of the gyrA and gyrB genes, which encode DNA gyrase (Takiff et al., 1994; Maruri
et al., 2012; Wollenberg et al., 2017). No horizontal gene-transfer or plasmid-based resistance to FQ
has been documented inMtb (Boritsch et al., 2016; Gygli et al., 2017). Studying FQ-R evolution in
Mtb populations thus provides a promising setting for elucidating how the genetic background may
affect the emergence andmaintenance of clinically relevant chromosomalAMRmutations in bacterial
populations.
While a great deal of literature exists on the biochemical mechanisms leading to the FQ-R phe-
notype inMtb (Zhou et al., 2000; Piton et al., 2010; Mustaev et al., 2014; Aldred et al., 2016; Blower
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et al., 2016), little is known on the evolutionary dynamics of FQ-R in different populations ofMtb.
Given that antimicrobial regimens againstMtb infections use standardized, empirical dosing strate-
gies (WHO, 2018), it is unclear whether differentMtb genetic backgrounds would acquire FQ-R at
the same frequency when exposed to the same antimicrobial concentration. Whether theMtb genetic
background would also modulate the mutational profile for FQ-R, or the phenotypic effects of FQ-R
mutations, is unknown. Such knowledge may provide insights on how to maintain or prolong the
efficiency of FQs against different genetic variants ofMtb in the clinic.
In this study, we tested whether theMtb genetic background plays a role in the evolution of FQ-
R. We showed that the Mtb genetic background can lead to differences in the frequency of FQ-R
emergence that span two orders ofmagnitude, as well as substantiallymodulate themutational profile
for FQ-R.We further demonstrated that the phenotypic effects of clinically relevant FQ-Rmutations
differed depending on theMtb genetic background they were present in. Analysis of publicly available
genomic sequences from clinicalMtb isolates also revealed a positive association between the FQ-R
mutational profiles observed in vitro and themutational profiles observed in the clinic. Taken together,
we showed that theMtb genetic background had a considerable role in evolution of FQ-R in the clinic.
3.3 Methods
3.3.1 Collection of Drug-Susceptible Clinical Isolates ofM. tuberculosis Strains for In Vitro Studies
We used nine genetically distinctMtb strains, with three strains from each of the followingMtb
lineages: Lineage 1 (L1; also known as the East-Africa and India Lineage), Lineage 2 (L2; the East Asian
Lineage), and Lineage 4 (L4; the Euro-American Lineage) (Comas et al., 2010; Gagneux, 2018). All
strains were previously isolated from patients, fully drug-susceptible, and previously characterized by
Borrell et al., 2019 (Table 7.1, see Supplementary Information). Prior to all experimentation, starter
cultures for eachMtb strain were prepared by recovering a 20 µl aliquot from frozen stocks into a
10 ml volume of Middlebrook 7H9 broth (BD), supplemented with an albumin (Fraction V, Roche),
dextrose (Sigma–Aldrich), catalase (Sigma–Aldrich), and0.05%Tween 80 (AppliChem) (hereafterdes-
ignated as 7H9 ADC). These starter cultures were incubated until their optical density at wavelength
of 600 nm (OD600) was∼0.50, and were then used for in vitro assays.
3.3.2 Fluctuation Analyses
Fluctuation analyseswere performedas describedbyLuria andDelbrück (Luria et al., 1943). Briefly,
an aliquot from the starter cultures for each strain was used to inoculate 350 ml of 7H9 ADC to have
an initial bacterial density of 5,000 colony forming units (CFU) permilliliter. This was immediately di-
vided into 33parallel cultures, eachwith 10mlof culture volume aliquoted into individual 50mlFalcon
Conical Centrifuge Tubes (Corning Inc.). The parallel cultures were incubated at 37 ◦C on standing
racks, with resuspension by vortexing (Bio Vortex V1, Biosan) every 24 h. Cultures were grown until
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an OD600 of between 0.40 and 0.65. Once at this density, final cell counts (Nt) from three randomly
chosen parallel cultures were calculated by serial dilution and plating onMiddlebrook 7H11 (BD), sup-
plemented with oleic acid (AppliChem), albumin, and catalase (hereafter referred to as 7H11 OADC).
To calculate the number of resistant colonies (r), the remaining 30 parallel cultures not used forNt
determination were pelleted at 800 × g for 10 min at 4 ◦C using the Allegra X-15R Benchtop Cen-
trifuge (Beckmann Coulter). The supernatants were discarded, and the bacterial pellets resuspended
in 300 µl of 7H9 ADC. The resuspensions were spread on 7H11 OADC plates supplemented with
the relevant drug concentration (2, 4, or 8 µg/ml of ofloxacin, or 100 µg/ml STR; Sigma). Resistant
colonies were observed and enumerated after 21–35 days of incubation, depending on theMtb strain.
The frequency of drug-resistantmutants per culture (r) was enumerated, and the estimated number of
drug-resistancemutations per culture (m) was estimated from the distribution of the r values (rdist) us-
ing theMa, Sarkar, Sandri-MaximumLikelihood Estimatormethod (MSS-MLE) (Rosche et al., 2000).
Values of r that were >300 were simply given a value of 300, as this would not change the precision
of the calculatedm value using the MSS-MLEmethod (Rosche et al., 2000). TheMSS-MLEmethod
is also only valid for a range ofm values between 0.3 and 20 (Rosche et al., 2000). The frequency of
drug-resistance mutations acquired per cell (F ) per strain was then calculated by dividing the calcu-
latedm values by their respectiveNt values. The 95% confidence intervals for each F were calculated
as previously described by Rosche and Foster (Rosche et al., 2000). Hypotheses testing for significant
differences between the rdist between strains for the fluctuation analyses at 4 µg/ml of OFX (Figure
3.1A) and at 100 µg/ml of STR (Figure 3.2) were performed using the Kruskal–Wallis test; significant
differences in the rdist between strains in the fluctuation analyses at 2 and 8 µg/ml of OFX (Figure
3.1B) were tested for using theWilcoxon rank-sum test. Statistical analyses were performed using the
R statistical software (v.3.5.1) (R Core Team, 2018).
3.3.3 Determining the Mutational Profile for Ofloxacin-Resistance In Vitro
From the parallel cultures plated on 4 µg/ml of OFX (Figure 3.1A), up to 120 resistant colonies
per strain (at least 1 colony per plated parallel culture if colonies were present, to amaximumof 6) were
transferred into 100 µl of sterile deionized H2O placed in Falcon 96-well Clear Microplate (Corning
Inc.). The bacterial suspensions were then heat-inactivated at 95 ◦C for 1 h, and used as PCR templates
to amplify the QRDR in gyrA and gyrB using primers designed by Feuerriegel et al., 2009. PCR
productswere sent toMacrogen, Inc. orMicrosynthAGforSanger sequencing, andQRDRmutations
were determined by aligning the PCR product sequences against theH37Rv reference sequence (Cole
et al., 1998). Sequence alignments were performed using the Staden Package (Staden, 1996), while the
amino acid substitutions identification were performed using the Molecular Evolutionary Genetics
Analysis Version 6.0 package (Tamura et al., 2013). Fisher’s exact test was used to test for significant
differences between the strains’ mutational profiles for OFX-R. Data analyses were performed using
the R statistical software (v.3.5.1) (R Core Team, 2018), and figures were produced using the ggplot2
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package (Wickham, 2016).
3.3.4 Isolation of Spontaneous Ofloxacin-Resistant Mutants
Spontaneous OFX-resistant mutants were isolated from strains belonging one of three genetic
backgrounds: N0157 (L1, Manila sublineage), N1283 (L4, Ural sublineage), and N0145 (L2, Beijing
sublineage) (Borrell et al., 2019). To begin, we transferred 50 µl of starter cultures for each strain into
separate culture tubes containing 10 ml of fresh 7H9 ADC. Cultures were incubated at 37 ◦C un-
til OD600 of ∼0.80, and pelleted at 800 × g for 5 min at 4 ◦C. The supernatant was discarded, and
the pellet resuspended in 300 µl of 7H9 ADC. The resuspension was plated on 7H11 OADC (BD)
supplemented with 2 µg/ml of OFX, and incubated until resistant colonies appeared (∼14–21 days).
Resistant colonies were picked and resuspended in fresh 10 ml 7H9 ADC, and incubated at 37 ◦C.
Once the culture reached early stationary phase, two aliquots were prepared. The first aliquot was
heat-inactivated at 95 ◦C for 1 h, and the gyrAmutation identified by PCR and Sanger sequencing, as
described in the mutational profile for OFX-R assay. If the first aliquot harbored one of four OFX-R
gyrA mutations (GyrAD94G, GyrAD94N, GyrAA90V, GyrAG88C), the second aliquot was stored in−80
◦C for future use.
Prior to further experimentation with the spontaneously OFX-resistant mutant strains, starter
cultures were prepared in the same manner as for the drug-susceptible strains.
3.3.5 Drug Susceptibility Assay
We determined theOFX-susceptibility levels of our spontaneousOFX-resistantmutants and their
respective drug-susceptible ancestors by performing the colorimetric, microtiter plate-based Alamar
Blue assay (Franzblau et al., 1998). Briefly, we used a Falcon 96-well ClearMicroplate, featuring a serial
2-fold dilution of OFX. For drug-susceptible strains, a range of OFX concentration from 15 to 0.058
µg/mlwas used.Meanwhile, forOFX-resistant strains, a range of 60–0.234µg/mlwas used. Eachwell
was inoculated with a 10 µl volume of starter culture to have a final inoculum of∼5× 106 CFU/ml.
The plates were incubated at 37 ◦C for 10 days. Following incubation, 10 µl of Resazurin (Sigma) were
added to each well, and the plates were incubated for another 24 h at 37 ◦C. After this incubation
period, plates were inactivated by adding 100 µl of 4% formaldehyde to every well. Measurement of
fluorescence produced by viable cells was performed on SpectraMAXGeminiXPSMicroplate Reader
(MolecularDevices). The excitation wavelengthwas set at 536 nm, and the emission wavelength at 588
nmwasmeasured.Minimum inhibitory concentration (MIC) forOFXwas determined by first fitting
a Hill curve to the distribution of fluorescence, and then defining theMIC as the lowest OFX concen-
tration where the fittedHill curve showed a≥95% reduction in fluorescence. Two sets of experiments
were performed for every strain, with three technical replicates per experiment. Analyses of MIC data
were performed and figures created using the numpy, scipy, pandas, and matplotlib modules for the
Python programming language.
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3.3.6 Cell Growth Assay
We set up three or four 1,000 ml roller bottles with 90 ml of 7H9 ADC and 10 ml borosilicate
beads. Each bottle was inoculated with a volume of starter cultures so that the initial bacterial density
was at an OD600 of 5× 10−7. The inoculated bottles were then placed in a roller incubator set to 37
◦C, and incubated for 12–18 days with continuous rolling. OD600 measurements were taken once or
twice every 24 h. Two independent experiments in either triplicates or quadruplicates were performed
per strain.
We defined the exponential phase as the bacterial growth phase where we observed a log2-linear
relationship betweenOD600 and time; specifically,we used a Pearson’sR2 value≥0.98 as the threshold.
The growth rate of a particular strain was then defined as the slope of the linear regression model.
The relative fitness of a given spontaneous OFX-R mutant was defined by taking the growth rate of
the OFX-resistant mutant strain and dividing it by the growth rate of its respective drug-susceptible
ancestor. Linear regression models for the cell growth assays data were performed using the numpy,
scipy,pandas, andmatplotlibmodules for thePythonprogramming language, aswell as theR statistical
software (v.3.5.1) and the ggplot2 package (Wickham, 2016; R Core Team, 2018).
3.3.7 Surveying the Fluoroquinolone-resistance Profile from Publicly AvailableM. tuberculosis
Genomes
We screened public databases to download global representatives ofMtb genomes, as described
byMenardo et al., 2018. We selected genomes that were classified as MDR-TB based on the presence
of both INH-R and RIF-R mutations. This provided a data set of 3,450 genomes with confirmed
MDR-TB. Due to excessive length, their accession numbers are only reported in the Supplementary
Material of Castro et al., 2019 (number of genomes = 3,450). These MDR-TB genomes were then
screened for the presence of FQ-R mutations, and we identified 854 genomes that were classified as
FQ-R.
The INH-R,RIF-R,andFQ-Rmutations used for screening are the samemutations usedbyPayne
et al., 2019a. List of these mutations are only available in the Supplementary Material of Payne et al.,
2019a andCastro et al., 2019, and not reported here due to excessive length (n= 196). A drug-resistance
mutationwas defined as “fixed” in the populationwhen it reached a frequency of≥90%.Meanwhile, a
drug-resistancemutationwas considered “variable” in the populationwhen its frequencywas between
10% and 90%; thus, multiple drug-resistance mutations may be present in the genomic data from a
singleMtb clinical isolate.
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3.3.8 Defining Transmission Clusters and Determining the Frequency of
Fluoroquinolone-resistance gyrAMutation Events
To define transmission clusters, the differences in the number of SNPs were used as a measure of
genetic distance between twoMtb genomes. Using the haplotypes package (v.1.0) for the R statisti-
cal software (v.3.5.1) (R Core Team, 2018), a genetic distance matrix was then inferred for the 3,450
MDR-TB genomes. Insertions/deletions were considered missing data. Agglomerative clustering was
performed using the agnes function from the cluster package (v.2.0.6) for the R statistical software
(R Core Team, 2018). A conservative threshold of 12 SNPs average distance was used to define likely
patient-to-patient transmission (Walker et al., 2013), and the tree was cut at a height of 12 SNPs using
the hclust function. All resulting transmission clusters,with aminimum size of two clustered genomes,
were used for further analysis. For every transmission cluster, each unique and fixed FQ-R gyrA mu-
tation was treated as an independent mutation event. Fixed FQ-R gyrA mutations in nonclustered
Mtb genomes were also treated as an independent mutation event. Figures were produced using the
ggplot2 package (Wickham, 2016).
3.4 Results
3.4.1 Frequency of Ofloxacin-Resistance inM. tuberculosis Is Strain-Dependent
We first tested forwhether theMtb genetic background led to differences in the frequency of FQ-R
acquisition. To do so, we performed a Luria–Delbrück fluctuation analysis on nine drug-susceptible
and genetically distinctMtb clinical strains belonging to Lineage 1 (L1), Lineage 2 (L2), and Lineage 4
(L4) (Table 7.1, see Supplementary Information) (Luria et al., 1943; Comas et al., 2010; Gagneux, 2018;
Borrell et al., 2019). We measured their frequency of resistance in vitro to the FQ ofloxacin (OFX), as
OFX was used extensively to treat MDR-TB patients in the past (Takiff et al., 2011). Given that anti-
TB treatment regimens use standardized drug concentrations (WHO, 2018), we also measured the
frequency of resistance to the same concentration of OFX (4 µg/ml) for all nine strains. We observed
significant strain-dependent variation in the frequency of OFX-resistance (OFX-R) at 4 µg/ml, with
the difference spanning two orders ofmagnitude (Figure 3.1A,P = 2.2× 10−16, Kruskal–Wallis). Sev-
eral of the nine drug-susceptibleMtb strains containedmissense substitutions in DNA gyrase that are
not associatedwith FQ-R (Table 7.2, see Supplementary Information) (Borrell et al., 2019). Thesemu-
tations are phylogenetic markers that reflect the population structure ofMtb and cannot be avoided
if strains from differentMtb lineages are used (Comas et al., 2010; Gagneux, 2018). We found no evi-
dence for any associations between the presence a given phylogenetic DNA gyrase missense mutation
and the frequency of OFX-R acquired.
The concentration of the antimicrobial can affect the observed frequencies ofAMR inMtb (Zhou
et al., 2000; Ford et al., 2013;McGrath et al., 2014). Therefore,we testedwhether changing the selective
concentration of OFX would affect the relative differences in strain-specific OFX-R frequencies. For
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Figure 3.1: Variation in the frequency of ofloxacin-resistance between genetically distinct, wild-type
Mycobacterium tuberculosis strains.
(A) Frequency of ofloxacin-resistance at 4µg/ml ofloxacin (OFX), asmeasured by fluctuation analysis.
Top panel: colored points represent the frequency of ofloxacin-resistance per cell per parallel culture,
with darker points representing multiple cultures with the same frequency. Colors denote the lin-
eage that theMtb strain belongs to (L1, pink; L2, blue; L4, red). Gray points represent the estimated
number of drug-resistance mutations per cell per strain as calculated by MSS-MLE, while black bars
denote the respective 95% confidence intervals. Bottom panel: the percentage of parallel cultures lack-
ing OFX-resistant mutants. (B) Frequency of ofloxacin-resistance at 2 or 8 µg/ml OFX. †† Due to
restrictions on the range of values that the MSS-MLE method is valid for (see Methods), the esti-
mated number of drug-resistance mutations per cell for N0157 at 2 µg/ml OFX, as presented here, is
an underestimate.
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Figure 3.2: The frequency of streptomycin-resistance at 100 µg/ml streptomycin (STR) for wild-type
N0157, N1283, and N0145Mycobacterium tuberculosis strains, as measured by fluctuation analysis.
Top panel: colored points represent the frequency of streptomycin-resistance per cell per parallel cul-
ture, with darker points representing multiple cultures with the same frequency. Colors denote the
lineage that the Mtb strain belongs to (L1, pink; L2, blue; L4, red). Gray points represent the esti-
mated number of drug-resistancemutations per cell per strain as calculated byMSS-MLE, while black
bars denote the respective 95% confidence intervals. Bottom panel: the percentage of parallel cultures
lacking STR-resistant mutants. Two biological replicates are presented for eachMtb strain, with each
replicate identifier suffixed after the strain name.
the sake of simplicity, we tested only two strains, with each strain at the opposite extremes of the fre-
quency of resistance to 4 µg/ml OFX, as shown in Figure 3.1A: N0157 (high OFX-R frequency) and
N0145 (low OFX-R frequency). We found that the frequency of OFX-R remained one to two orders
of magnitude higher in N0157 than in N0145 across all the concentrations we tested (Figure 3.1B, P
= 2.46× 10−5 for 2 µg/ml OFX, and P = 4.03× 10−6 for 8 µg/ml OFX,Wilcoxon rank-sum test).
The N0157 strain had nearly confluent growth at 2 µg/ml OFX, which is the OFX concentration that
has been shown to inhibit 95% ofMtb strains that have not been previously exposed toOFX, but does
not inhibitMtb strains that are considered resistant to OFX in the clinic (Ängeby et al., 2010; Coeck
et al., 2016). This suggested that N0157 has low-level resistance to OFX, despite having no mutation
in theQRDR.Meanwhile, at 8µg/mlOFX,we observed only four resistant colonies forN0145 across
all samples, with all colonies arising within the same culture.
The variation in OFX-R frequencies when selecting on the same concentration of OFX may be
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driven by several, non-exclusive biological factors. Firstly, theMtb strains we tested may have different
baseline DNA mutation rates. Secondly, the number and relative frequency of potential mutations
that confer OFX-R may vary depending on the Mtb genetic background. Thirdly, the relative cost
of OFX-R mutations may differ between Mtb genetic backgrounds. As the observed frequency of
OFX-R inMtb is likely the result from a combination of multiple factors, we took advantage of the
fact that we had identified strains with a range ofOFX-R frequencies. We selected three representative
strains with significantly different OFX-R frequencies: N0157, N1283, and N0145. These strains had
a high-, mid-, and low frequency of OFX-R, respectively (Figure 3.1A). We then explored the relative
contributions of each biological factor listed above in driving the variation inOFXR across genetically
distinctMtb strains.
3.4.2 Mutation Rate Differences Do Not Drive the In Vitro Variation in Ofloxacin-Resistance
Frequency inM. tuberculosis
We first tested for the presence of differential mutation rates between our panel ofMtb strains in
Figure 3.1A.Mutations in dnaE, which encodes the replicative DNA polymerase and serves as the ma-
jor replicative exonuclease inMtb, have been shown to confer a hypermutator phenotype inMtb in the
absence of environmental stress (Rock et al., 2015; Baños-Mateos et al., 2017). While dnaE mutations
were present in the genomic data of our panel of drug-susceptibleMtb strains (Table 7.2, see Supple-
mentary Information) (Borrell et al., 2019), none was in the polymerase and histidinol phosphatase
domain of DnaE, the region where mutations would impart a hypermutator phenotype (Rock et al.,
2015; Baños-Mateos et al., 2017). We did not test for the presence of dnaE mutations in the resistant
colonies following the fluctuation analysis, as we reasoned that the likelihood of gaining both a dnaE
and a gyrA double mutation within this relatively short period is extremely low as to be considered
negligible. To test for mutation rate variation in vitro, we again conducted a fluctuation analysis on
N0157,N1283, andN0145 (the high-, mid-, and low-frequencyOFX-R strains, respectively), but used
streptomycin (STR; 100 µg/ml) instead of OFX. We hypothesized that if the frequency of OFX-R
is driven by differential mutation rates, then we should expect similar differences in the frequency of
STR-resistance (STR-R). However, we observed no evidence for differences in the frequency of STR-
R between the strains tested (Figure 3.2, P = 0.135, Kruskal–Wallis; Table 7.3, see Supplementary
Information). This suggested that the observed differences in frequency of resistance are specific to
OFX, and that there are limited, if any, inherent differences in mutation rates between theMtb strains
tested.
3.4.3 Mutational Profile for Ofloxacin-Resistance Is Highly Strain-Dependent
We next determined the mutational profile for OFX-R for each strain used in the fluctuation anal-
ysis at 4 µg/ml OFX (Figure 3.1A). The QRDRmutations in 680 gyrA and 590 gyrB sequences were
identified in the resistant colonies. We observed that gyrA mutations made up 99.7% of the QRDR
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mutations observed (645 gyrA mutations, 2 gyrB mutations), and no QRDR double mutants were
present (Figure 7.1, Tables 7.4 & 7.5, see Supplementary Information). The mutational profiles for
OFX-R were also highly strain-specific (Figure 3.3A, P = 5.00× 10−4, Fisher’s exact test). Specifi-
cally, the GyrAA90Vmutation wasmost prevalent in the high-frequencyOFX-R strains, while GyrA
D94G was most prevalent in all other strains. There was also a slight trend showing that strains with
a greater number of unique gyrA mutations present also had higher rates of OFX-R (Figures 3.1A &
3.3B).
The strain-dependent variation in the mutational profile for OFX-R may be due to gyrA muta-
tions conferring different resistance levels depending on theMtb strain they are present in. To test this
hypothesis, we first isolated OFX-R mutants carrying one of four possible GyrA mutations (G88C,
A90V, D94G, or D94N) in the three strains used in Figure 3.2: N0157, N1283, and N0145. The OFX
MIC was determined for each of the 12 OFX-Rmutant strains, along with their respective wild-type
ancestors. We found that each parental wild-type strain had different susceptibilities to OFX, with
N0157, N1283, and N0145 having OFXMICs of 2, 0.6, and 0.5 µg/ml, respectively (Figure 3.4A and
Table 7.6, see Supplementary Information). This was consistent with the fluctuation analysis results
shown in (Figure 3.1B). Furthermore, we observed that the OFXMIC conferred by a given gyrA mu-
tation varied depending on the strain it was present in (Figure 3.4B and Table 7.6, see Supplementary
Information). For example, mutants in the N0157 strain generally had higher OFX MICs than mu-
tants in either theN0145 orN1283 strains. The onlymutation that deviated from this trendwas GyrA
G88C, which conferred a higher OFXMIC when in the N0145 strain. Notably, the GyrA A90Vmu-
tation conferred a resistance level≥4 µg/ml OFX in the N0157 and N1283 strains, but not in N0145.
This was consistent with the presence of GyrA A90V in the OFXRmutational profile for N0157 and
N1283, but not in N0145, in the fluctuation analysis using 4 µg/ml OFX (Figures 3.1A and 3.3). In
summary, the differences in OFXMIC reflected the strain-dependent mutational profiles for OFX-R
inMtb, as expected.
3.4.4 Fitness of Ofloxacin-Resistance Mutations Are Associated with Their Relative Frequency In
Vitro
While the OFXMICs may determine which mutations may be observed in a fluctuation analysis,
it is not the sole parameter to influence theOFX-Rmutational profile for a given strain.We found that
while the same gyrA mutation can be observed in two differentMtb strains, their relative frequencies
may vary (Figure 3.3). This variation may be due to the fitness of a given gyrAmutant being different
across genetic backgrounds. To test this hypothesis, we used cell growth assays in antibiotic-free condi-
tions tomeasure the in vitro fitness of our panel ofOFX-Rmutants relative to their respective parental
wild-type ancestors. We observed that the relative fitness of the OFX-R mutants was modulated by
both the gyrA mutation and theMtb strain they were present in (Figure 3.5A; Figures 7.2 & 7.3, Ta-
ble 7.7, see Supplementary Information). Furthermore, there was a positive association between the
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Figure 3.3: Variation in the mutational profile for ofloxacin-resistance after fluctuation analyses using
nine genetically distinctMycobacterium tuberculosis strains.
(A) Mutations in the quinolone-resistance-determining region (QRDR) of gyrA were analyzed in
680 ofloxacin (OFX)-resistant colonies from the fluctuation analysis performed in Figure 3.1A (nm,
no identified QRDR gyrA mutations). Strains are ordered left to right based on their frequency of
OFX-resistance at 4 µg/ml OFX. Numbers of colonies analyzed per strain are reported directly above
each column. (B) The number of uniqueQRDR gyrAmutations perMtb strain for OFX-resistance.
Bar colors denote theMtb lineage the strain belongs to (L1, pink; L2, blue; L4, red).
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Figure 3.4: TheMycobacterium tuberculosis genetic backgroundmodulates the ofloxacin (OFX)min-
imum inhibitory concentration (MIC).
(A) Heat-map of OFX-susceptibility via Alamar Blue assay for gyrAmutant strains ofMtb, as well as
their wild-type ancestor, in three genetic backgrounds (N0157, N0145, or N1283). Light areas repre-
sent growing cultures, while dark areas represent nongrowing cultures. Yellow points represent esti-
mates forOFXMIC (≥95% reduction in fluorescence). Areas of solid black colors (at 16+µg/mlOFX
for wild-type) and solid light beige colors (at <0.125µg/mlOFX formutants) were notmeasured and
colored in for illustrative purposes. (B) OFX MIC estimates for each strain per genetic background,
superimposed. Colored points and lines represent MIC measurements for highlighted genetic back-
ground, with the line color denoting the lineage that the strain belongs to (L1, pink, L2, blue, L4,
red). Gray points and lines represent the other two genetic backgrounds. Solid horizontal black line
denotes 4 µg/ml OFX, while dashed horizontal black line denotes 1 µg/ml OFX.
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Figure 3.5: The Mycobacterium tuberculosis genetic background modulates the fitness effect of
fluoroquinolone-resistance mutations.
(A) Fitness of ofloxacin-resistant Mtb strain with specified gyrA mutation relative to the fitness of
their respective wild-type ancestral strain. Fitness was measured by cell growth assay in antibiotic-free
conditions. Ancestral strain per gyrA mutant is indicated in the gray bar above each panel. (B) Asso-
ciation between the relative fitness of specified gyrA mutant and their absolute frequency after the
fluctuation analysis performed in Figure 3.1A and as reported in Figure 3.3A, in three genetic back-
grounds (N0157, N1283, and N0145).
fitness of a given gyrA mutation with its relative frequency in the fluctuation analysis for the N0157
and N1283 strains (Figure 3.5B, P = 0.03 for N0157, P = 0.05 for N1283). There was no evidence
of an association in the N0145 background due to the lack of GyrA G88C and A90V mutants in its
fluctuation analysis.
The results from Figures 3.4 and 3.5, as well as the apparent lack of mutation rate differences
between our strains (Figure 3.2), suggested that differential mutational profiles were an important
contributor in the variation in OFX-R frequency inMtb. These mutational profile differences appear
to be driven by the Mtb genetic background’s effect on both the MIC and the relative fitness cost
of OFX-R mutations. We next explored whether these in vitro results would be relevant in clinical
settings.
3.4.5 Mutational Profile for Fluoroquinolone-resistance In Vitro Reflects Clinical Observations
To explore the clinical relevance of our in vitro work, we surveyed the FQ-R mutational profile
from publicly availableMtb genomes obtained from clinical isolates. FQs are generally used for treat-
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Figure 3.6: Mutational profile for fluoroquinolone-resistance gyrA mutations is lineage-specific in
clinical isolates ofMycobacterium tuberculosis.
An initial data set consisting of 3,450 genomes with confirmed MDR-TB mutations were surveyed.
About 854 genomes were identified as fluoroquinolone-resistant, with 848 of these genomes contain-
ing at least one gyrA mutation. Only fixed fluoroquinolone-resistance mutations in the gyrA gene
are enumerated here (n = 710). No fixed mutations were observed in Lineage 5 strains. Numbers of
genomes analyzed per lineage are presented directly below their respective bar graph.
ment against MDR-TB (WHO, 2018). While it is unclear whether resistance mutations for isoniazid
(INH) and/or rifampicin (RIF) predispose a strain to become FQ-R, the prevalence of FQ-R is heav-
ily biased toward MDR-TB strains due to treatment practices. We therefore based our analyses on a
collated data set of 3,450 publicly available MDR-TB genomes (Castro et al., 2019), which we con-
firmed to be MDR-TB based on the presence of known INH-resistance (INH-R) and RIF-resistance
(RIF-R) mutations. This data set provided a reasonable sampling of the overall genetic diversity of
Mtb, as six of the seven known phylogeneticMtb lineages were represented (Lineages 1–6) (Comas
et al., 2010; Gagneux, 2018). We catalogued their FQ-R mutational profiles, and found 950 FQ-R
mutations in 854 genomes (Tables 7.8 & 7.9, see Supplementary Information), showing that multi-
ple FQ-R mutations may be present in the genome of a singleMtb clinical isolate. The frequency of
FQ-R differed between lineages, with the highest frequencies present in L2 and L4 strains (Table 7.8,
see Supplementary Information; P < 2.20× 10−16, Chi-square Goodness of Fit Test). Moreover, we
noticed a lineage-dependent mutational profile for FQ-R (Figure 3.6, P = 7.10× 10−5, Fisher’s exact
test; Tables 7.9 & 7.10). For example, while the GyrA D94G mutation was most prevalent in strains
belonging to L1, L2, and Lineage 3 (L3), the GyrA A90V mutation was most prevalent in L4 and
Lineage 6 (L6).
We observed that the mutational profile for FQ-R in the fluctuation analysis experiments mim-
icked published clinical data. Firstly, gyrAmutations made up the large majority of FQ-Rmutations
in vitro (Figure 3.3; Tables 7.4& 7.5, see Supplementary Information) and 944 out of the 950QRDR
mutations in the clinic (99.6%; Table 7.9 , see Supplementary Information). We then tested whether
theMtb genetic background had an impact on FQ-R gyrAmutational profiles in the clinic as it did in
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vitro.However, transmission events canmodulate the frequency of FQ-R gyrAmutations in the clinic,
but not in a fluctuation analysis. If each genome from the clinical data is treated as an independent
event, then number of FQ-R gyrA mutation events in the clinic would be overestimated compared
with the number of mutation events in a fluctuation analysis. Therefore, rather than directly compare
the frequency of gyrAmutations from theOFX-Rmutational profile in Figure 3.3 to the absolute fre-
quency of gyrA mutations in the genomic data survey, we instead compared the in vitro frequency of
gyrA mutations in Figure 3.3 to the frequency of mutation events per gyrA mutation in the genomic
data. To do so, we first used differences in the number of single-nucleotide polymorphisms (SNPs) as a
measure of genetic distance between two genomes, then defined transmission clusters within the 3,450
MDR-TB genomes via a conservative cutoff of 12 SNPs average distance (Walker et al., 2013). Each
unique and fixed FQ-R gyrA mutation present per transmission cluster, as well as each fixed FQ-R
gyrAmutations present in nonclustered genomes, were counted as independent mutation events. We
limited our analysis to L2 and L4 strains, as these two lineages had the highest clinical frequencies of
FQR.We observed that the profile for FQ-R gyrAmutation events in L2 strains differed significantly
to L4 strains (Figure 7.5, Table 7.11, see Supplementary Information; P = 0.02, Fisher’s exact test). Fur-
thermore, there was a positive association between the frequency of a given FQ-R gyrA mutation in
our fluctuation analysis compared with the frequency of its mutation event in the clinic for both L2
and L4 strains (Figure 3.7, P = 0.02 for L2, P = 0.04 for L4). Based on the adjusted R2 values, 51%
of the variability in the clinical frequencies of FQ-R gyrA mutation events in L2 strains and 39% of
the variability in L4 strains can be attributed to how FQ-R evolves inMtb in vitro. As the in vitro
evolution of FQ-R is itself modulated by theMtb genetic background, this provided evidence for the
Mtb genetic background’s role in the evolution of FQ-R in the clinic.
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Figure 3.7: Association between the clinical frequency of mutation events of each fluoroquinolone-
resistance (FQ-R) gyrA mutations with their respective in vitro frequencies amongMycobacterium
tuberculosis strains belonging to either the L2 or L4 lineages.
Mutation events per FQ-R gyrAmutationwere enumerated from an initial data set of 3,450 genomes
with confirmedMDR-TBmutations. Each unique and fixed FQ-R gyrAmutation present per trans-
mission cluster (cutoff = 12 SNPs average distance), as well as each fixed FQ-R gyrAmutation present
in nonclustered genomes, were counted as independent mutation events. The in vitro frequencies of
FQ-R gyrA mutations presented here are the same as in Figure 3.3A, grouped by lineage.
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3.5 Discussion
Overall, we illustrate theMtb genetic background’s considerable role in the evolution of resistance
to FQs, a clinically important antimicrobial. We first explored whether the genetic variation among
natural populations ofMtb can influence FQ-R evolution in vitro. Specifically, considering thatMtb
treatment regimens are based on standardized antimicrobial concentrations (WHO, 2018), we tested
whether different genetic variants ofMtbwould acquire FQ-R at the same frequencywhen exposed to
the same concentration of FQ. Fluctuation analysis on nine, genetically distinct, drug-susceptibleMtb
strains showed that the genetic background can have a drastic effect on the rate of OFX-R acquisition
whenusing the same concentration ofOFX (Figure 3.1). Our results provide the first evidence showing
that theMtb genetic background can modulate the frequency of FQ-R acquisition.
However, the effect of the Mtb genetic background on AMR frequencies observed here in the
context of OFX-R differed from those reported in previous work focusing on other antibiotics. Past
literature has focused on the positive association between MDR-TB and L2 Beijing (Borrell et al.,
2009; Fenner et al., 2012; Merker et al., 2015; Eldholm et al., 2016). Initial genetic analysis on a global
collection of strains showed that mutations in DNA repair genes were associated with being MDR-
TB, and that these mutations were specific to L2 Beijing isolates (Rad et al., 2003). The authors thus
hypothesized that L2 Beijing strains may have a hypermutator phenotype, which would lead to higher
rates ofAMRmutations acquisition (Rad et al., 2003). Based on this L2 Beijing hypermutator hypoth-
esis, one would expect that L2 Beijing strains would also show higher frequencies of FQ-R. However,
this was not the case in our fluctuation analysis for OFX-R, as one of our L2 Beijing strains (N0145)
repeatedly acquired the lowest frequency of OFX-R (Figure 3.1). Moreover, we saw minimal, if any,
DNA base-pair mutation rate differences between threeMtb strains (one of which was L2 Beijing)
with different in vitro OFX-R frequencies (Figure 3.2). Our results therefore contradict the L2 Bei-
jing hypermutator hypothesis. Published experimental work have also provided varying results. Initial
fluctuation analyses showed no difference in the frequency of RIF-R in L2 Beijing strains compared
with non-L2 Beijing strains (Werngren et al., 2003). In contrast, a fluctuation analysis performed by
Ford et al. (2013) showed that L2 Beijing strains had higher frequencies of resistance for INH, RIF,
and ethambutol compared with L4 strains, even after correcting for differences in AMRmutational
profiles. Lastly, a more recent fluctuation analysis using the same concentrations of INH or RIF as
Ford et al. showed that while differentMtb strains had different frequencies of INH-R, a L2 Beijing
strain did not have higher frequencies of INH-R nor RIF-R compared with non-L2 Beijing strains
(Carey et al., 2018). Although diverging in their results, these in vitro and genetic studies, togetherwith
the study conducted here, highlight the importance of the genetic background when testing for the
frequency of AMR inMtb. Furthermore, these results show that differential DNAmutation rates is
not the only parameter relevant in determining the frequency of FQ-R inMtb.
If DNAmutation rates do not contribute to the variation in OFX-R frequency, we hypothesized
that differences in the phenotypic effects of OFX-R mutations, and their consequent effect on the
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mutational profiles for OFX-R, may be important contributors. By sequencing the QRDR from re-
sistant colonies in ourOFX fluctuation analysis, we observed strain-specific patterns in themutational
profiles forOFX-R (Figure 3.3). This suggested that themutational profile for FQ-R is not only a func-
tion of the FQ type and concentration (Zhou et al., 2000; Malik et al., 2010; Huseby et al., 2017) but
that epistatic interactions between a given FQ-Rmutation and the genetic background may also play
a role. Similar epistasis between the phenotype of a given AMRmutation and the genetic background
have been observed in other bacteria. For example, a given RIF-R rpoBmutation can confer differen-
tial MIC and fitness costs depending on the genetic background it occurred in, or on the presence of
other AMRmutations, in Escherichia coli (Angst et al., 2013), Pseudomonas spp. (Vogwill et al., 2014;
Vogwill et al., 2016),Mycobacterium smegmatis (Borrell et al., 2013), andMtb (Gagneux et al., 2006c;
Zaczek et al., 2009). In line with these previous studies, we found that the OFXMIC and the fitness
effect conferred by a given gyrA mutation varied significantly depending on the Mtb genetic back-
ground they occur in (Figures 3.4 and 3.5A; Tables 7.6 & 7.7, see Supplementary Information). These
results suggest that epistasis plays a role in determining the strain-dependent OFX-R frequencies and
mutational profiles observed during our fluctuation analyses (Figures 3.3 and 3.5B).
The epistasis between theMtb genetic background and FQ-Rmutations may have clinical conse-
quences. A recent study has shown that drug-susceptibleMtb strains with higher MICs to INH and
RIF were associated with increased risk of relapse following first-line treatment (Colangeli et al., 2018).
FQ-R gyrA mutations that confer higher MICs, such as any gyrA mutation in codon D94 except for
D94A, have also been associatedwith poorer treatment outcomes inMDR-TBpatients (Rigouts et al.,
2016; Farhat et al., 2017). Considering our observation that theMtb genetic background affected both
the OFXMICs and OFX-R mutational profiles (Figures 3.3 and 3.4; Tables 7.4, 7.5, & 7.6, see Sup-
plementary Information), the genetic background may therefore contribute to differences in patient
treatment outcomes when using FQs as first-line drugs.
Using publicly available genomic data fromMtb clinical isolates, we observed significant lineage-
dependent variation in the frequency of and mutational profiles for FQ-R (Figure 3.6). As expected,
the vast majority of FQ-R mutations were observed in gyrA (Tables 7.9 & 7.10, see Supplementary
Information) (Takiff et al., 1994; Zhou et al., 2000; Piton et al., 2010; Maruri et al., 2012; Aldred et al.,
2016; Blower et al., 2016; Wollenberg et al., 2017). FQ-R was also most frequent in L2 and L4. This
was also as expected, as strains from the L2 Beijing sublineage are known to associate withMDR-TB
(Borrell et al., 2009; Fenner et al., 2012; Merker et al., 2015; Wollenberg et al., 2017), while L4 strains
are themost prevalent globally, including in regions classified as high burden forTB (Stucki et al., 2016;
WHO, 2018; Brynildsrud et al., 2018; Gagneux, 2018). Consequently, strains from L2 and L4 would
be more exposed to FQs, leading to the higher FQ-R frequencies observed in these two lineages. Fur-
thermore, we observed that more than half of the variability in the clinical frequency of FQ-R gyrA
mutation events in L2 strains can be explained by howMtb evolves in vitro (Figure 3.7). However,
the in vitro FQ-R evolution could only account for 39% of the variability for the frequency of FQ-R
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gyrAmutation events in clinical L4 strains. This suggested that while theMtb genetic background can
influence the evolution of FQ-R in the clinic, other factors (which may be independent of theMtb ge-
netic background) likely played strong roles as well. Epidemiological factors including socioeconomic
disruptions, health system inefficiencies, and human behavior are well known risk factors for the emer-
gence and transmission of AMR inMtb (Dalton et al., 2012; Merker et al., 2015; Alvarez-Uria et al.,
2016; Eldholm et al., 2016; Shah et al., 2017). Meanwhile, biological factors not explored in this study,
such as antibiotic type and concentration (Zhou et al., 2000; Ford et al., 2013; Lindsey et al., 2013;
McGrath et al., 2014;Mustaev et al., 2014;Malik et al., 2016), pharmacodynamic and pharmacokinetic
features (Pienaar et al., 2017; Sarathy et al., 2018), and the selective pressure of the host immune system
(Handel et al., 2009), may also influence the evolution of FQ-R.
Howthe geneticbackgroundmodulates FQ-Revolution in the clinicmayalsodifferbetweendiffer-
entbacterial pathogens. In contrast toMtbwhereDNAgyrase is the sole target forFQs,Gram-negative
bacteria such as E. coli and Salmonella have two targets for FQs: DNA gyrase and topoisomerase IV
(Hooper, 1999). In E. coli, the evolutionary trajectory toward high-level FQ-R generally involves the
stepwise acquisition of FQ-R mutations in either DNA gyrase or topoisomerase IV (Huseby et al.,
2017). Therefore, the genetic background of Gram-negative bacteria maymodulate the phenotypes of
FQ-Rmutations not only inDNAgyrase but in topoisomerase IV as well. Nevertheless, a recent study
has shown that a common FQ-R mutation in Gram-negative bacteria, GyrA S83L, confers different
phenotypes depending on whether it is present in E. coli or in Salmonella (Apjok et al., 2019). This
suggests that the genetic background of Gram-negative bacteria may affect the evolution of FQ-R in
the clinic. This type of epistasis is also not restricted to bacteria. The genetic background modulated
the phenotypes of AMRmutations in the protozoan parasite Leishmania donovani (Decuypere et al.,
2012), and the phenotypes of mutations in yeast when exposed to different environments, including
antimicrobial exposure (Mullis et al., 2018). Thus, while the mode of epistasis between the genetic
background and the phenotypes of mutations may differ in different organisms and environments,
published work and the results of our study provide compelling evidence that this epistasis is a major
factor in the evolution of AMR in both prokaryotic and eukaryotic organisms.
Our study is limited by the fact that our survey of clinical FQ-R frequencies involved a genomic
data set that was sampled by convenience. This data set was used due to its public availability, andmay
not be fully representative of FQ-R frequencies inMtb populations. We noted that lineage-specific
frequencies of FQ-R were likely biased due to the overrepresentation L2 and L4 strains. Thus, to
acquire a better understanding on which FQ-R mutations appeared and at what frequency they oc-
curred at in differentMtb lineages, eithermore genomes from clinical isolates from otherMtb lineages
must bemade available, or a population-based studymust be undertaken, preferably in a high-burden
MDR-TB region.
Exposure to quinolones have been shown to lead to SOS response-mediated mutagenesis, which
can increase the rate of AMR acquisition, including resistance to quinolones themselves (Cirz et al.,
33
2005;Malik et al., 2010; Frenoy et al., 2018). Therefore, the strain-dependentOFX-R acquisition rates
Figure 3.1 may be due to strain-dependent differences in the magnitude of quinolone-induced mu-
tagenesis. We did not explicitly test for this possibility. However, phylogenetic SNPs present in SOS
response-related genes may lead to strain-dependent differences in quinolone-induced mutagenesis,
andwe observed no such SNPs present across our panel of drug-susceptibleMtb strains (Table 7.2, see
Supplementary Information) (Borrell et al., 2019). Thus, we observed no genetic evidence for strain
specific SOS response-mediated mutagenesis. Furthermore, in E. coli, quinolone-induced quinolone-
resistant mutations may only be observed after 5 days of incubation with quinolones, which is equiva-
lent to >220 generations for wild-type E. coli (Cirz et al., 2005; Fujikawa et al., 2005). Meanwhile, our
wild-typeMtb strains were incubated for 40 generations atmost in the presence ofOFX (seeMethods;
Table 7.7, see Supplementary Information),making the likelihood of observingOFX-inducedOFX-R
mutants in our in vitro system extremely low.
Another limitation of our study is that fluctuation analyses only model AMR emergence. Long-
term population dynamics also play an important role in AMR evolution (Wiesch et al., 2011; Lindsey
et al., 2013; Huseby et al., 2017). For example, population bottleneck eventsmodulate AMRevolution
during serial transfer experiments (Comas et al., 2012; Barrick et al., 2013; Vogwill et al., 2016;Huseby et
al., 2017), andhave also been hypothesized to strongly influenceMtb evolution in the clinic (Hershberg
et al.,2008). Thus,modelingFQRevolution inMtb in epidemiological settingswouldbenefit from the
use of somemeasure of long-term population dynamics and between-host transmission. Nevertheless,
the fitness of AMRmutants is an important factor in determining its evolutionary fate (Wiesch et al.,
2011; Angst et al., 2013; Barrick et al., 2013; Lindsey et al., 2013;Hughes et al., 2017;Huseby et al., 2017)
and its potential for between-host transmission (Comas et al., 2012; Vos et al., 2013). Considering that
theMtb genetic background modulated the fitness effect of FQ-R mutations (Figure 3.5; Table 7.7,
see Supplementary Information), the genetic background may modulate how likely FQ-R mutants
transmit between patients.
In conclusion, we illustrate how the genetic variation present in natural populations ofMtbmod-
ulates FQ-R evolution. Considering the nonrandom geographic distribution of differentMtb genetic
variants (Comas et al., 2010; Gagneux, 2018), our work suggests that there may be regional differences
in the rate of FQ-R emergence and FQ-R prevalence when using FQs as a first-line drug.We therefore
highlight the importance of standing genetic variation in determining how FQ-R evolves inMtb and,
in general, how AMR evolves in pathogens.
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4.1 Abstract
Fluoroquinolones (FQs) are being tested in new experimental treatment regimens against
Mycobacterium tuberculosis (Mtb) infections. In vitro work has shown that the frequency of
fluoroquinolone-resistance (FQ-R) emergence inMtb is dependent on bacterial genetics. Further in
vitro assays suggests that the differences in FQ-R frequencies is not due toMtb strain-dependent mu-
tation rates, but likely due to strain-dependent mutational target sizes for FQ-R and strain-dependent
fitness effects of FQ-R mutations. To test the contribution of strain-dependent FQ-R mutational
target sizes and FQ-R mutation fitness effects, we adapted the stochastic, time-step model of drug-
resistance evolution developed by Ford et al. (2013) to include these parameters. We observed that
the use experimentally-measured or inferred strain-dependent values for FQ-Rmutational target sizes
and FQ-R mutation fitness effects, coupled with the use of the same mutation rate value for every
strain, were insufficient to simulate theMtb strain-dependent FQ-R frequencies. Sensitivity analysis
showed that while varying the FQ-Rmutational target size can modulate FQ-R frequencies in silico,
varying the mutation rate had the greatest effect. Considering minimal mutation rate differences were
observed in vitro, we conclude that other, yet-to-be-identified biological factors that are not included
in our model may play a role determining FQ-R frequencies in vitro. Similarly, we show that new
models are required to accurately simulate theMtb strain-dependent FQ-R frequencies.
4.2 Introduction
Drug resistance (DR) in pathogens presents both a formidable risk for treatment failure in patients,
and an economic burden to patients and health care systems (Laxminarayan et al., 2013; Alvarez-Uria
et al., 2016). Multiple socioeconomic and behavioural factors modulate the prevalence of DR (Dalton
et al., 2012; Laxminarayan et al., 2013; Eldholm et al., 2016; Alvarez-Uria et al., 2016; Shah et al., 2017).
However, the emergence ofDR is ultimately an evolutionaryprocess,where an environmental pressure
(i.e. the antibiotics) selects for a preexisting phenotype in a given population (i.e. the DR phenotype)
(Luria et al., 1943; Hughes et al., 2017). StudyingDR evolutionmay allow for the development of new
strategies that suppress the prevalence ofDR in the clinic, potentially saving patient lives and reducing
burdens on health care systems.
Previous work suggest that the emergence ofDR in pathogens is dependent onmultiple biological
factors (Wiesch et al., 2011; Hughes et al., 2017). Firstly, DNA mutations are the ultimate source for
variation in a population (Luria et al., 1943; Wiesch et al., 2011). Pathogen strains with higher DNA
mutation rates have a higher likelihood of acquiringDRmutations, and have also been associatedwith
higher DR prevalence in the clinic (Oliver et al., 2000; Giraud et al., 2001; Gould et al., 2007; Couce
et al., 2016). The emergence of DR may also be dependent on the number of potential mutations
that can confer DR (hereafter referred to as the mutational target size for DR); pathogens with larger
mutational target sizes are hypothesized to associate with higher DR prevalence (Ford et al., 2013; Vog-
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will et al., 2014; Hughes et al., 2017). The fitness effects of the DRmutations may also modulate the
frequency of DR (Gagneux et al., 2006c; Hughes et al., 2017). Mathematical modeling and molecu-
lar epidemiological studies have shown that DR mutations with low or no fitness costs are generally
the most prevalent in the clinic (Cohen et al., 2004; Gagneux et al., 2006c; Huseby et al., 2017; Cas-
tro et al., 2019). Understanding how these biological factors modulate the rate of DR emergence in
pathogens may provide insights into new treatment strategies that could suppress DR emergence and,
consequently, restrict DR prevalence.
Pathogen populations comprise genetically distinct strains, and this standing genetic variation has
been shown to modulate DR evolution (Gagneux et al., 2006c; Decuypere et al., 2012; Fenner et al.,
2012; Apjok et al., 2019; Castro et al., 2019). Of particular note is the impact of pathogen genetics in the
evolution of DR inMycobacterium tuberculosis (Mtb), the aetiological agent of human tuberculosis
(TB).Mtb caused the highest number of deaths due to a pathogen in 2018 (WHO, 2019a), and was re-
sponsible for nearly 200,000 out of the approximately 700,000 deaths due to a drug-resistant pathogen
infection in 2016 (O’Neill, 2016). While the genetic diversity inMtb is relatively small compared to
other bacterial pathogens, this limited genetic diversity has substantial consequences onDR evolution
(Comas et al., 2010; Gagneux, 2018). For instance,Mtb strains belonging to the Lineage 2 (L2) "Bei-
jing" genetic family has repeatedly been associated with multidrug-resistance in the clinic (defined as
a patient infected with anMtb strain that is resistant to at least the two most potent first-line drugs,
isoniazid and rifampicin) (Borrell et al., 2009; Casali et al., 2014; Merker et al., 2015; Wollenberg et al.,
2017). Publishedmolecular epidemiological and in vitro studies suggest that L2 strains may have a "hy-
permutator" phenotype, which allows for a higher rate of acquiring DRmutations and, consequently,
higher DR prevalence (Rad et al., 2003; Ford et al., 2013). However, this hypothesis is disputed, as
other published in vitro studies have shown that L2 strains do not acquire DR mutations at higher
frequencies (Werngren et al., 2003; Carey et al., 2018). Lastly, bacterial genetics may also affect the fre-
quency of DR emergence inMtb by modulating the mutational target sizes for DR (Gagneux et al.,
2006a; Fenner et al., 2012; Ford et al., 2013), and the phenotypic effects of DR mutations (Gagneux
et al., 2006c; Zaczek et al., 2009).
In our previous work, we demonstrated that bacterial genetics can modulate the frequency of
FQ-R emergence in Mtb (Figure 3.1, ) (Castro et al., 2019). Specifically, our in vitro results showed
minimal mutation rate differences between the differentMtb strains tested (Figure 3.2), and suggests
that themutational profiles for FQ-Rwas themain contributor in leading to the strain-dependent FQ-
R frequencies (Figure 3.3). The differences in mutational profiles for FQ-R were driven by theMtb
genetic background’s effect on both the mutational target size for FQ-R (Figures 3.3 and 3.4), and the
fitness effect of FQ-R mutations (Figure 3.5). However, the relative contribution of each parameter
in determining the frequency of FQ-R is unclear.
Mathematical models have been used understand or test the relative contributions of biological
factors inDRevolution (Spicknall et al.,2013; Blanquart,2019). For example, theoreticalmodels ofDR
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evolution have been used to test the role of different drug treatment strategies (Bonhoeffer et al., 1997),
the role of competition between the drug-susceptible (DS) and DR populations (Cohen et al., 2004;
Hansen et al., 2017; Khan et al., 2018), the role of the immune system (Handel et al., 2009), the role
of treatment with sub-inhibitory drug concentrations (Frenoy et al., 2018), and the role of tolerance
and persistence phenotypes (Levin-Reisman et al., 2017). For this chapter, we adapted a mathematical
model designed by Ford et al. (Ford et al., 2013) to test whether the observedMtb strain-dependent
FQ-Rmutational target sizes and mutation fitness effects would be sufficient in simulating the strain-
dependent FQ-R frequencies in vitro (Figure 3.1) (Castro et al., 2019). Further, we tested whether
changes to the mutation rate, the mutational target size, or the fitness effects of mutations would lead
to the greatest variation in FQ-R frequencies.
4.3 Methods
4.3.1 Model for the Frequency of Fluoroquinolone-resistance inM. tuberculosis
We adapted the stochastic, time-stepmodel for the evolution of drug-resistance developed by Ford
et al. (2013). Our model included the processes of births, deaths, mutation, and the fitness effect from
being amutant, as designed by Ford et al.We then extended themodel to includemultiple types ofmu-
tations that are possible for a drug-susceptible cell tomutate into.We usedSit to represent the number
of drug-susceptible bacteria for genetic background i, where i is one ofN0157,N1283, orN0145, and t
represents the time-step. Each time-step twas equivalent to 1 hour. The birth rate b represents the rate
that new bacteria are added to the population due to cell division per time-step t, while the death rate
d represents the rate that bacteria are removed from the population per time-step t due to some form
of environmental stress. The parametermijt represented the number of bacteria transitioning from
the drug-susceptible Sit population to the respective drug-resistant Rijt population, where j repre-
sents the gyrAmutation that the drug-resistant mutant acquired. The gyrAmutation j can be one of
nine potential FQ-R-conferring gyrA mutations observed in the mutational profile assay following a
fluctuation analysis of nineMtb strains on 4 µg/ml of the FQ ofloxacin (Figures 3.1 & 3.3; Tables 7.4
& 7.5, see Supplementary Information): G88C, A90V, S91P, D94A, D94G, D94H, D94N, D94Y, or
nm (i.e. non-gyrA mutant, but FQ-R) (Castro et al., 2019). The number of drug-susceptible bacteria
at time-step t, Sit, is calculated by taking the number of drug-susceptible bacteria at time-step t − 1,
S(it−1), adding new bateria from cell division of drug-susceptible bacteria produced that did not die,
S(it−1)× (b−d), and subtracting the sum of the new gyrAmutants,∑Jj=1mijt, so thatSit is defined
as in Equation (1):
Sit = S(it−1) + (Sit−1 × (b− d))−
∑J
j=1mijt. (1)
The mutation rate µi was defined as the probability of a drug-susceptible Si cell mutating into
a drug-resistant Rij cell. As in Ford et al. (2013), we set the number of new mutants at time-step t,
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mijt, to follow a Poisson distribution around µi multiplied by the drug-susceptible Si population at
time-step t− 1, so thatmijt is defined as in Equation (2):
mijt ∼ Poisson(µi × Sit−1) (2)
The fitness effect of gyrA mutation j when present in genetic background i is represented by cij .
A value of 0 for fitness effect cij meant that the growth rate of themutantwas equivalent to the growth
rate of its drug-susceptible ancestor. Fitness effect cij values above 0 meant that the j mutation was
costly, while values below 0meant that the j mutation conferred a fitness advantage over wild-type.
The number of drug-resistant bacteria with genetic background i and gyrA mutation j at time-
step t,Rijt, was given by the number of drug-resistant bacteria at time-step t− 1,Rijt−1, adding new
bacteria from cell-division of drug-resistant cells that did not die,Rijt−1(b(1− cij)− d), and adding
the new gyrA mutants produced at time-step t,mijt, so thatRijt−1 is defined as in Equation (3):
Rijt = Rijt−1 + (Rijt−1(b(1− cij)− d)) +mijt (3)
Each simulation aimed to simulate the results of an in vitro fluctuation analysis. Thus, every simu-
lationwas run 100 times,with each simulation run treated as one parallel culturewithin an in silico fluc-
tuation analysis experiment. At the beginning of every simulation run, the number of drug-susceptible
bacteria at time-step 0, Si0, was initially set to a population size of 10. Each simulation ran up to time-
step t = 500. For every simulation run, we determined the time-step that the total population size
(i.e. total sum of Sit and Rijt) was closest to, but did not exceed 109, which we designated as time-
step t = T . This was an arbitrarily chosen target population size, but a similar value to the bacterial
population size that we incubated our in vitro fluctuation analysis cultures to prior to selecting on 4
µg/ml of the FQ ofloxacin (Figure 3.1, see Chapter 3) (Castro et al., 2019). We then calculated the total
population size of all drug-resistant mutants at the target population size (t = T ) per simulation run,
as in the Equation (4):
∑J
j=1Rijt=T (4)
TheMa,Sarkar,Sandri-MaximumLikelihoodEstimatormethod (MSS-MLE)wasused to estimate
the most likely number of mutations per culture,m, from the distribution of the number of drug-
resistant mutants across the 100 simulation runs, rdist, at the time-step t = T (Rosche et al., 2000).
The frequency of drug-resistance per cell per strain, F was then calculated by dividing the calculated
m values by the total population size (i.e. total sum of Sit and Rijt) at time-step t = T . Significant
differences in the frequency of drug-resistance per cell per strain,F , between any two given simulations
were defined by non-overlapping 95% confidence intervals (Rosche et al., 2000; Carey et al., 2018). All
simulations were performed using the R statistical software (R Core Team, 2018).
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4.3.2 Simulation: In silico Frequency of Fluoroquinolone-resistance inM. tuberculosis
For the first set of simulations, we testedwhether we could recapitulate the differential in vitro FQ-
R frequencies between the N0157, N1283, and N0145 genetic backgrounds (Figure 3.1, see Chapter
3) using parameter values that were either confirmed or could be inferred from experimental results.
These parameter values are listed in Table 4.1. Specifically, we set birth rate b to have a default value of
0.053 for all genetic backgrounds, as this was the average growth rate of the drug-susceptible wild-type
strains across the threeMtb strains tested in our previous in vitro cell growth assays (N0157, N1283,
and N0145), in units of log2(OD600)/hour (Figure 3.5, see Chapter 3; Table 7.7, see Supplementary
Information) (Castro et al., 2019). Meanwhile, the death rate d was set to 0 by default, as we were
simulating the frequencyofdrug-resistantmutants in the absence of environmental stress. Considering
that we previously observed no hypermutator phenotypes in the N0157, N1283, and N0145 strains
(Figure 3.2, see Chapter 3) (Castro et al., 2019), themutation rate parameterµiwas set to 4.52× 10−10
by default; this value was the measured number of mutations per base-pair per generation produced
by wild-type Mtb DNA polymerase DnaE1 in a mutation accumulation assay performed by Rock
et al. (2015). In the absence of stress, chromosomal mutational events generally occur during DNA
replication events and, consequently, should only happen with every cell division event rather than at
every hour. Thus, mutation rate µi was corrected for by dividing it by the generation time of drug-
susceptible Si. Considering that the birth rate b was equivalent to the log2(OD600)/hour of drug-
susceptible Si, the generation time of drug-susceptible Si was equivalent to 1/b.
Table 4.1: Parameter values used for simulating the frequency of fluoroquinolone-resistance in the
N0157, N1283, and N0145 strains
Parameter N0157 simulation N1283 simulation N0145 simulation
b 0.053 0.053 0.053
d 0 0 0
µ 4.52× 10−10 4.52× 10−10 4.52× 10−10
cG88C 0.156 0.311 1
cA90V -0.156 0.115 1
cS91P 1 0.311 1
cD94A 1 1 1
cD94G 0.0222 -0.0164 0.0566
cD94H 0.156 0.295 1
cD94N 0.0667 0.148 0.0377
cD94Y 0.156 0.148 1
cnm 0.156 1 1
The fitness effect cij was mutation- and genetic background-specific, and set based on measured
values in our previous in vitro cell growth assays (Figure 3.5, see Chapter 3; Table 7.7, see Supplemen-
taryMaterial) (Castro et al., 2019). In cases where no cell growth assay measurements were present, we
inferred the cost of the mutation based on its relative frequency in the mutational profile assay follow-
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ing a fluctuation analysis of nineMtb strains on 4 µg/ml of ofloxacin (Figures 3.1 & 3.3, see Chapter 3;
Tables 7.4 & 7.5, see Supplementary Information) (Castro et al., 2019). For example, while no growth
rate measurements were available for the GyrA D94H mutation when present in the N0157 genetic
background, it was found in the same frequency as the G88Cmutation in themutational profile assay;
therefore, the cij parameter value for GyrA D94Hwas set to be equivalent to the GyrA G88Cmuta-
tion when present in the N0157. Another example is GyrA S91P mutation, which was not present in
the mutational profile assay for N0157; thus its fitness effect cij value was set to 1.00 (fully lethal) for
the N0157 simulations.
4.3.3 Simulation: Sensitivity Analysis
We performed a sensitivity analysis of ourmodel to test whether themutation rate, themutational
target size for FQ-R, or the fitness effects of FQ-R mutations would have the greatest impact on the
in silico frequency of FQ-R. To do so, we ran different sets of simulations where we let one param-
eter’s value vary while keeping the other two parameters’ values fixed. We ran an initial simulation
(designated as simulation SA.1) to compare the other test simulations against. The SA.1 simulation
used a default set of parameter values, with a mutation rate µi value of 4.52× 10−10. We set the de-
fault mutational target size to equal 8 mutations in SA.1 by setting the "nm" mutation to be lethal
(cnm = 1.00). This was done so that the values set for each parameter can be made different from
their SA.1 value by amultiplicative of 2 in subsequent simulations. Each of the 8 FQ-Rmutations that
are possible in SA.1 had their fitness cost set at 5% (cij = 0.05). To test the impact of mutation rates
on the frequency of FQ-R in silico, we ran two simulations where the mutation rate value was equal
to either one-half (designated as SA.2) or one-quarter (SA.3) of the mutation rate value in SA.1. We
next tested the impact of fitness costs in a similar manner by running two simulations that had double
(SA.4) or quadruple (SA.5) the fitness cost values for each of 8 potential FQ-Rmutations compared to
their SA.1 values. Finally, we tested the impact of mutational target sizes using two simulations where
the mutational target size was reduced to 4 (SA.6) or to 2 (SA.7). The parameter values for all seven
Sensitivity Analysis simulations are presented in Table 4.2.
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Table 4.2: Parameter values used for the sensitivity analysis of the model for the emergence of fluoroquinolone-resistance
Param. SA.1 SA.2 SA.3 SA.4 SA.5 SA.6 SA.7
b 0.053 0.053 0.053 0.053 0.053 0.053 0.053
d 0 0 0 0 0 0 0
µ 4.52× 10−10 2.26× 10−10 1.13× 10−10 4.52× 10−10 4.52× 10−10 4.52× 10−10 4.52× 10−10
cG88C 0.05 0.05 0.05 0.10 0.20 1 1
cA90V 0.05 0.05 0.05 0.10 0.20 0.05 0.05
cS91P 0.05 0.05 0.05 0.10 0.20 1 1
cD94A 0.05 0.05 0.05 0.10 0.20 1 1
cD94G 0.05 0.05 0.05 0.10 0.20 0.05 0.05
cD94H 0.05 0.05 0.05 0.10 0.20 1 1
cD94N 0.05 0.05 0.05 0.10 0.20 0.05 1
cD94Y 0.05 0.05 0.05 0.10 0.20 0.05 1
cnm 1 1 1 1 1 1 142
4.3.4 Simulation: Simulating theM. tuberculosis strain-specific Differences in the Frequency of
Fluoroquinolone-resistance In Vitro
To simulate theMtb strain-specific differences in the frequency of FQ-R in vitro,we again used the
fitness costs andmutational target size values for FQ-R that were either confirmed or could be inferred
fromexperimental results (Figures 3.3&3.5, seeChapter3; Tables 7.4,7.5,&7.7, see Supplementary In-
formation) (Castro et al., 2019). Thus, the fitness effects of FQ-Rmutations cij were identical to those
used in the set of simulations simulating the frequency of FQ-resistancewhenusing the samemutation
rateµi value of 4.52× 10−10 for theN0157,N1283, andN0145 strains (Table 4.1). However, for these
sets of simulations, themutation rateµi wasmade variable for each simulation and for every strain. All
parameters used are listed in Table 4.3. Specifically, for the N0157 simulations, 100 different mutation
rate µi values were tested. These ranged from aminimum value of 3.55× 10−10 to a maximum value
of 3.55× 10−8, and all values were equidistant from each other in magnitude. For the N1283 simu-
lations, the mutation rate µi values tested ranged from 1.98× 10−11 to 1.98× 10−9, while for the
N0145 simulations, the mutation rate µi values ranged from 1.53× 10−12 to 1.53× 10−10. These
mutation rate µi value ranges were chosen as they produced a range of values for the frequency of
FQ-Rmutations per cell (as calculated byMSS-MLE) that were similar to what was observed in the in
vitro fluctuation analysis on 4µg/ml ofloxacin (Figure 3.1, see Chapter 3) (Castro et al., 2019). For each
Mtb strain, we defined the model’s estimate of the strain’s mutation rate as the initial mutation rate µi
value set in a simulation that resulted in a frequency of FQ-Rmutations per cell,F , that was closest to
the in vitro fluctuation analysis on 4 µg/ml ofloxacin (Figure 3.1, see Chapter 3) (Castro et al., 2019).
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Table 4.3: Parameter values used to simulate the strain-specific differences in the frequency of
fluoroquinolone-resistance in vitro
Parameter N0157 simulation N1283 simulation N0145 simulation
b 0.053 0.053 0.053
d 0 0 0
µmin 3.55× 10−10 1.98× 10−11 1.53× 10−12
...
...
...
...
µmax 3.55× 10−8 1.98× 10−9 1.53× 10−10
cG88C 0.156 0.311 1
cA90V -0.156 0.115 1
cS91P 1 0.311 1
cD94A 1 1 1
cD94G 0.0222 -0.0164 0.0566
cD94H 0.156 0.295 1
cD94N 0.0667 0.148 0.0377
cD94Y 0.156 0.148 1
cnm 0.156 1 1
There are 98 µi values between µmin and µmax, with each value equidistant in magnitude from each other, from
µmin, and from µmax.
4.4 Results
4.4.1 In silico Frequency of Fluoroquinolone-resistance inM. tuberculosis
Based on our previous experimental data (Castro et al., 2019), the mutational target size for FQ-R
and the fitness effects of FQ-Rmutationsmay play a role in determining FQ-R frequencies inMtb. To
explore their relative contributions,we adapted the stochastic time-stepmodel on the evolution ofDR
developed by Ford et al. (2013) to simulate the frequency of FQ-R inMtb. As in Ford et al., ourmodel
included the processes of births, deaths, mutation, and the fitness effect from being a drug-resistant
mutant (Figure 4.1). However, we extended the model so that a drug-susceptible cell can mutate and
become an FQ-Rmutant with one of the nine possible mutations observed in the mutational profile
assay following a fluctuation analysis on 4 µg/ml of OFX (Figures 3.1 & 3.3, see Chapter 3; Tables
7.4 & 7.5, see Supplementary Information) (Castro et al., 2019). We used this model to simulate the
population dynamics of an in vitro fluctuation analysis for FQ-R for three strains with differential
FQ-R frequencies in vitro: N0157 (high FQ-R frequency), N1283 (mid-FQ-R frequency), andN0145
(low FQ-R frequency). We used experimentally-determined values for the FQ-R mutational target
sizes and fitness costs for eachMtb strain when we had the relevant measurement, and inferred pa-
rameter values if they were missing (see Methods). These simulation values are presented in Table
4.1. We expected that the strain-dependent variation in both the mutational target sizes and relative
fitness costs for FQ-R would be sufficient to simulate the strain-dependent in vitro FQ-R frequencies
variation (Figure 3.1, see Chapter 3) (Castro et al., 2019). However, this was not the case (Figure 4.2;
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Table 4.4). We observed that the frequency of FQ-R acquired per cell (F ) for the N0157 simulation
(designated as N0157_S) was one order of magnitude lower than what was observed following the in
vitro fluctuation analysis (designated as N0157_F) (FN0157_S = 3.26× 10−9, 95% CIs [2.74× 10−9,
3.81× 10−9]; FN0157_F = 3.55× 10−8, 95% CIs [2.75× 10−8, 4.42× 10−8]). Conversely, the sim-
ulation for N0145 (N0145_S) produced an F value that was one order of magnitude higher than
what was observed in the in vitro fluctuation analysis (N0145_F) (FN0145_S = 2.41× 10−9, 95% CIs
[1.99× 10−9,2.86× 10−9];FN0145_F = 1.53× 10−10, 95%CIs [5.44× 10−11,2.85× 10−10]). The
N1283 simulation (N1283_S) was the only simulation that provided an F value that did not differ sig-
nificantly from the observed in vitro value (N1283_F) based on their overlapping 95% confidence in-
tervals (FN1283_S = 3.02× 10−9, 95% CIs [2.53× 10−9, 3.55× 10−9]; FN1283_F = 1.98× 10−9, 95%
CIs [1.35× 10−9, 2.70× 10−9]). Thus, our results suggests that the mutational target size and the
fitness costs for FQ-R do not have large contributions in determining the frequency of FQ-R inMtb
in our in silicomodel. We tested this hypothesis in the next section.
Table 4.4: Frequency of fluoroquinolone-resistance per cell following an in vitro fluctuation analysis
at 4 µg/ml of the FQ ofloxacin and an in silico simulation
Strain Experiment F F :Lower 95% CI
F :
Upper 95% CI
Mean Population
Size
N0157 N0157_F 3.55× 10−8 2.75× 10−8 4.42× 10−8 2.00× 108
N0157 N0157_S 3.26× 10−9 2.74× 10−9 3.81× 10−9 1.05× 109
N1283 N1283_F 1.98× 10−9 1.35× 10−9 2.70× 10−9 1.10× 109
N1283 N1283_S 3.02× 10−9 2.53× 10−9 3.55× 10−9 1.02× 109
N0145 N0145_F 1.53× 10−10 5.44× 10−11 2.85× 10−10 9.57× 108
N0145 N0145_S 2.41× 10−9 1.99× 10−9 2.86× 10−9 1.02× 109
Frequency of fluoroquinolone-resistance (F ) per cell was reported for three M. tuberculosis strains (N0157,
N1283, andN0145) following in vitro fluctuation analysis at 4 µg/ml of ofloxacin (denoted by the suffix "_F" in
the Experiment column) or following the in silico simulation (denoted by the suffix "_S").
4.4.2 Sensitivity Analysis
Using a sensitivity analysis experiment, we tested whether the bacterial mutation rate, the muta-
tional target size for FQ-R, or the fitness effects of FQ-R mutations had the greatest effect on the
frequency of FQ-R in silico. An initial simulation was run (designated as simulation SA.1), where a
mutation rate µi value of 4.52× 10−10 was used (as measured by Rock et al., 2015) with a mutational
target size of 8 mutations. All 8 potential mutations had fitness costs of 5% (i.e. cij = 0.05). Using
these parameters, we observed that the frequency of FQ-R acquired per cell for SA.1, FSA.1, was equal
to 3.68× 10−9 (95% CIs [3.12× 10−9, 4.28× 10−9]) (Figure 4.3; Table 4.5). When we simulated
different input mutation rate µi values, we observed that dividing the mutation rate µi value from
SA.1 by 2 (SA.2) or by 4 (SA.3) both led to a significant decreases in the observed frequency of FQ-R
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Figure 4.1: Visualization of the stochastic model for the frequency of fluoroquinolone-resistance.
A. The structure of the model. The population size of drug-susceptible and drug-resistant bacteria at
time-step t are represented by Sit andRijt, respectively. Total population sizeNt is defined by taking
the sum of Sit andRijt. The bacterial birth and death rates per time-step t are represented by b and d,
respectively. The fitness effect of gyrA mutant j is represented by cij , with positive values conferring
a fitness cost and negative values conferring a fitness gain. The mutation rate per time-step t is repre-
sented by µi. So that mutations occur per cell division and not per time-step t, the mutation rate µi
is corrected for dividing it by the generation time of drug-susceptible Si, which is equivalent to 1/b.
B. Population size for sensitive and resistant bacteria across 100 simulation runs testing the frequency
of fluoroquinolone-resistance. The results for N0145 are used as an example. Dashed black line rep-
resents population size of drug-susceptible SN0145 over time. The variability in the SN0145 across 100
simulation runs was negligible, as the population lost due tomijt in Equation (2) was extremely small
compared to the totalSN0145. The variability in the population sizes of each gyrAmutant population
(RN0145,j) across all simulation runs are visualized as coloured polygons, with each colour denoting
a different gyrA mutant j. The upper-bound of the coloured polygons show the highest population
size, while the lower-bound shows the lowest population size, for that given mutant across all simu-
lation runs. The time-point t that the total population size was closest to but did not exceed 1× 109
was identified (Target t = T, in blue dash-dotted line). The total drug-resistant population (RN0145,j)
at target time-point t = T was then determined for each simulation to create rdist. The frequency of
drug-resistance per cell was then calculated from rdist using the MSS-MLE method (Rosche et al.,
2000).
compared to SA.1 (FSA.2 = 2.03× 10−9, 95% CIs [1.66× 10−9, 2.43× 10−9]; FSA.3 = 1.01× 10−8,
95% CIs [7.83× 10−10, 1.26× 10−9]). Conversely, increasing the fitness costs to double (SA.4) or
quadruple (SA.5) the values from SA.1 for every FQ-R mutation had no significant effects on the
frequency of FQ-R compared to SA.1 (FSA.4 = 3.60× 10−9, 95% CIs [3.05× 10−9, 4.19× 10−9];
FSA.5 = 3.74× 10−9, 95% CIs [3.17× 10−9, 4.35× 10−9]). Reducing the mutational target size
from 8 to 4 (SA.6) had no significant effect on FQ-R frequency FQ-R (FSA.6 = 2.88× 10−9, 95%
CIs [2.40× 10−9, 3.38× 10−9]), but further reducing the mutational target size down to 2 (SA.7)
did lead to a significant decrease compared to SA.1 (FSA.7 = 2.50× 10−9, 95% CIs [2.07× 10−9,
2.96× 10−9]). However, the four-fold reduction in the mutational target size (SA.7) led to a smaller
decrease in the frequency of FQ-R than what was observed following a four-fold reduction in the mu-
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Figure 4.2: Frequency of fluoroquinolone-resistance in vitro versus in silico for threeM. tuberculosis
strains.
Top panels: Coloured points represent frequency of fluoroquinolone-resistance per cell per parallel
culture asmeasured by fluctuation analysis at 4µg of ofloxacin (suffixedwith "_F" afterM. tuberculosis
strain names N0157, N1283, and N0145), with darker points representing multiple cultures with the
same frequency. Fluctuation analysis data presented here is identical as in Figure 3.1 (see Chapter 3)
(Castro et al., 2019).Colours denote the lineage that theM. tuberculosis strainbelongs to (L1=pink;L2
= blue; L4 = red). Violin plots show the distribution of the frequency of resistance per cell across 100
simulated cultures (suffixed with "_S"), per genetic background. Grey points represent the estimated
number of mutations per cell across all parallel cultures as calculated by MSS-MLE (Rosche et al.,
2000), while black bars denote the respective 95% confidence intervals. Significant differences in the
frequency of fluoroquinolone-resistance per cell between the in vitro fluctuation analysis data and
their respective simulation counterparts were defined by non-overlapping 95% confidence intervals
(Rosche et al., 2000; Carey et al., 2018). Bottom panels: the percentage of parallel cultures lacking
drug-resistant mutants.
tation rate (SA.3) when compared to SA.1. These results suggest that the mutation rate had a greater
impact on the in silico frequency of FQ-R compared to either the FQ-Rmutational target size or fitness
effects of FQ-Rmutations in our model.
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Figure 4.3: Sensitivity analysis of the model for the frequency of fluoroquinolone-resistance, using
simulation parameters listed in Table 4.5.
Violin plot in white (left-most plot; SA.1) shows the rdist for the simulation using default parameters,
with the diamond representing the frequency of resistance per cell as calculated byMSS-MLE (Rosche
et al., 2000). Violin plots and diamonds coloured in different shades of grey show the rdist for simula-
tions using variablemutation ratesµi (SA.2& SA.3). Violin plots and diamonds in different shades of
purple show simulation results using variable fitness effect parameters cij (SA.4 & SA.5), while plots
in different shades of red show simulations with variable mutational target sizes (SA.6 & SA.7).
Table 4.5: Frequency of fluoroquinolone-resistance per cell per Sensitivity Analysis (SA) simulation.
Simulation F F :Lower 95% CI
F :
Upper 95% CI
SA.1 3.68× 10−9 3.12× 10−9 4.28× 10−9
SA.2 2.03× 10−9 1.66× 10−9 2.43× 10−9
SA.3 1.01× 10−9 7.83× 10−10 1.26× 10−9
SA.4 3.60× 10−9 3.05× 10−9 4.19× 10−9
SA.5 3.74× 10−9 3.17× 10−9 4.35× 10−9
SA.6 2.88× 10−9 2.40× 10−9 3.38× 10−9
SA.7 2.50× 10−9 2.07× 10−9 2.96× 10−9
Parameters for each SA simulation are presented in Table 4.2.
4.4.3 Simulating theM. tuberculosis Strain-specific Differences in the Frequency of
Ofloxacin-resistance In Vitro
We previously showed that we cannot simulate theMtb strain-specific frequency of FQ-R in vitro
while using the same mutation rate µi value per strain (Figure 4.2; Table 4.4). Indeed, our sensitivity
analysis showed that the bacterial mutation rate had the greatest impact on the in silico frequency of
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FQ-R in our model (Figure 4.3; Table 4.5). Therefore, we next aimed to explicitly simulate the strain-
specific frequency of FQ-R in vitro by using differentmutation rateµi values per strain.We again used
the strain-specific fitness costs and mutational target size values for FQ-R that were either confirmed
or could be inferred from experimental results; however, for these set of simulations, themutation rate
µi values were also made variable per simulation per strain. All parameter values are listed in Table 4.3.
We found that in order to simulate the observed differences in the in vitro frequency of FQ-R
between N0157, N1283, and N0145, the input mutation rate µi values per strain had to be different
(Table 4.6). Specifically, the model broadly estimated that the N0157 strain would have to have had
a mutation rate of 4.62× 10−9, the N1283 strain mutation rate would be 2.78× 10−10, while the
N0145 strain mutation rate would be 1.68× 10−11 to simulate their differences in FQ-R frequency
in vitro. The relative difference in the estimatedmutation rates between the differentMtb strains (one
order ofmagnitude difference betweenN0157 andN1283, one order ofmagnitude difference between
N1283 and N0145, and two orders of magnitude difference between N0157 and N0145) mirrored the
relative differences in the frequency of FQ-R mutations per cell in vitro (Figure 3.1, see Chapter 3;
Table 4.4) (Castro et al., 2019).
Therefore, our model suggested that there may be large differences in mutation rates between our
Mtb strains. Alternatively, a yet-to-be identified biological factor or factors may also be contributing
significantly to theMtb strain-dependent variation in FQ-R frequency in vitro.
Table 4.6: Mutation rate estimates for the N0157, N1283, and N0145Mtb strains based on the com-
parison between the simulation for fluoroquinolone-resistance emergence and the in vitro fluctuation
analyses on 4 µg/mL of ofloxacin.
N0157 Simulation N1283 Simulation N0145 Simulation
Model estimate of
mutation rate*
4.62× 10−9 2.78× 10−10 1.68× 10−11
*in number of DNAmutations per cell per generation.
4.5 Discussion
Mathematicalmodels provide a usefulmethod tounderstand the relative contributions ofdifferent
biological factors in DR evolution (Spicknall et al., 2013; Blanquart, 2019). In this Chapter, we used
the stochastic time-stepmodel developed by Ford et al. (2013) to test the roles of the bacterialmutation
rate, themutational target size for FQ-R, and the fitness effects of FQ-Rmutations in determining the
frequency of FQ-R from an initially drug-susceptible population ofMtb. While our previous in vitro
work suggests that the mutational target size for FQ-R and the fitness effects of FQ-Rmutations are
the greatest contributor in determining the strain-dependent frequency of FQ-R inMtb (Castro et al.,
2019), our in silico results suggest that mutation rates play the greatest role. However, our previous
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in vitro results showed little to no strain-dependent variation in mutation rates (Castro et al., 2019).
While we included into our model all biological parameters that are hypothesized to be relevant in
the emergence of drug-resistance mutations in the absence of external stress or competition (Ford et
al., 2013; Hughes et al., 2017), the mismatch between our in silico and in vitro results implies that
important parameters were missing. Three potential parameters are discussed below.
First, the rate of cell death may play a role in the frequency of FQ-R inMtb. An appreciable rate
of cell death has been shown to lead to an overabundance ofmutations under stressful conditions and,
consequently, to an overestimation of mutation rates (Frenoy et al., 2018). If cell death rates did play a
role in our study, thenMtb strainswith higher rates of cell death during our fluctuation analyses would
have higher frequencies of FQ-R. While we did not explicitly measure death rates in our fluctuation
analyses, potential differences in death rates are likely negligible in our in vitro system as we incubated
our cultures under stress-free and nutrient-rich conditions.
Secondly, differences in the rate of acquiring phenotypicmutationsmay influence the frequency of
FQ-R,and is alsonot considered inourmodel. Phenotypicmutations occurduring transcription, trans-
lation, epigenetic modifications, or due to protein promiscuity, ultimately leading to non-heritable er-
rors in protein structure and function (Loftfield et al., 1972; Ozbudak et al., 2002; Payne et al., 2019b).
Phenotypic mutations can lead to differences in antimicrobial tolerance and persistence, which may
potentiate the acquisition of heritableDNAmutations forDR (Javid et al., 2014; Levin-Reisman et al.,
2017;Hicks et al., 2018). Our panel of nineMtb strainsmay have differences in their rate of phenotypic
mutations acquisition, andMtb strains with higher phenotypicmutation rates may have higher FQ-R
frequencies.
Lastly, our model did not include efflux pump expression as a parameter. While the clinical rele-
vance of efflux pump overexpression for FQ-R inMtb has not been established, it has been observed
in vitro (Gygli et al., 2017). Our previous genomic analysis of the nineMtb strains used in the fluctua-
tion analysis at 4 µg/ml ofloxacin showed no mutations in genes that putatively control efflux pump
expression (Castro et al., 2019). However, there may be strain-dependent differences in efflux pump
expressionwhen exposed to FQ, andwe did not test for this possibility. Aswith phenotypicmutations,
up-regulation of efflux pumps expressionmay potentiate the acquisition of heritable DNAmutations
for drug-resistance.
Although our model failed to capture the in vitro frequency of FQ-R in the N0157 and N0145
strains when using the relevant FQ-R parameter values from our previous in vitro work (Castro et al.,
2019), the model accurately simulated the frequency of FQ-R for the N1283 strain. Considering that
approximately half of theMtb strains in our panel had a similar FQ-R frequency as N1283 (Figure 3.1,
See Chapter 3) (Castro et al., 2019), we conclude that our model can simulate the in vitro evolution
of FQ-R for many strains ofMtb. Our results also suggest that more work is required to elucidate all
relevantbiologicalmechanisms that leads to theMtb strain-dependentdifferences in FQ-R frequencies.
Similarly, the design of new DR evolution models forMtb are required.
50
5 Testing the Impact of Fluoroquinolone-resistance on the Genetic
Diversity ofMycobacterium tuberculosis
RhastinA.D. Castro1,2,ChloéLoiseau1,2,LujekoKamwela1,2,MiriamReinhard1,2, Julia Feldmann1,2,
Sonia Borrell1,2, Daniela Brites1,2, Andrej Trauner1,2, and Sebastien Gagneux1,2,∗
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
∗Corresponding Author: E-mail: sebastien.gagneux@swisstph.ch.
This Chapter is a working manuscript.
51
5.1 Abstract
Fluoroquinolones (FQs) are a critical component in experimental treatment regimens against
drug-susceptible tuberculosis (TB), and in current treatment regimens against multidrug-resistant TB
(MDR-TB). Investigating how populations ofMycobacterium tuberculosis (Mtb; the etiological agent
ofTB) evolve underFQpressuremayprovide insights intomaintaining the currentpotency and future
clinical use of FQs. Clinically-relevant FQ-resistance (FQ-R)mutations are restricted to chromosomal
mutations in genes encoding DNA gyrase: gyrA and gyrB. FQ-R mutations may disrupt the DNA
gyrase function of regulating DNA topology, leading to increased DNA damage; this may induce hy-
permutator phenotypes, and increase the adaptive potential ofMtb populations through increased
genetic diversity. Therefore, we tested whether FQ-Rmutations can increase frequencies of acquiring
further drug-resistance mutations. We observed that FQ-R can associate with increased frequencies of
streptomycin-resistance (STR-R) in vitro; this associated increase in STR-R was dependent on both
the FQ-R gyrA mutation present, as well as in whichMtb strain the gyrA mutation was present. We
then testedwhether FQ-Rmutations associatedwith increased genetic diversity in natural populations
ofMtb. Analysis of 2,502 publicly availableMtb genomes isolated from a global sample of MDR-TB
patients, as well as Mtb genomes isolated from 118 serially sampled MDR-TB patients from Geor-
gia, showed no evidence for an association between FQ-R mutations and increased genetic diversity.
We therefore conclude that FQ-Rmutations do not induce stable nor transient hypermutator pheno-
types inMtb. Furthermore, we demonstrate the usefulness of evolutionary studies in predicting how
bacterial populations respond to new treatment regimens.
5.2 Introduction
Tuberculosis (TB) caused themost deaths in humans due to a single infectious agent in 2018, with
an estimated 1.2 million deaths due to TB alone and an additional 0.3 million deaths due to TB-HIV
co-infections (WHO, 2019a). This is despite the availability of antimicrobials that can be used to treat
infections caused byMycobacterium tuberculosis (Mtb), the etiological agent of TB. Two of the most
potent antimicrobials againstMtb, isoniazid (INH) and rifampicin (RIF), are an integral part of first-
line treatment regimen against drug-susceptible strains. However, this first-line treatment regimen
requires taking daily doses for 6 to 9 months. This long-term and substantial treatment regimen can
be a burden to healthcare systems and can have low patient adherence (Munro et al., 2007; Barter et al.,
2012; Alipanah et al., 2018; Ruru et al., 2018). Further compounding the difficulty in TB treatment
is the rise of multidrug-resistant TB (MDR-TB), defined as an infection with an Mtb strain that is
resistant to at least RIF and INH. Treatment for MDR-TB can be 9 to 24 months in duration, and
generally have lower treatment success rates than first-line treatment regimen (Kibret et al., 2017; Par-
mar et al., 2018; Zhang et al., 2018; WHO, 2019a). Thus, there is a vital need to design and produce
shorter and more potent treatment regimens that treat both fully drug-susceptible and drug-resistant
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strains ofMtb.
Fluoroquinolones (FQs) are currently being tested to be part of new treatment regimens against
drug-susceptible anddrug-resistant strains ofMtb (Gillespie et al., 2014; Jindani et al., 2014;Merle et al.,
2014; Imperial et al., 2018; Vjecha et al., 2018). FQs have been and are currently used to treatMDR-TB
patients (Takiff et al., 2011; Pranger et al., 2019). The previous use of FQs has led to the development
of FQ-R in Mtb populations, with FQ-R being one of the defining properties of extensively drug-
resistant TB (XDR-TB). However, newer generations FQs are more potent againstMtb compared to
previous generations (Ji et al., 1995; Ji et al., 1998; Yu et al., 2016). These new generation of FQs are
associated with greater treatment success rates inMtb-infected mice and humans (Nuermberger et al.,
2004; Ahmad et al., 2018), and may even be used against someMtb strains that were resistant to the
older generations of FQs (Chien et al., 2016;Maitre et al., 2017; Pranger et al., 2019). Consequently, one
of the aims for the experimental first-line regimens containing FQs is to decrease treatment duration
down to 4 months for drug-susceptibleMtb, and down to 6 months forMDR-TB. FQs are therefore
a critical component in the current and potential strategies to treat TB. Investigations into howMtb
populations evolve to FQs pressure may aid in maintaining the potency and potential use of FQs.
The sole target of FQs inMtb is DNA gyrase (Takiff et al., 1994; Piton et al., 2010; Maruri et al.,
2012). DNA gyrase is the only type II topoisomerase inMtb (Cole et al., 1998) and is responsible for
introducing negative supercoils in the bacterial chromosome (Gellert et al., 1976; Levine et al., 1998).
DNAgyrase achieves this through anATP-dependent process that involves creating a double-stranded
DNA break (DSB), looping a segment of the chromosome through the DSB, and then re-ligating the
DSB (Gellert et al., 1976; Levine et al., 1998). Therefore, DNA gyrase is essential for regulating DNA
topology, transcription, and DNA replication (Levine et al., 1998). DNA gyrase is composed of two
subunits of GyrA and two subunits of GyrB, which are encoded by the gyrA and gyrB, respectively
(Cole et al., 1998; Levine et al., 1998). The region where FQs binds to in DNA gyrase, known as the
"Quinolone-binding Pocket" (QBP), is located within the active site of the enzyme (Piton et al., 2010;
Aldred et al., 2016; Blower et al., 2016); consequently, the presence of a FQmolecule within the QBP
inhibits the re-ligation activity of DNA gyrase, leading to the toxic effect of FQs (Piton et al., 2010;
Aldred et al., 2016; Blower et al., 2016). Clinically-relevant FQ-Rmutations are restricted to a limited
set of mutations in the "quinolone-resistance-determining region" (QRDR) of gyrA and gyrB (Takiff
et al., 1994;Maruri et al., 2012; Castro et al., 2019). TheQRDR is also located in the same region as the
QBP, showing a direct relationship between the FQ-DNA gyrase binding site and FQ-R mutations
(Piton et al., 2010; Aldred et al., 2016; Blower et al., 2016). Mutations in the QRDR can affect DNA
gyrase structure. Structural characterization and molecular dynamics-based simulations suggest that
the two most prevalent FQ-R mutations, gyrA A90V and D94G (Maruri et al., 2012; Castro et al.,
2019), reduce FQ-binding either by disrupting the biochemical interaction between FQs and DNA
gyrase (Aldred et al., 2016; Blower et al., 2016), or by increasing the surface area and volume of theQBP
and leading to a decreased stability of FQs within the QBP (Pandey et al., 2018).
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Structural changes caused by QRDR mutations may affect not only FQ-R binding, but the ef-
ficiency of DNA gyrase supercoiling functions as well. For example, we hypothesize that structural
changes in the QBPmay affect the precision of the DNA gyrase’s re-ligation of DSB. This would con-
sequently result in DNA damage, and the presence of either single-stranded DNA breaks or DSBs
would lead to the activation of DNA repair mechanisms (Ayora et al., 2011; Singh, 2017). These DNA
repair mechanismsmay be error-prone, leading to changes in the DNA sequence and highermutation
rates observed (Gong et al., 2005; Aniukwu et al., 2008; Gupta et al., 2011). The use of FQs against
Mtb infections may therefore lead to FQ-Rmutant strains ofMtb that also have a hypermutator phe-
notype.
Hypermutator phenotypes may increase the adaptive capabilities of bacterial populations (Taddei
et al., 1997; Hughes et al., 2017). Namely, due to the greater mutation supply generated by hypermu-
tator phenotypes, rare beneficial mutations have a higher likelihood of emerging in bacterial popu-
lations with hypermutators (Giraud et al., 2001; Wielgoss et al., 2013; Lynch et al., 2016; Hughes et
al., 2017; Raynes et al., 2018). Indeed, hypermutator phenotypes have been associated with increased
drug-resistance (DR)mutations in clinical populations ofPseudomonas aeruginosa (Oliver et al., 2000;
Maciá et al., 2005),Escherichia coli (Örlén et al., 2006), and Staphylococcus aureus (Prunier et al., 2003;
Wang et al., 2013). However, hypermutator phenotypes also increase the accumulation of common
deleterious mutations, a phenomenon known as genetic load (Haldane, 1937; Muller, 1950; Zhang
et al., 2019). Thus, hypermutator phenotypes may be transient in a population, reflecting the tension
between the benefit of acquiring rare beneficial mutations and the cost of increased genetic load (Wiel-
goss et al., 2013; Swings et al., 2017). Nevertheless, even if the hypermutator phenotype is transient,
FQ-R mutantMtb strains with hypermutator phenotypes may be more adaptable thanMtb strains
with normal mutation rates.
If hypermutator phenotypes are induced by FQ-Rmutations inMtb, their presencemay be depen-
dent on bacterial genetics. While the genetic diversity inMtb is small compared with other bacterial
pathogens, natural populations ofMtb can currently be grouped into seven distinct genetic lineages
(Comas et al., 2010; Gagneux, 2018). This genetic diversity has been shown tomodulate the frequency
and phenotypes for INH-R (Gagneux et al., 2006a; Fenner et al., 2012; Ford et al., 2013), RIF-R (Gag-
neux et al., 2006c; Zaczek et al., 2009; Ford et al., 2013) and FQ-R (Castro et al., 2019). Therefore, the
Mtb genetic background may modulate the frequency and magnitude of hypermutator phenotypes
that would be caused by FQ-Rmutations.
In this Chapter, we tested whether FQ-R mutations in DNA gyrase can induce a hypermutator
phenotype in Mtb. Firstly, we used a fluctuation analysis as a measure of mutation rate, and tested
whether FQ-R mutants would associate with higher frequencies of DR in vitro compared to their
wild-type ancestor. We then used a collated set of publicly available genomic data from clinical iso-
lates ofMtb to detect whether FQ-R mutations can modulate the frequency of mutations observed;
specifically,we tested for an association between the presence of FQ-Rmutations and increased genetic
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diversity in natural populations ofMtb. Lastly, we tested whether FQ-R mutations can induce tran-
sient hypermutator phenotypes during the within-host evolution ofMtb. We used the genomic data
from serially sampledMtb isolates fromMDR-TBpatients fromGeorgia, and tested for an association
between FQ-Rmutations and changes in genetic diversity per serialMtb isolate.
5.3 Methods
5.3.1 Collection ofMtb Strains for In Vitro Studies
We used the three genetically distinct, and fully drug-susceptibleMtb strains for our in vitro work:
N0157 (a Lineage 1 or L1 strain), N1283 (Lineage 4 or L4), andN0145 (Lineage 2 or L2) (Comas et al.,
2010; Gagneux, 2018). All strains were previously isolated frompatients and characterized by Borrell et
al., 2019 (Table 7.1, see Supplementary Information). We isolated spontaneous ofloxacin-resistant mu-
tants from each of the three strains as described in theMethods of Chapter 3 and in Castro et al., 2019.
The ofloxacin-resistant mutants harboured one of four ofloxacin-resistance gyrA mutations: G88C,
A90V, D94G, or D94N. All strains were stored in−80 ◦C. Prior to experimentation, starter cultures
were prepared for eachMtb strain by recovering a 20 µl aliquot from frozen stocks into a 10 ml vol-
ume of Middlebrook 7H9 broth (BD), supplemented with an albumin (Fraction V, Roche), dextrose
(Sigma–Aldrich), catalase (Sigma–Aldrich), and 0.05% Tween 80 (AppliChem) (hereafter designated
as 7H9 ADC). These starter cultures were incubated until their optical density at wavelength of 600
nm (OD600) was∼0.50, and were then used for in vitro assays.
5.3.2 Fluctuation Analyses
Fluctuation analysis experiments were designed based on Luria et al., 1943. Experiments and sta-
tistical analysis of data were performed as described as described in the Methods of Chapter 3 and in
Castro et al., 2019, with the selective plates containing 100 µg/ml of streptomycin. Of particular note,
significant differences between strains in their frequency of streptomycin-resistance mutations were
defined by non-overlapping 95% confidence intervals (Rosche et al., 2000; Carey et al., 2018). Data
analyses were performed using the R statistical software (v.3.5.1; R Core Team, 2018), and figures were
produced using the ggplot2 package (Wickham, 2016).
5.3.3 Determining the Mutational Profile for Streptomycin-resistance In Vitro
From the parallel cultures plated on 100 µg/ml of streptomycin, the mutational profile for
streptomycin-resistance was performed as described in the Methods of Chapter 3 and in Castro et al.,
2019. Notably, heat-inactivated bacterial cultures were used as PCR templates to amplify the rpsL gene
using the forward primer CGTGAAAGCGCCCAAGATAG and the reverse primer GAACCGCG-
GATGATCTTGTAG. This produces 333 bp PCR products, which were sent to Macrogen, Inc. or
Microsynth AG for Sanger sequencing. Amino acid substitutions in the K43 or K88 codons of the
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rpsL gene were identified by first aligning the PCR product against the H37Rv reference sequence
using the Staden Package (Cole et al., 1998; Staden, 1996), and base-pair substitutions were identified
using a custom R script (R Core Team, 2018). Fisher’s exact test was used to test for significant differ-
ences between strains’ mutational profiles for streptomycin-resistance. Figures were produced using
the ggplot2 package (Wickham, 2016).
5.3.4 Whole Genome Sequencing Analysis of Publicly AvailableM. tuberculosisGenomic
Sequences
Publicly available genomic sequences from clinical isolates ofMtb were collected as described in
Menardo et al., 2018. Their accession numbers are listed in theAdditional Files ofMenardo et al., 2018,
and not included here due to excessive length (n = 10,303). Publicly available genomic sequences from
the study by Casali et al., 2014 were also downloaded and used for analysis.
All downloaded genomic sequences were re-analyzed using the sequence analysis pipeline
described in Loiseau et al., 2019. Specifically, reads were trimmed with Trimmomatic (v.0.33;
Bolger et al., 2014), and only reads longer than 20 bp were kept for analysis. Identification
and merging of overlapping paired-end reads were performed using the SeqPrep software
(https://github.com/jstjohn/SeqPrep). The MEM algorith of BWA (v.0.7.13; Li et al., 2009)
was used to align the reads to the reconstructed ancestral sequence of Mtb (Comas et al.,
2010). Duplicated reads were identified using the MarkDuplicates module of Picard (v.2.9.1;
https://github.com/broadinstitute/picard). Local realignment of reads around Insertion/Deletions
(INDELs) were performed using the RealignerTargetCreater and IndelRealigner modules of GATK
(v.3.4.0; McKenna et al., 2010). Single nucleotide polymorphisms (SNPs) were called using the Sam-
toolsmpileup (v.1.2; Li, 2011) andVarScan (v.2.4.1; Koboldt et al., 2012) using the following thresholds:
mapping quality≥ 20, base quality at a given position≥ 20, read depth at a given position≥ 7×, and
strandbias at a given position≤ 90%. SNPswere defined as “fixed” in the populationwhen it reached a
frequency of≥90%, and considered “variable” in the populationwhen its frequencywas between 10%
and 90%. SNPs were annotated using snpEff (v.4.1144; Cingolani et al., 2012) using theMtbH37Rv
reference annotation (NC_000962.3).
5.3.5 Defining Transmission Clusters in Publicly AvailableM. tuberculosisGenomic Sequences
Transmission clusters were defined as described in the Methods of Chapter 3 and in Castro et al.,
2019. Specifically, the haplotypes package (v.1.0) for the R statistical software (v.3.5.1; R Core Team,
2018) was used to infer a genetic distancematrix, using differences in the number of SNPs as a measure
of genetic distance. Of particular note, a threshold of 5 SNPs average distance was used to define likely
patient-to-patient transmission (Walker et al., 2013), and the treewas cut at a height of 5 SNPs using the
hclust function. All resulting transmission clusters of strains, with a minimum size of three clustered
genomes, were used for further analysis.
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5.3.6 Measurement of Genetic Diversity
Genetic diversity as measured by pairwise nucleotide diversity (pi) was performed as described by
Nei et al., 1979 and Russell et al., 2017. Only fixed SNPs were used to measure pi. The pi for a given
group of genomes was calculated per site and averaged across 10 kb non-overlapping windows, as in
Equation (5):
pi =
∑l
j=1
∑a
i=1 xi(n−xi)
n(n−1)
L
(5)
Where n is the total number of genomes sampled and xi is the number of genomes with allele i.
Theparameteradenoted thenumberof alleles present at locus j, and l denoted the total numberof loci
within a 10 kb window. The sequence length (10 kb) was denoted by L. Significant differences in the
distribution of pi per 10 kb non-overlapping regions between two groups of genomes were performed
using Bonferonni-correctedMann-WhitneyU test.
Genetic diversity as measured bymean heterozygosity (H) was performed as described by Li, 1997
and Cuevas et al., 2015. Only variable SNPs were used to measureH . Per site heterozygosity (hl) in a
given genome was calculated according to Equation (6):
hl = 1−
∑a
i=1 f
2
li (6)
Where fli is the frequency of allele i, and a is the total number of alleles present at locus l. The
average heterozygosity of a given genome was calculated as in Equation (7):
H = 1
L
∑L
l=1 hl (7)
Where L is equal to 4,411,529 bp, the length of the Mtb genome according to Cole et al., 1998.
Significant differences in the distribution ofH between two groups of genomes were performed using
Bonferonni-correctedMann-WhitneyU test.
All measuments of genetic diversity were performed using customR scripts (v.3.5.1; R Core Team,
2018), and figures were produced using the ggplot2 package (Wickham, 2016).
5.3.7 Calculating Terminal Branch Lengths in the Genomic Data Set from Casali et al., 2014
Terminal branch lengths for the genome data set from Casali et al., 2014 were calculated by first
using RAxML (v.8.2.8; Stamatakis, 2014) to infer a maximum likelihood phylogeny using the vari-
able SNP alignment file. We used the general time-reversible model of sequence evolution, and boot-
strapped the highest scoringmaximum likelihood tree (1000 pseudoreplicates) to infer branch support
values. The phylogenywas rootedusing theM. canettii sequence (accession number: SRR011186). Ter-
minal branch length per genome was extracted from the resulting phylogenetic tree using a custom
R script (v.3.5.1; R Core Team, 2018) that first identified the node numbers per terminal branch, and
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then extracted the branch length that was associated with it.
5.3.8 Genomic Data ofM. tuberculosis Isolates that were Serially-sampled fromMDR-TB Patients
from Georgia
Serial sputum samples were collected from 118 smear-positive MDR-TB patients from Georgia.
All samples were part of the collection of the National Center for Tuberculosis and Lung Diseases, lo-
cated in Tblisi, Georgia. Ethical review and approval for the use and analysis of these samples was part
of the 309540-EVODRTB research agreement granted by the European Research Council. The given
118MDR-TB patients were chosen for sample collection as these patients had slow sputum smear con-
version, resulting in repeated visits. No patient data are currently available for these samples, with the
exception of drug-susceptibility testing (DST) data, which was performed at variable intervals during
patient treatment. At least 3 serial samples for a given patient had to be present to be included for down-
stream analysis. Sputum samples were decontaminated, and then grown on Löwenstein-Jensen (L-J)
solidmedium. Resulting colonies on the L-J mediumwere scraped, andDNAwas extracted according
to the CTAB method (Soolingen et al., 1991). DNA sequencing was performed on Illumina HiSeq
2000/2500 paired end technology (PRJNA488343), and only genomes with a minimum sequencing
depth of 15×were kept. This provided a data set with 425 genomes, with a resulting median coverage
per genome of 75× and an interquantile range of 40× to 110×. Genomes were grouped depending
on whether theMDR-TB patients they were isolated from acquired additional drug-resistance during
treatment based onDST results (DRGain group), or did not gain additional resistance based onDST
results (Control group).
5.4 Results
5.4.1 Fluoroquinolone-resistant gyrA mutations can increase frequencies of acquiring further
streptomycin-resistance acquisition inM. tuberculosis
We tested whether FQ-R gyrAmutations canmodulate the in vitro mutation rates ofMtb. To do
so, we used the Luria-Delbrück fluctuation analysis to measure the frequency of resistance to a high
concentration of streptomycin (STR; 100 µg/mL). We reasoned that this high STR concentration
provided an accurate measurement of the DNA base-pair mutation rate in Mtb when using a fluc-
tuation analysis model because of two features. Firstly, STR-resistance (STR-R) inMtb is generally
restricted to chromosomal base-pair mutations (Finken et al., 1993; Sreevatsan et al., 1996; Nhu et al.,
2012; Jagielski et al., 2014). Secondly, the high STR concentration would further restrict the STR-R
mutations to a handful of codon positions that can provide the necessary resistance level to grow in the
presence of the drug, namely the codons K43 andK88 from the rpsL gene (Sreevatsan et al., 1996; Nhu
et al., 2012; Sun et al., 2018). We previously performed the high-level STR-R fluctuation analysis on
three genetically distinct anddrug-susceptibleMtb strains: N0157 (Lineage 1 orL1,Manila sublineage),
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N1283 (Lineage 4 or L4, Ural sublineage), and N0145 (Lineage 2 or L2, Beijing sublineage) (Castro
et al., 2019). Using two biological replicates perMtb strain, we observed no evidence for a difference
in the frequency of high-level STR-R in N0157, N1283, or N0145 (Figure 3.3, see Chapter 3) (Castro
et al., 2019). This suggested that there were minimal, if any, differences in their mutation rates.
We then isolated FQ-R mutants carrying one of four possible gyrA mutations (G88C, A90V,
D94G, or D94N) in either N0157, N1283, or N0145. The frequency of high-level STR-R was mea-
sured for each GyrA mutant, with the number of biological replicates performed per GyrA mutant
summarized in Table 5.1. We observed that the frequency of high-level STR-R for GyrAmutants was
dependent on both the gyrAmutation present and theMtb strain themutationwas present in (Figure
5.1). Firstly, the GyrAD94G mutants derived from two strains (N0157 and N0145) had higher frequen-
cies of STR-R compared to their respective wild-type ancestral strain. Unfortunately, no fluctuation
analysis data could be made available for N1283-derived GyrAD94G mutants due to potential contami-
nation of the non-selective plates. In contrast to the GyrAD94G results, the GyrAA90V mutants derived
from two strains (N1283 and N0145) showed no difference in their frequency of STR-R compared
to their respective wild-type strains. All N1283-derived GyrA mutants acquired the same frequency
of STR-R as their wild-type ancestor. Lastly, the GyrAG88C and GyrAD94N mutants derived from two
strains (N0157 and N0145) produced contradicting results between their respective biological repli-
cates (if more than one replicate was performed), with one replicate having a higher frequency of
STR-R than their respective wild-type ancestor, while the other replicate showed no difference.
Table 5.1: Number of biological replicates performed per GyrA mutant per M. tuberculosis genetic
background for the fluctuation analysis at 100 µg/mL streptomycin
Strain Lineage gyrAMutation Genetic Background (Ancestral Strain) Number of replicates
N0157 L1 WT — 2
N3661 L1 G88C N0157 1
N2034 L1 A90V N0157 0
N2036 L1 D94G N0157 2
N2035 L1 D94N N0157 2
N1283 L4 WT — 2
N2508 L4 G88C N1283 1
N2505 L4 A90V N1283 1
N3915 L4 D94G N1283 0
N2507 L4 D94N N1283 1
N0145 L2 WT — 2
N3659 L2 G88C N0145 2
N2847 L2 A90V N0145 1
N1893 L2 D94G N0145 2
N1895 L2 D94N N0145 2
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Figure 5.1: The frequency of streptomycin-resistance at 100 µg/mL forM. tuberculosismay be modulated by the presence of gyrA mutations.
Top panel: coloured points represent the frequency of streptomycin-resistance per cell per parallel culture, with darker points representing multiple
cultures with the same frequency. Colours denote the lineage that theM. tuberculosis strain belongs to (L1 = pink; L2 = blue; L4 = red). Grey points
represent the estimated number of drug-resistance mutations per cell per strain as calculated byMSS-MLE, while black bars denote the respective 95%
confidence intervals. Bottom panel: the percentage of parallel cultures lacking streptomycin-resistant mutants. Two biological replicates are presented
for eachM. tuberculosis strain, with each replicate identifier suffixed after the strain name.
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We next explored the mutational profile for STR-R amongst the GyrAmutants and their respec-
tive wild-type ancestors by screening 760 resistant colonies for STR-R mutations. Specifically, we
screened for mutations present in either the K43 or the K88 codons of the rpsL gene, as mutations
in these codons confer high-level STR-R (Sreevatsan et al., 1996; Nhu et al., 2012; Sun et al., 2018).
While no fluctuation analysis data were available for N1283-derived GyrAD94G mutants due to poten-
tial contamination of the non-selective plates, the mutational profile for one replicate of the N1283-
derived GyrAD94G mutant was reported here (replicate "D94G_2"). We reasoned that any contamina-
tion would not survive the high STR concentration on the selective plates. Indeed, the rpsL sequences
from the STR-R colonies from theN1283 replicate D94G_2 did not differ from theH37Rv reference
sequence, with the exception of known STR-R mutations, if present, and were thus kept for analy-
sis. We observed that the mutational profiles between the wild-type ancestral strains (N0157, N1283,
and N0145) differed from each other (Figure 5.2; Table 5.2). For example, the majority of mutations
observed in the N0157 strain was rpsL K43T, while the K43R mutation was the most prevalent in
the N1283 and N0145 strains. For the GyrA mutants, we observed that STR-R mutational profiles
were dependent on both the gyrAmutation present and in whichMtb strain that the gyrAmutation
was present. Specifically, N0157-derived GyrA mutants had similar STR-R mutational profiles com-
pared to their ancestor, with the rpsLK43Tmutation beingmost common. TheN0145-derivedGyrA
mutants also had similar STR-Rmutational profiles as their ancestor, with the rpsLK43Rmutation
being most prevalent. In contrast, the N1283-derived GyrAmutants had different mutational profiles
compared to their ancestor; while the rpsL K43R mutation made up the vast majority of mutations
observed forwild-typeN1283, themajority of STR-R colonies isolated from theGyrAmutants lacked
any mutations in codons K43 and K88.
Therefore, our results show that FQ-R gyrA mutations can modulate the frequency of acquiring
further STR-R, as well as the mutational profile for STR-R in vitro. We next tested whether these in
vitro findings have relevance in a clinical setting.
5.4.2 Testing the impact of fluoroquinolone-resistance mutations on the genetic diversity present
in natural populations ofM. tuberculosis
In general, STR is no longer in use againstMtb infections (WHO, 2019a). Therefore, there are lim-
itedMtb genomic data available that are both FQ-R and STR-R. Thus, we focused our investigation
on the clinical relevance of our in vitro findings by testing whether the FQ-R mutations had an im-
pact onMtbmutation rates. Compared to bacterial strains with normalmutation rates, hypermutator
strains are hypothesized to have higher levels of genetic diversity due to the higher mutation supply
available (Taddei et al., 1997; Giraud et al., 2001; Wielgoss et al., 2013; Hughes et al., 2017). There-
fore, we tested whether FQ-R mutations associated with changes in the genetic diversity in natural
populations ofMtb. To do so, we collated a set of publicly available genomic sequences from clinical
isolates ofMtb. We limited our analysis to L2 and L4 strains, as these two lineages had the highest
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Table 5.2: Mutations present in the K43 and K88 codons of the rpsL gene for 760 streptomycin-
resistant colonies following fluctuation analysis on 100 µg/mL of streptomycin (part 1 of 2).
Genetic Background (Ancestral Strain) Lineage GyrAMutant Replicate rpsLMutation Frequency
N0157 L1 WT_1 K43N 1
N0157 L1 WT_1 K43R 5
N0157 L1 WT_1 K43T 9
N0157 L1 WT_1 nc_nc 1
N0157 L1 WT_1 wt_wt 2
N0157 L1 G88C_1 K43M 2
N0157 L1 G88C_1 K43N 14
N0157 L1 G88C_1 K43R 19
N0157 L1 G88C_1 K43T 38
N0157 L1 G88C_1 wt_wt 3
N0157 L1 G88C_1 nc_wt 1
N0157 L1 D94N_2 K43R 14
N0157 L1 D94N_2 K43T 40
N0157 L1 D94N_2 wt_wt 1
N1283 L4 WT_2 K43M 4
N1283 L4 WT_2 K43N 4
N1283 L4 WT_2 K43R 73
N1283 L4 WT_2 K43T 13
N1283 L4 WT_2 K88E 3
N1283 L4 WT_2 K88R 5
N1283 L4 WT_2 wt_wt 9
N1283 L4 WT_2 nc_nc 2
N1283 L4 WT_2 wt_nc 1
N1283 L4 D94G_2 K43N 3
N1283 L4 D94G_2 K43R 1
N1283 L4 D94G_2 wt_wt 40
N1283 L4 D94G_2 nc_nc 3
N1283 L4 D94G_2 nc_wt 1
N1283 L4 D94N_1 wt_wt 44
N1283 L4 D94N_1 nc_wt 1
N1283 L4 D94N_1 wt_nc 1
Note: wt_wt, wild-type in both K43 an K88; nc_nc, sequence not conclusive in codon K43 nor K88; nc_wt,
sequence not conclusive in K43, but wild-type in K88; wt_nc, wild-type in K43, but sequence not conclusive
in K88
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Table 5.2: Mutations present in the K43 and K88 codons of the rpsL gene for 760 streptomycin-
resistant colonies following fluctuation analysis on 100 µg/mL of streptomycin (part 2 of 2).
Genetic Background (Ancestral Strain) Lineage GyrAMutant Replicate rpsLMutation Frequency
N0145 L2 WT_1 K43R 1
N0145 L2 WT_1 K43T 1
N0145 L2 WT_2 K43R 42
N0145 L2 WT_2 K43T 12
N0145 L2 WT_2 wt_wt 8
N0145 L2 WT_2 nc_nc 1
N0145 L2 WT_2 nc_wt 1
N0145 L2 G88C_1 K43M 2
N0145 L2 G88C_1 K43N 2
N0145 L2 G88C_1 K43R 40
N0145 L2 G88C_1 K43T 37
N0145 L2 G88C_1 wt_wt 1
N0145 L2 G88C_1 nc_nc 11
N0145 L2 D94N_1 K43M 1
N0145 L2 D94N_1 K43N 2
N0145 L2 D94N_1 K43R 63
N0145 L2 D94N_1 K43T 16
N0145 L2 D94N_1 wt_wt 1
N0145 L2 D94N_1 nc_nc 3
N0145 L2 D94N_1 nc_wt 10
N0145 L2 D94N_2 K43M 5
N0145 L2 D94N_2 K43N 1
N0145 L2 D94N_2 K43R 67
N0145 L2 D94N_2 K43T 58
N0145 L2 D94N_2 wt_wt 1
N0145 L2 D94N_2 nc_nc 10
N0145 L2 D94N_2 nc_wt 5
Note: wt_wt, wild-type in both K43 and K88; nc_nc, sequence not conclusive in codon K43 nor K88; nc_wt,
sequence not conclusive in K43, but wild-type in K88; wt_nc, wild-type in K43, but sequence not conclusive
in K88
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Figure 5.2: Variation in the mutational profile for streptomycin-resistance after fluctuation analysis
on 100 µg/mL of streptomycin.
Mutations in the K43 and K88 codons of the rpsL gene was analyzed in 760 streptomycin-resistant
colonies from the fluctuation analysis performed in Figure 5.1 (wt_wt, wild-type in both K43 an K88;
nc_nc, sequence not conclusive in codon K43 nor K88; nc_wt, sequence not conclusive in K43, but
wild-type in K88; wt_nc, wild-type in K43, but sequence not conclusive in K88). Mutational profiles
for streptomycin-resistance of each GyrA mutant and their respective wild-type ancestors are shown
here. The ancestral strain of each GyrA mutant is indicated in the grey bar above each panel. The
biological replicates are presented for each GyrA mutant M. tuberculosis strain, with each replicate
identifier suffixed after the gyrAmutation present in the strain. Numbers of colonies analyzed perM.
tuberculosis genetic background are reported directly above each column.
clinical frequencies of FQ-R (Maruri et al., 2012; Castro et al., 2019). Due to standardized treatment
regimens, the prevalence of FQ-R is heavily biased towards MDR-TB strains. Therefore, we analyzed
only genomes thatwere classified asMDR-TBbased on the presence of knownRIF-resistance (RIF-R)
rpoBmutations. We reasoned that RIF-R rpoBmutations are an acceptable genetic marker for MDR-
TB, as they are generally acquired after INH-R in the clinic (Manson et al., 2017). Furthermore, we
controlled for the potential bias that shared mutations in epidemiologically-linkedMtb strains would
lead to lower observed genetic diversities (that is independent of FQ-Rmutations) when compared to
epidemiologically-independentMtb strains. Therefore, we further filtered the data set to contain only
genomes that were hypothesized to be epidemiologically-linked.We used differences in the number of
single nucleotide polymorphisms (SNPs) as a measure of genetic distance between any two genomes,
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Table 5.3: Number of clustered MDR-TB genomes per Lineage and per FQ-R group used in this
analysis.
FQ-R Group L2 L4
WT 1198 572
A90V 172 32
D94A 58 21
D94G 209 29
D94N 22 1
Other 151 37
and defined transmission clusters using a threshold of 5 SNPs average distance (Walker et al., 2013).
This provided an initial set of clusteredMDR-TB genomes with 1,810 genomes belonging to L2, and
692 genomes belonging to L4. The genomes were then assigned to a given group based on whether
FQ-Rmutations were absent (hereafter known as the "WT" group), or whether the fixed FQ-R gyrA
mutations A90V, D94A, D94G or D94N were exclusively present. These mutation groups were cho-
sen as they are four of the most prevalent FQ-R mutations in the clinic and in vitro (Maruri et al.,
2012; Castro et al., 2019). These FQ-R groups provided reasonable sample sizes to test the association
between FQ-R mutations andMtb genetic diversity, with the exception of the D94N group in L4
where only 1 genome was present. Genomes that contained any other FQ-R mutations, including if
they containedmultiple FQ-Rmutations, were simply assigned to the group "Other." The number of
genomes per FQ-R group are presented in Table 5.3.
We measured the genetic diversity per FQ-R group (with the exception of the "Other" group, due
to its heterogeneity in FQ-R mutations present). Specifically, we measured the pairwise nucleotide
diversity (pi) per FQ-R group, as described by Nei & Li (1979) and as performed by Russell & Ca-
vanaugh (2017). For every FQ-R group, pi was calculated per site and averaged across 10 kb nonover-
lapping windows. We observed that for L2 strains, the distribution of pi for the A90V, D94A, D94G,
or D94N groups was significantly higher compared to their respective WT group (Figure 5.3, P for
A90V = 0.03, P for D94A = 9.84× 10−5, P for D94G = 2.09× 10−4, P for D94N = 1.23× 10−9,
Bonferonni-correctedMann-WhitneyU test). However, for L4 strains, the distribution of pi was sig-
nificantly lower in the A90V and D94A groups compared to their respective WT group (P for A90V
= 1.40× 10−19, P for D94A = 1.06× 10−59, Bonferonni-corrected Mann-Whitney U test), while
the D94G group showed no difference (P for D94G = 0.25, Bonferonni-corrected Mann-WhitneyU
test). No comparisons could be performed for the D94N group as only 1 genome was present. These
genomic data results only partially supports our fluctuation analysis results as shown in Figure 5.1.
Specifically, FQ-R gyrAmutations in L2 strains could increase mutation rates in vitro, and associated
with increased genetic diversity in L2 strains in the clinic asmeasured bypi. In contrast, we observed no
evidence for FQ-Rmutations modulating mutation rates in L4 strains in vitro, yet FQ-Rmutations
associated with decreased pi in L4 strains in the clinic.
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Figure 5.3: Variation in the genetic diversity amongst clusteredM. tuberculosis strains isolated from
MDR-TB patients, as measured by pairwise nucleotide diversity pi.
Genomic data from clustered M. tuberuclosis strains (cut-off = 5 SNPs average distance) belonging
to either the L2 (blue hues) or L4 (red hues) lineages with known rifampicin-resistance rpoB muta-
tions were included for analysis. Genomes were grouped based on whether they lacked FQ-R muta-
tions (WT; darker hues), or if one of the following FQ-R gyrA mutations were exclusively present:
A90V, D94A, D94G, or D94N (lighter hues). Values of pi per genome group were calculated per 10
kb nonoverlapping window along the reconstructed ancestral M. tuberculosis genome, as described
in Nei et al., 1979; Russell et al., 2017. The distribution of pi values were illustrated using boxplots.
Each box corresponds to the 25% and 75% quantiles, the black line represents the median, and the
whiskers extend to 1.5 times the interquartile range. Number of 10 kb non-overlapping windows that
pi could be calculated for per group (denoted as nP ), as well as the number of genomes analyzed per
group (denoted as nG) were reported below each respective box plot. Significance was tested using
Bonferroni-corrected pairwise Mann-WhitneyU test.
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The genetic diversity measured at the population-level, as is the case for using pi, is not only a func-
tion of the individual strain mutation rates, but of population structure as well. Although our current
data set includes only clustered genomes, this clustering is based on an average SNP distance of 5. Any
two genomes may have larger distances between them, so long as the average distance between a given
groupof genomes is less than 5 SNPs. Therefore, even if therewere no inherent differences inmutation
rates, large distances between individual genomes in a set of clustered genomes would lead to higher
observed values for pi, and vice-versa. To control for this bias, we also measured the genetic diversity of
each FQ-R group at the per-genome level. Specifically, we measured the mean heterozygosity (H) per
genome in each FQ-R group, as described by Li (1997). We observed no evidence for a difference in
the distribution ofH between the A90V,D94A,D94G, or D94N groups compared to theWT group
in L2 (Figure 5.4) (P for A90V = 1.72, P for D94A = 0.72, P for D94G = 1.27, P for D94N = 0.20,
Bonferonni-correctedMann-WhitneyU test). We also observed no evidence for a difference in the dis-
tribution ofH between the A90V, D94A, and D94G group compared to the WT group in L4 (P for
A90V = 0.25, P for D94A = 0.25, P for D94G = 0.37, Bonferonni-corrected Mann-WhitneyU test).
While no tests could be performed to test for significance between theD94N group and theWTgroup
for L4, the single measure ofH for the D94N group was well within the 25% and 75% interquantile
range of theWT group. These results suggest that FQ-Rmutations do not have an impact on the ge-
netic diversity of these clusteredMDR-TB strains when using per-genome level measures. Therefore,
FQ-Rmutations do not likely modulate mutation rates in these clusteredMDR-TB genomes.
Although the clusteredMDR-TB genomes are closely related genetically, they were collected from
a global sample set. We next aimed to analyze a genomic data set that was collected from a specific
regional area. We chose the data set collected by Casali et al. (hereafter designated as "Casali 2014 data
set"), as it provided a large collection of genomes that were prospectively collected between 2008 to
2010 in SamaraOblast, Russia (Casali et al., 2014).We initially analyzed 1,079 genomes from the Casali
2014 data set (Table 5.4). However, due to the few numbers of genomes with FQ-Rmutations in L4
strains, we focused our analysis on L2 strains, and again grouped the genomes according the presence
of specific FQ-Rmutations. We measured their per-genome genetic diversity via mean heterozygosity
(H) (Li, 1997), and found no evidence for a difference in the distribution ofH when comparing the
A90V, D94A, D94G, or D94N groups to theWT group in L2 strains (Figure 5.5; P for A90V = 3.52,
P for D94A = 2.68, P for D94G = 0.66, P for D94N = 2.71, Bonferonni-corrected Mann-WhitneyU
test). These results suggest that FQ-Rmutations do not have an impact on the genetic diversity of the
Mtb strains from the Casali 2014 data set, and likely do not modulate mutation rates in these strains.
To further test whether FQ-Rmutations have an impact on strain mutation rates from the Casali
2014 data set,we useddifferences in the terminal branch lengths of each strain in a phylogeny as another
measure of strain-specific mutation rates. We hypothesized that for a given phylogenetic tree,Mtb
strains with highermutation rates would have longer terminal branch lengths due to the higher rate of
mutation acquisition. Therefore, if FQ-Rmutations increased mutation rates, then FQ-Rmutations
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Figure 5.4: The genetic diversity amongst clustered M. tuberculosis strains isolated from MDR-TB
patients, as measured by mean heterozygosityH .
Genomic data from clusteredM. tuberuclosis strains (cut-off = 5 SNPs average distance) belonging to
either the L2 (blue hues) or L4 (red hues) lineages with known rifampicin-resistance rpoBmutations
were included for analysis. Genomes were grouped based on whether they lacked FQ-R mutations
(WT; darker hues), or if one of the following FQ-R gyrA mutations were exclusively present: A90V,
D94A, D94G, or D94N (lighter hues). TheH per genome were calculated as described in Li, 1997;
Cuevas et al., 2015.The distribution ofH valueswere illustratedusing boxplots. Eachbox corresponds
to the 25% and 75% quantiles, the black line represents the median, and the whiskers extend to 1.5
times the interquartile range. Number of genomes analyzed per group (denoted as nG) were reported
below each respective box plot. Significance was tested using Bonferroni-corrected pairwise Mann-
WhitneyU test.
Table 5.4: Number of genomes per Lineage and FQ-R grouping in the Casali et al., 2014 data set used
in this analysis.
FQ-R Group L2 L4
WT 587 368
A90V 11 2
D94A 13 1
D94G 38 1
D94N 7 0
Other 49 2
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Figure 5.5: The genetic diversity amongst clinicalM. tuberculosis strains from the Casali 2014 data set,
as measured by mean heterozygosityH .
Only genomic data fromM. tuberuclosis strains belonging to L2 were included for analysis. Genomes
were grouped based onwhether they lacked FQ-Rmutations (WT; dark blue), or if one of the follow-
ing FQ-R gyrA mutations were exclusively present: A90V, D94A, D94G, or D94N (light blue). The
H per genome were calculated as described in Li, 1997. The distribution ofH values were illustrated
using boxplots. Each box corresponds to the 25% and 75% quantiles, the black line represents theme-
dian, and the whiskers extend to 1.5 times the interquartile range. Number of genomes analyzed per
group (denoted as nG) were reported below each respective box plot. Significance was tested using
Bonferroni-corrected pairwise Mann-WhitneyU test.
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Figure 5.6: Edge length of terminal branches amongst clinicalM. tuberculosis strains from the Casali
2014 data set.
Only genomic data fromM. tuberuclosis strains belonging to L2 were included for analysis. Genomes
were grouped based on whether they lacked FQ-R mutations (WT; dark blue), or if one of the fol-
lowing FQ-R gyrA mutations were exclusively present: A90V, D94A, D94G, or D94N (light blue).
The distribution of branch lengths were illustrated using boxplots. Each box corresponds to the 25%
and 75% quantiles, the black line represents the median, and the whiskers extend to 1.5 times the in-
terquartile range. Number of genomes analyzed per group (denoted as nG) were reported below each
respective box plot. Significance was tested using Bonferroni-corrected pairwise Mann-Whitney U
test.
would associate with longer terminal branch lengths. To test this hypothesis, we used the variable sites
information frommapping the Casali 2014 data set to a reconstructed ancestral genome to construct a
maximum-likelihood phylogeny, and calculated the terminal branch lengths for each strain. We found
no evidence for a difference in terminal branch lengths between the A90V, D94A, D94G, or D94N
groups compared to the WT group in L2 (Figure 5.6; P for A90V = 0.39, P for D94A = 2.92, P for
D94G=3.78,P forD94N=0.61,Bonferonni-correctedMann-WhitneyU test). This further supports
our conclusion that FQ-Rmutations do not have an impact on theMtbmutation rates from theCasali
2014 data set.
Hypermutator phenotypes may be transient in a population and gradually lost after the majority
of mutations with large adaptive potential are acquired (Taddei et al., 1997; Desai et al., 2011; Lynch
et al., 2016; Wielgoss et al., 2013; Swings et al., 2017). Any transient mutation rate changes would not
be captured using the clusteredMDR-TB or Casali 2014 data sets, as they have limited temporal infor-
mation with eachMtb strain sampled for genomic information using only one time-point. Thus, we
tested for an association between FQ-Rmutations and transient hypermutator phenotypes by using
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Table 5.5: Number of patient cases included per DST Group and FQ-R Index, and number of
genomes analyzed per patient from the GeorgianMDR-TB Serial Isolates data set
DSTGroup FQ-R Index Number of serially
sampled MDR-TB
patients included
Number of genomes
analyzed per patient
Mean number of
genomes analyzed
per patient
Control FQ-R: Initial 19 62 3.26
Control FQ-R: No Gain 47 153 3.26
Control FQ-R: Gained 2 8 4
DRGain FQ-R: Initial 8 26 3.25
DRGain FQ-R: No Gain 12 39 3.25
DRGain FQ-R: Gained 26 113 4.35
Mtb genomes that were serially sampled from 118 TB patients from the country of Georgia. These
TB patients were all classified as MDR-TB based on drug-susceptibility testing (DST). Patients were
serially sampled forMtb isolates during treatment, with a total of 547Mtb samples collected between
2009 and 2013. The TB patient cases were grouped into whether their DST results went unchanged
during the treatment and serial sampling (DST Group: Control), or whether they gained resistance
to kanamycin, ofloxacin, ethambutol, capreomycin, para-aminosalicylic acid, or any of these combina-
tions (DST Group: DR Gain). We performed a preliminary analysis, as of the 547 samples collected,
only 425 genomes with a sequencing coverage of at least 15× could be made presently available. The
median coverage per isolate was 75×, with an interquantile range of 40× to 110×. The genomes were
then grouped into whether FQ-R mutations were already present at the earliest available serial iso-
late (FQ-R Index: Initial), no FQ-R mutations were acquired during serial sampling (FQ-R Index:
No Gain), or FQ-Rmutations were acquired (FQ-R Index: Gained). We summarized the number of
genomes analyzed per group in Table 5.5, and illustrated the sampling dates per serial isolate for the
DR Gain group in Figure 5.7. Notably, two TB cases from the Control group (i.e. did not gain any
further drug-resistance during treatment, as defined byDST) actually acquired and then subsequently
lost FQ-Rmutations.
We first calculated themean heterozygosity (H) per genome from theMtb serial isolates (Li, 1997).
We observed some variability inH through the serial sampling for all DST groupings and FQ-R In-
dices (Figures 5.8 & 5.9). To detect transient hypermutator phenotypes, we calculated the differentials
inH by substracting theH of a given genome sample by theH of the genome sample previous to it in
its respective series. We illustrate the differentialH per serial isolate in Figures 5.10 & 5.11. Transient
hypermutator phenotypes due to FQ-R mutations may be identifiable by the presence of a positive
association between FQ-R mutations and positive differentialH . We found no evidence for a differ-
ence in differentialH between genomes with or without FQ-R mutations, irrespective of the FQ-R
Index grouping (Figure 5.12; P = 0.46 for the FQ-R Index: Initial group, P = 0.25 for the FQ-R In-
dex: Gained group,Welch’s Two Sample t-Test). Thus, FQ-Rmutations didnot associatewithpositive
differentialH . These results suggest thatMtb populations that acquired FQ-Rmutations during treat-
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Figure 5.7: Isolation Dates for M. tuberculosis genomes that were serially sampled from MDR-TB
patients from the country of Georgia.
Coloured points denote the isolation date of a given serial sample, with the colours denoting the pres-
ence (dark red) or absence (salmon)of FQ-Rmutations. Serial isolates for a givenpatient are connected
by black lines. Only the isolation dates for theM. tuberculosis genomes from the DRGain group are
represented here (i.e. Patient group whose DST results changed during treatment due to the acquisi-
tionof further drug-resistance to kanamycin, ofloxacin, ethambutol, capreomycin, para-aminosalicylic
acid, or any of these combinations).
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Figure 5.8: Mean heterozygosity (H) per serialM. tuberculosis isolate per MDR-TB patient from the
Control group.
Patients were classified into the Control group if their DST results remained unchanged during treat-
ment. Coloured points signifyH of anM. tuberculosis isolate, while coloured lines connect serial iso-
lates belonging to a givenpatient. Colours denote the presence (dark red) or absence (salmon) of FQ-R
mutations in a given serial isolate. Serial isolates were further grouped into an FQ-R Index, which is
based on whether the earliest serial isolate had a FQ-R mutation ("Initial"), had no FQ-R mutation
("None"), or gained FQ-R mutation at any point during the treatment, even if the FQ-R mutations
were eventually lost ("Gained"). Number of patients (denoted as nP ) and number of genomes (de-
noted as nG) analyzed per group were reported in top right of each panel.
ment were not anymore likely to undergo transient hypermutator phenotypes thanMtb populations
without FQ-Rmutations.
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Figure 5.9: Mean heterozygosity (H) per serialM. tuberculosis isolate per MDR-TB patient from the
DRGain group.
Patients were classified into theDRGain group if they acquired further DR phenotypes during treat-
ment according to DST. Coloured points signifyH of anM. tuberculosis isolate, while coloured lines
connect serial isolates belonging to a given patient. Colours denote the presence (dark red) or absence
(salmon) of FQ-Rmutations in a given serial isolate. Serial isolates were further grouped into an FQ-
R Index, which is based on whether the earliest serial isolate had a FQ-Rmutation ("Initial"), had no
FQ-R mutation ("None"), or gained FQ-R mutation at any point during the treatment, even if the
FQ-R mutations were eventually lost ("Gained"). Number of patients (denoted as nP ) and number
of genomes (denoted as nG) analyzed per group were reported in top right of each panel.
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Figure 5.10: Differential mean heterozygosity (H) per serialM. tuberculosis isolate per MDR-TB pa-
tient from the Control group.
Patients were classified into the Control group if their DST results remained unchanged during treat-
ment. Coloured points signify differentialH of anM. tuberculosis isolate,while coloured lines connect
serial isolates belonging to a given patient. Serial isolates are coloured based on the presence (dark red)
or absence (salmon) of FQ-R mutations. Serial isolates were further grouped into an FQ-R Index,
which is based on whether the earliest serial isolate had a FQ-R mutation ("Initial"), had no FQ-R
mutation ("None"), or gained FQ-R mutation at any point during the treatment, even if the FQ-
R mutations were eventually lost ("Gained"). Number of patients (denoted as nP ) and number of
genomes (denoted as nG) analyzed per group were reported in top right of each panel.
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Figure 5.11: Differential mean heterozygosity (H) per serialM. tuberculosis isolate per MDR-TB pa-
tient from the DRGain group.
Patients were classified into theDRGain group if they acquired further DR phenotypes during treat-
ment according to DST. Coloured points signify differential H of an M. tuberculosis isolate, while
coloured lines connect serial isolates belonging to a given patient. Serial isolates are coloured based on
the presence (dark red) or absence (salmon) of FQ-R mutations. Serial isolates were further grouped
into an FQ-R Index, which is based on whether the earliest serial isolate had a FQ-R mutation ("Ini-
tial"), had no FQ-Rmutation ("None"), or gained FQ-Rmutation at any point during the treatment,
even if the FQ-Rmutations were eventually lost ("Gained"). Number of patients (denoted as nP ) and
number of genomes (denoted as nG) analyzed per group were reported in top right of each panel.
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Figure 5.12: Distribution of differential mean heterozygosities (differentialH) perM. tuberculosis se-
rial isolate versus the presence or absence of fluoroquinolone-resistance mutations.
DifferentialH perM. tuberculosis serial isolate were first grouped by FQ-R Index, which is based on
whether the earliest serial isolate had a FQ-Rmutation ("Initial"), had noFQ-Rmutation ("None"), or
gained FQ-Rmutation at any point during the treatment, even if the FQ-Rmutationswere eventually
lost ("Gained"). DifferentialH were further grouped and coloured based on the presence (dark-red) or
absence (salmon) of FQ-Rmutations. The distribution of differentialH values were illustrated using
boxplots. Each box corresponds to the 25% and 75% quantiles, the black line represents the median,
and thewhiskers extend to 1.5 times the interquartile range. Significance was tested usingWelch’s Two
Sample t-Test (alpha = 0.05). Number of genomes analyzed per group (denoted as nG) were reported
below each respective box plot.
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5.5 Discussion
In this Chapter, we showed that specific FQ-Rmutations can modulate the rate of acquiring fur-
ther drug-resistance mutations inMtb in vitro. However, analysis of publicly available genomic data
from clinical isolates of Mtb showed no evidence for an association between FQ-R mutations and
increased genetic diversity. Further, analysis of genomic data from isolates that were serially sampled
fromMDR-TB patients fromGeorgia showed no evidence for FQ-Rmutations associating with tran-
sient hypermutator phenotypes during treatment. Thus, our results suggest that FQ-Rmutations do
not generally induce hypermutator phenotypes, nor lead to higher genetic diversity inMtb.
We first used a fluctuation analysis on high-level STR-R as a proxy measurement for detecting hy-
permutator phenotypes in three genetically-distinctwild-typeMtb strains (N0157,N1283, andN0145)
and in their respective FQ-Rmutants with one of four possible gyrAmutations (G88C,A90V,D94G,
orD94N). Our results showed that,with the exception of the gyrAD94Gmutation, FQ-Rmutations
generally conferred no mutation rates differences (Figure 5.1). Previous work attempting to associate
FQ-Rmutationswithhypermutatorphenotypes in other bacteria have provided similar results. Specif-
ically, Gould et al. have shown that clinical isolates of FQ-R Escherichia colimay have hypermutator
phenotypes (Gould et al., 2007). However, this hypermutator phenotypewas associatedwithmissense
mutations in the DNA repair genemutS (Gould et al., 2007), a gene where mutations are known to
confer a hypermutator phenotype (Chopra et al., 2003; Maciá et al., 2005; Oliver et al., 2010). In con-
trast, the most common FQ-R mutations in gyrA, parC, and parE did not associate with increased
mutation rates in E. coli. Therefore, while specific FQ-R gyrA mutations may modulate mutation
rates, FQ-R gyrA mutations do not generally induce hypermutator phenotypes.
However, our results show that the presence of a hypermutator phenotypewas dependent on both
the FQ-R gyrAmutationpresent. Indeed,only the FQ-R gyrAD94Gmutation clearly associatedwith
increased frequencies of STR-R, irrespective of in which strain it was present. This is in accordance
with our previous work showing that FQ-Rmutation phenotypes are dependent on the given FQ-R
mutation present (Castro et al., 2019).
An epistatic interaction between the FQ-R gyrAmutation andMtb genetic background had a no-
table effect on the mutational profile for STR-R. Firstly, rpsLmutations in codon K43 (most notably,
K43R andK43T)made up the vast majority of STR-Rmutations present after fluctuation analysis of
the N0157 and N0145 strains, as well as in their respective GyrAmutants (Figure 5.2; Table 5.2). This
was as expected, asmutations in theK43 andK88 codon of rpsL are known to confer high-level STR-R
(Sreevatsan et al., 1996; Nhu et al., 2012). However, while the STR-R rpsLK43Rmutation was most
prevalent in the wild-type N1283 strain, the vast majority of STR-R colonies present in the N1283-
derivedGyrAmutants had nomutations in the rpsLK43 nor theK88 codons. This suggested that two
types of epistasis modulate the evolution of STR-R in our in vitro system. First, there was an epistatic
interaction between FQ-R gyrA and STR-R rpsL mutations, as the N1283-derived GyrA mutant
strains had different mutational profiles for STR-R compared to their wild-type ancestor. This may
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be due to rpsLmutations conferring different levels of resistance to STR when they were co-present
with gyrAmutations. Epistatic interactions between chromosomalDRmutations have been reported
in the literature. The phenotype of STR-R rpsLmutations differed when they were in the presence of
RIF-R rpoBmutations in E. coli (Trindade et al., 2009; Angst et al., 2013; Durão et al., 2015). Of par-
ticular note, the phenotypes of STR-R rpsLmutations inM. smegmatis differed depending on which
FQ-R gyrA mutations were present (Sun et al., 2018). This suggests that epistasis between STR-R
rpsLmutations and FQ-R gyrA mutations may be conserved amongst mycobacteria.
The second epistatic interaction that governed the evolution of STR-R in our in vitro system was
an interaction between chromosomal DR mutations and the bacterial genetic background. Specifi-
cally, only GyrA mutants derived from the N1283 strain differed in their STR-Rmutational profiles
compared to their respective wild-type ancestor. The role of the genetic background in modulating
DRmutational profiles has been reported in the literature. The genetic background has been shown
to modulate the mutational profile for INH-R (Gagneux et al., 2006a; Fenner et al., 2012) and for
FQ-R (Castro et al., 2019) inMtb. The genetic background also modulated the mutational profile for
RIF-R in Pseudomonas spp. (Vogwill et al., 2014; Vogwill et al., 2016) and in E. coli (Angst et al., 2013).
These previous studies, along with the results shown here, suggest that the epistasis between chro-
mosomal DR mutations and the bacterial genetic background, as well as epistasis between different
chromosomal DRmutations, are general phenomena in bacterial DR evolution.
We next explored the clinical relevance of our in vitro work, and focused on whether the presence
of FQ-Rmutations can affect mutation rates in natural populations ofMtb by using levels of genetic
diversity as a proxy measure. We first used the average pairwise nucleotide diversity (pi) as a measure
of genetic diversity (Nei et al., 1979) in a collated set of genomes isolated from clustered MDR-TB
strains belonging to either L2 or L4.We found that while L2 strains with FQ-Rmutations had higher
pi than L2 strains without FQ-R mutations, L4 strains with FQ-R mutations did not associate with
higher pi than L4 strains without FQ-R mutations (Figure 5.3). Rather than inherent differences in
mutation rates,we hypothesize that this is likely due to differences in the population structure between
L2 and L4 strains that developed FQ-R. This is due to two, non-exclusive reasons. Firstly, L2 strains
are more associated with MDR-TB than L4 strains (Borrell et al., 2009; Fenner et al., 2012; Casali et
al., 2014; Merker et al., 2015). We thus hypothesize that L2MDR-TB strains have been transmitting
between patients for a longer time than L4 strains, leading to L2 strains becoming FQ-R earlier than
L4 strains. This would consequently allow the FQ-R L2 strains more time to acquire subsequent
mutations and further diverge from one another, leading to the higher pi observed in FQ-R L2 strains
compared to FQ-R L4 strains. A second reason that we hypothesize that the differences in nucleotide
diversity may be due population structure rather than inherent mutation rate differences comes from
when we use the mean heterozygosity (H) perMtb strain as another measure of genetic diversity (Li,
1997). Specifically, we observed that for both L2 and L4 strains in the clustered MDR-TB genomes,
there were no differences in theH of strains with FQ-Rmutations compared to strains without FQ-
79
R mutations (Figure 5.4). We controlled for a geographic sampling bias in the clustered MDR-TB
genomes by using onlyMtb genomes from the Casali 2014 data set, and again observed no differences
in H between strains with or without FQ-R mutations (Figure 5.5) (Casali et al., 2014). Thus, FQ-
R mutations do not appear to increase genetic diversity, and consequently may not lead to a stable
hypermutator phenotype in natural populations ofMtb.
However, hypermutator phenotypesmay be transient in a population (Taddei et al., 1997; Desai et
al., 2011; Wielgoss et al., 2013; Lynch et al., 2016; Swings et al., 2017), and transient hypermutator phe-
notypesmay only be observedusing serial sampleswith temporal information. Therefore,we tested for
the presence of transient hypermutator phenotypes conferred by FQ-Rmutations by using genomes
from serially sampledMtb isolates fromMDR-TB patients that were undergoing treatment in Geor-
gia. While usingH as the measure of genetic diversity, we showed some variability in genetic diversity
was present between serial isolates per patient (Figures 5.10, 5.11). However, there was no evidence for
FQ-R mutations associating with positive value changes inH (Figure 5.12). Therefore, FQ-R muta-
tions do not appear to lead to transient hypermutator phenotypesMtb populations within patients
undergoing treatment for MDR-TB.
Our study was limited by the fact that no fluctuation analysis data for the N1283-derived D94G
mutant could be made available due to potential contamination in the non-selective solid media in
separate experiments. Therefore, it is unclear whether the gyrA D94G mutation would consistently
lead to increased STR-R frequencies across theMtb genetic background we tested.
The timing between the sampling of the serial isolates from theMDR-TB patients may limit our
ability to detect transient hypermutator phenotypes. Indeed, FQ-R samples may be separated from
previously non-FQ-R samples by up to two years in some patient cases (Figure 5.7). It has been shown
that hypermutatorphenotypes can emerge and then be lost up to three timeswithin 200 generations of
anE. coli population evolving in the presence of environmental stress (Swings et al., 2017).WhileMtb
populations in vitro can have generation times ranging from approximately 16 to 26 hours (Castro
et al., 2019), their exact generation times within patients are currently unknown due to the extremely
invasive procedure such a measurement would require. If theMtb populations within the MDR-TB
patients underwent approximately 200 generations between the sampling times, then any transient
hypermutator phenotypes would not be captured due to the lack of temporal resolution. Therefore,
a greater temporal resolution may be required to confidently conclude whether FQ-Rmutations can
induce a transient hypermutator phenotype.
Lastly, we focused our detection of hypermutator phenotypes using differences in DNA base-pair
mutation rates. However, DNA base-pair mutations are not the only consequence of error-prone
DNA repair mechanisms. For example, if the predominant DNA damage produced by FQ-R gyrA
mutations are DSBs, then the hypermutator phenotypes would primarily manifest in increased inser-
tion/deletion (INDELs) mutations. This is because DNA damage in the form of DSBs are repaired
through one of the three DNA repair pathways in Mtb: homologous recombination (HR), non-
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homologous end joining (NHEJ), or single-strand annealing (SSA) (Gupta et al., 2011; Singh, 2017).
Of these repair mechanisms, NHEJ and SSA are the most error-prone (Gong et al., 2005; Gupta et al.,
2011). Rather than base-pair mutations, NHEJ primarily leads to either single base-pair insertions, or
multiple base-pair deletions (Gong et al., 2005; Aniukwu et al., 2008). We did not explicitly test for
an association between FQ-Rmutations and the frequency of INDELs due to the current limitations
of bioinformatic programs to confidently identify INDELs along theMtb chromosome using whole
genome sequencing data. Further work is therefore required to elucidate whether FQ-R mutations
lead to an increased frequency of INDELs in Mtb. This may be of critical importance, as multiple
anti-TB drugs can have INDELs-based DR mechanisms, including the current first-line drugs INH
and pyrazinamide (Gygli et al., 2017).
Overall, we showed that epistasis canmodulate the in vitro evolution of DR inMtb. Furthermore,
we observed that FQ-Rmutations had limited impact on the genetic diversity present inMtb. There-
fore, FQ exposure may not lead to more adaptiveMtb populations. Understanding howMtb popula-
tions evolve in the presence of FQpressure is of vital importance, as FQs are required to treatMDR-TB
patients, and forman integral part in experimental first-line treatment regimen againstdrug-susceptible
Mtb. Thus, ourwork highlights the potential usefulness of evolutionary studies in predicting the effect
of new treatment regimens on natural populations of bacterial pathogens.
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6 General Discussion
6.1 Synopsis of Main Findings
Fluoroquinolones (FQs) are important components in current treatment regimens against
multidrug-resistantTB (MDR-TB) (VanDeun et al., 2010; Takiff et al., 2011; Nunn et al., 2019;WHO,
2019b), and in experimental treatment regimens against drug-susceptible TB (Gillespie et al., 2014;
Merle et al., 2014; Jindani et al., 2014; Vjecha et al., 2018; Imperial et al., 2018). Investigations into
the evolution of FQ-R inM. tuberculosis (Mtb) populations may provide insights in maintaining the
current and potential efficacy of FQs.
Bacterial genetics have been shown to modulate the evolution of resistance to multiple anti-TB
drugs (Gagneux et al., 2006a; Gagneux et al., 2006c; Zaczek et al., 2009; Fenner et al., 2012; Ford et al.,
2013). Meanwhile, antimicrobial resistance (AMR) phenotypes, such as transmission potential and re-
sistance levels,maydifferdependingon the givenAMRmutationpresent (Gagneux et al.,2006c;Angst
et al., 2013; Borrell et al., 2013; Vogwill et al., 2014; Vogwill et al., 2016; Huseby et al., 2017; Hughes
et al., 2017). The main Aims of this study were to investigate whether bacterial genetics modulated
FQ-resistance (FQ-R) inMtb, and determine whether FQ-R mutations themselves could modulate
the evolutionary trajectory ofMtb populations. In our first objective, we used extensive in vitro as-
says coupled with analysis of publicly availableMtb genomic sequences isolated from clinical strains
to demonstrate that the genetic variation inMtb can substantially modulate the frequency of FQ-R
emergence and themutationalprofiles forFQ-R. Furthermore,weobserved that theFQ-Rphenotypes
were dependent on both the given FQ-Rmutation present and theMtb genetic background in which
the mutation was present. For our second objective, we adapted the model of drug-resistance (DR)
evolution developed by Ford et al. (2013) to test the relative contributions of three bacterial factors in
determining the strain-dependent FQ-R frequencies inMtb: DNAmutation rates, mutational target
sizes for FQ-R, and fitness effects of FQ-R mutations. Our simulations provided two, non-exclusive
conclusions. First, bacterial factors not studied here may play a large role in determining FQ-R fre-
quencies. Second, a new model of DR evolution is required to explain the strain-dependent variation
in FQ-R frequencies inMtb. For our last objective, we again used in vitro assays coupled with popu-
lation genomics analysis to test whether FQ-Rmutations could confer a hypermutator phenotype in
Mtb and consequently increase the levels of genetic diversity present inMtb populations. Our in vitro
results show that FQ-Rmay associate with increased frequencies of further DR acquisition; this asso-
ciation is dependent on both the FQ-Rmutation present, and in whichMtb genetic background the
FQ-Rmutation was present. However, population genomics analysis showed no association between
FQ-Rmutations and increased genetic diversity, suggesting that FQ-Rmutations have limited impact
on the genetic diversity present inMtb populations.
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Wenext discuss the general limitations of our study. Considering these limitations,we then discuss
the contributions of our findings to the study of FQ-R evolution inMtb, to the study of pathogen
genetics onDR evolution in general, and to public health. Throughout this chapter, we discuss poten-
tial research avenues that would be relevant to the given section, as well as provide additional research
avenues that were not previously discussed but can also build upon our work.
6.2 General Limitations
Our study is limited by the fact that pathogen phenotypes in vitro may differ from pathogen phe-
notypeswithin patients. For example,our in vitro assays generally use nutrient richmedium that allows
for optimal bacterial growth (seeMethods of Chapters 3 and 5). However, bacterial growth in patients
is generally curtailedby immune system functions including nutritional immunity (Berney et al., 2017),
innate immunity (Liu et al., 2017), and adaptive immunity (Jasenosky et al., 2015). Furthermore, the
immune system itself has also been hypothesized to modulate the prevalence of DR observed (Read
et al., 2001;Handel et al., 2009; Chiang et al., 2018). Thus, ourmeasurements of FQ-R frequencies and
phenotypes in in vitro populations ofMtbmay not be fully representative of the FQ-R frequencies
and phenotypes inMtb populations residing in patients. Nevertheless, we observed that up to 51%
of the variability in the clinical frequency of FQ-R gyrA mutation events can be attributed to how
Mtb evolves in vitro (see Chapter 3; Castro et al., 2019). Furthermore, multiple studies (Gagneux et al.,
2006c; Andersson et al., 2010; Maruri et al., 2012; Angst et al., 2013; Vogwill et al., 2014; Vogwill et al.,
2016; Huseby et al., 2017), including published work from this Thesis (see Chapter 3; Castro et al.,
2019), have shown strong positive associations between the fitness of a given DR mutation in vitro
with its respective prevalence in the clinic. Thus, while in vitro conditions may not be perfect repre-
sentatives of patient infections, the combination of extensive in vitro work coupled with population
genomics analysis can aid in understanding how Mtb populations evolve FQ-R in patients and, in
general, how DR evolves in pathogens.
The adapted mathematical model from our second objective shares the same inherent limitation
as other theoretical models. Namely, designing models generally requires a balance between maximiz-
ing the amount of variability in the experimental results that can be explained by the model, while
minimizing the amount of variables that are required in the model to explain the variability (Spicknall
et al., 2013; Blanquart, 2019). If the experimental data that the model is built around is itself biased or
controversial, then the model would share the same biases. We hypothesize that this limitation may
play a crucial role in explaining why our adaptedmodel could not recapitulate the strain-dependent in
vitro FQ-R frequencies when using experimentally-confirmed or inferred values for DNAmutation
rates, mutational target sizes for FQ-R, and the fitness effects of FQ-Rmutations (see Chapter 4). The
original model developed by Ford et al. that we adapted for this study was designed based on their
results suggesting that L2 Beijing strains have a hypermutator phenotype (Ford et al., 2013). There-
fore, the Ford et al. model may inherently set mutation rates to have a higher relative contribution in
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determining the DR frequencies than other bacterial factors. This suggests that our adapted model is
also biased towards providing a higher relative contribution of mutation rates in determining FQ-R
frequencies in vitro, while minimizing the relative contribution of mutational target sizes and fitness
effects. An alternative, non-exclusive hypothesis is that there may be other bacterial factors relevant in
determining FQ-R frequencies which we have not measured in vitro.
Our population genomics analyses are limited by the fact that most of theMtb genomes we an-
alyzed were sampled by convenience due to their public availability. While we controlled for differ-
ences in sequence analysis by reanalyzing all genomes using our standard sequence analysis pipeline
(see Methods of Chapters 3 and 5), we cannot control for differences in DNA isolation techniques
or sequencing methods between different studies. Differences in DNA isolation, processing, and se-
quencingmay lead to differences in the SNPs that can be identified from genomic data,which can skew
the level of genetic diversity present in a givenMtb sample (Meehan et al., 2019; Colman et al., 2019).
Furthermore, the sequencing depth provided by the publicly genomes lacks the resolution to confi-
dently identify minor variants in the population (i.e. variable SNPs that represent less than 10% of the
population). Identifying minor variants in a population requires deep sequencing of DNA samples,
which imposes a substantial financial cost (Trauner et al., 2017; Colman et al., 2019; Schwarze et al.,
2019). Identifying minor variants may be important for studying FQ-R evolution. For instance, we
may be underestimating the amount of genetic diversity present during our study outlined in Chapter
5. Furthermore, heteroresistance, defined as the co-existence of both wild-type and DR strains in the
same infecting pathogen population, can be common in FQ-R evolution (Zhang et al., 2012; Eilertson
et al., 2014; Trauner et al., 2017; Rigouts et al., 2019). Identification of low frequency FQ-RMtb vari-
ants in patients may aid in designing personalized treatment regimens, which may reduce the overall
prevalence of FQ-RMtb strains. Thus, more work is required to determine whether minor variants
have an impact on studying FQ-R evolution inMtb.
6.3 Aspects in the Molecular Evolution of Fluoroquinolone-Resistance inM.
tuberculosis
Considering the limitations listed above, we nevertheless observed robust signals that provide in-
sights into the molecular evolution of FQ-R inMtb. Specifically, we showed significant differences in
FQ-R phenotypes depending on the FQ-R mutations present. For instance, gyrA G88C mutation
conferred a large fitness cost irrespective of theMtb genetic background it occurred in (see Chapter
3; Castro et al., 2019). This was as expected, as the gyrA G88C mutation is one of the least prevalent
FQ-Rmutation observed in the clinic (Maruri et al., 2012; Castro et al., 2019). The cost of G88Cmay
be due to two features resulting from substituting in a cysteine in lieu of a glycine. Firstly, cysteine
residues are larger than glycine residues. Secondly, cysteine residues can also interact with other cys-
teine residues to create disulfide bridges (Yen et al., 2000). The resulting change in residue size and/or
interaction potential conferred by a gyrA G88C mutation may severely destabilize the structure and
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function of DNA gyrase (Piton et al., 2010; Aldred et al., 2016; Blower et al., 2016; Pandey et al., 2018).
Regardless of how the cost is inferred by the gyrA G88Cmutation, designing new FQs types that can
predominantly select for the gyrA G88C mutation may reduce the frequency of FQ-R observed in
Mtb.
We also observed that gyrAD94G andA90Vmutations conferred little or no fitness costs in vitro,
and were the most prevalent FQ-Rmutations both in vitro and in the clinic (see Chapter 3; Castro et
al., 2019). Previous studies have shown that theD94G andA90Vmutations confer different structural
changes to DNA gyrase (Blower et al., 2016; Pandey et al., 2018). Therefore, we hypothesize that gyrA
D94G and gyrA A90V confer low to no fitness costs through different biochemical and/or biological
mechanisms. This potential difference in the causative mechanism of their respective fitness effects
may be modulated by theMtb genetic background. Indeed, we observed that gyrA D94G and gyrA
A90V have different fitness effects in vitro depending on theMtb strain they were present in, and had
lineage-specific differences in clinical prevalence.
Interestingly, while gyrA D94A was the third-most prevalent in the clinic, gyrA D94N was the
third-most prevalentmutation in vitro (see Chapter 3; Castro et al., 2019). Althoughwe have no fitness
measurements for the gyrA D94A mutation to compare with the fitness of gyrA D94N, out of 680
FQ-R colonies isolated during the in vitromutational profile assay, only 3 gyrAD94Amutations were
observed compared to 94 gyrA D94Nmutations. This suggests that while gyrA D94Amay confer a
higher cost than gyrA D94N in vitro, the opposite is true in patients. Differences in the in vitro and
clinical prevalence of DRmutations have been shown for other anti-TB drugs. For example, while the
katG S315T is the most prevalent isoniazid-resistance (INH-R) mutation in the clinic (Gagneux et al.,
2006a; Fenner et al., 2012; Casali et al., 2014; Manson et al., 2017; Wollenberg et al., 2017), it is rarely
observed in vitro (Bergval et al., 2009; Brossier et al., 2016). One hypothesis to explain this is that katG
S315T has a fitness advantage in the presence of host immune system pressure (Brossier et al., 2016).
The same phenomenon may govern the higher than expected frequency of gyrA D94A in the clinic
when compared to its in vitro prevalence. To test this hypothesis, studies that explore whether gyrA
D94Amutations have higher fitness in infection models versus in vitro are required.
An alternate hypothesis for gyrA D94A being more prevalent than expected is that gyrA D94A
interacts epistatically with other DR mutations. We hypothesize this due to two reasons. Firstly, all
the genomes we surveyed for FQ-R mutations had both INH-R and rifampicin-resistance (RIF-R)
mutations. Secondly, FQ-Rmutations have been shown to confer different fitness effects depending
on the presence of other DR mutations (Borrell et al., 2013; Huseby et al., 2017; Sun et al., 2018).
Therefore, gyrAD94Amutationmay confer lower fitness costs than gyrAD94Nwhen in the presence
of INH-R and/or RIF-R mutations.
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6.4 Aspects in the Study of Pathogen Genetics modulating Drug-Resistance
Evolution
We observed that the Mtb genetic background modulates multiple aspects in FQ-R evolution
(see Chapters 3 and 5). This is in line with multiple studies showing Mtb lineages associating with
differences DR evolution (Borrell et al., 2009; Fenner et al., 2012; Casali et al., 2014; Coscolla et al.,
2014; Merker et al., 2015; Eldholm et al., 2016; Gagneux, 2018). However, we found that while FQ-R
mutational profiles in the clinic associated with specificMtb lineages, both in vitro FQ-Rmutational
profiles and frequencies associated with specificMtb strains and not per lineage (see Chapter 3). This
may be due to the use of only three strains per lineage for the in vitro studies,whichmay not be enough
to delineate lineage-specific distributions for FQ-R phenotypes. Furthermore, the three representative
Mtb strains per lineage were chosen to represent the greatest genetic diversity within a given lineage
(Borrell et al., 2019); this decision may increase the likelihood of phenotypingMtb strains with out-
lier phenotypes within a given lineage. Thus, the use of more strains per lineage may provide greater
resolutions to delineate lineage-specific distributions for a given FQ-R phenotype.
This Thesis also highlights the role of the genetic background in modulating DR evolution in
general. Indeed, the genetic background has been shown tomodulate DR evolution not only in bacte-
rial pathogens (Angst et al., 2013; Vogwill et al., 2014; Vogwill et al., 2016; Huseby et al., 2017; Apjok
et al., 2019), but in eukaryotic organisms such as Leishmania donovani (Decuypere et al., 2012) and in
yeast as well (Mullis et al., 2018). Thus, the epistasis between DRmutations and the genetic variation
present in any given organism appears to be a major factor in the DR evolution.
6.5 Public Health Relevance
The role ofMtb genetics influencing FQ-R evolution may have a clinical impact. Specifically, con-
sidering the non-random geographic distribution of Mtb genotypes (Comas et al., 2010; Gagneux,
2018), differentMtb strains associating with different FQ-R frequencies in vitro may translate into re-
gional differences in FQ-Rprevalence. For instance, theLineage 1 "N0157" strain is associatedwithhigh
FQ-R frequencies in vitro (see Chapter 3; Castro et al., 2019), and belongs to the "Manila" sublineage,
the predominantMtb genotype in the Philippines and in TB patients of Filipino descent (Douglas
et al., 2003; Gagneux et al., 2006b; Wan et al., 2017). We hypothesize that FQ-R prevalence may be
higher in the Philippines and in Filipinos compared to other countries or ethnic groups when using
FQs as a first-line anti-TB drug. However, the frequency of FQ-R in more Manila sub-lineage strains
should bemeasured before this hypothesis can be supported. Nevertheless, considering that the Philip-
pines has the second-highest incidence of TB globally (WHO, 2019a), future work in FQ-R evolution
should address this question.
Differences in the molecular evolution of FQ-Rmay also lead to differential treatment outcomes
when using FQs as a first-line anti-TB drug. For instance, while both gyrA D94G and A90V muta-
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tions are the most frequent FQ-R mutations in vitro and in the clinic (see Chapter 3; Castro et al.,
2019), gyrAD94G associated with poorer treatment outcomes compared to gyrA A90V inMDR-TB
patients (Rigouts et al., 2016; Farhat et al., 2017). Our results showed that while gyrA A90Vwas most
prevalent in high-frequency FQ-RMtb strains like the Lineage 1ManilaN0157 strain, gyrAD94Gwas
most prevalent in the other strains (see Chapter 3). Furthermore, the gyrAD94GandA90Vmutations
associated with differences in further DR acquisition, with gyrA D94G associating with increased fre-
quencies of furtherDRwhile gyrAA90Vdidnot (see Chapter 5). Thismay lead to regional differences
in treatment outcomes. For instance, regionswhereMtb strainsmore likely to acquire gyrAA90Vmay
associatewithbetter treatment outcomes and less furtherDRmutations acquired compared to regions
whereMtb strains would more likely acquire gyrA D94G. Future studies could therefore address the
potential impact of FQ-Rmolecular evolution differences on treatment outcomes.
6.6 Potential Future Directions
In addition to the open questions posited in the preceding subsections and chapter discussions,
we highlight two other potential avenues of research for FQ-R evolution inMtb. Firstly, the fitness of
any given genotype can be modulated by the environmental conditions it is present in (Wiesch et al.,
2010; Huseby et al., 2017; Mullis et al., 2018). While we measured the fitness of FQ-Rmutants in the
absence of drug pressure, the fitness effects of FQ-R mutations may differ if FQs or other drugs are
present.Measuring the fitness effects of FQ-Rmutations in the presence of drugsmay provide insights
into the potential evolutionary trajectories of FQ-Rmutants (Huseby et al., 2017). The fitness of FQ-
R mutants in the presence of bedaquiline, pretomanid, or pyrazinamide are of particular interest, as
a current Phase III clinical trial is testing the use of these three drugs in combination with FQs as a
potential first-line anti-TB regimen (Vjecha et al., 2018).
Secondly, the further acquisition of secondary mutations may alleviate any initial fitness costs of
FQ-R mutations. Such "compensatory" mutations have been observed alleviating costs of RIF-R in
Mtb andSalmonella (Comas et al., 2012; Brandis et al., 2013; Song et al., 2014), andhave been associated
with ongoing transmission of RIF-RMtb strains in the clinic (Vos et al., 2013; Merker et al., 2018).
Compensatory mutations for FQ-R have yet to be identified; however, their existence may lead to
more transmissible FQ-RMtb strains.
6.7 Conclusion
In general, this Thesis highlights the importance of bacterial genetics on AMR evolution. Specifi-
cally, we provide the TB community, and the AMR community more broadly, with the first evidence
showing that theMtb genetic backgroundmodulates FQ-R frequencies and phenotypes. Further, we
provide the TB community with the first in vitro fitness measurements for FQ-R mutations, one of
the most extensive phenotyping of FQ-R mutants, and one of the largest in vitro and clinical muta-
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tional profiling for FQ-R inMtb. More generally, our study illustrates how the genetic variation in
bacterial populations affects the emergence, themaintenance, and the phenotypes of clinically relevant
chromosomal AMR mutations. The work presented in this Thesis, coupled with results from pub-
lished studies, provides compelling evidence that the epistasis between pathogen genetics and AMR
mutations is a major factor in AMR evolution. Our work may provide insights into how to maximize
the time-span in which antimicrobials remain effective in the clinic.
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7 Supplementary Information
7.1 Supplementary Information for Chapters 3 and 4
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Figure 7.1: Proportion of each gyrA mutation after sequencing of the QRDR of gyrA in 680
ofloxacin-resistant colonies from the fluctuation analysis performed in Figure 3.1A (nm = no iden-
tified QRDR gyrA mutations).
The numbers of colonies with the given gyrA mutation are reported directly below each respective
column.
Table 7.1: Classification ofM. tuberculosis strains used for in vitro assays
Strain Lineage Sub-
lineage
Alternate Sub-lineage/Strain Nomenclatures
N0069 L1 L1.1.1 EAS042 (Hershberg et al., 2008)
N0072 L1 L1.1.2 EAS053 (Hershberg et al., 2008)
N0157 L1 L1.2.1 Manila; T92 (Tsolaki et al., 2004)
N0052 L2 L2.2.2 Beijing, Asia Central 1; 98_1833 (Hershberg et al.,
2008; Coll et al., 2014; Shitikov et al., 2017)
N0145 L2 L2.2.1.1 Beijing,PacificRD150;T67 (Tsolaki et al.,2004; Coll
et al., 2014; Shitikov et al., 2017)
N0155 L2 L2.2.1 Beijing; T85 (Tsolaki et al., 2004; Gagneux et al.,
2006c)
N0136 L4 L4.3.3 Beijing; Latin America-Mediterranean; T4 (Tsolaki
et al., 2004; Coll et al., 2014; Stucki et al., 2016)
N1216 L4 L4.6.2.2 Cameroon (Coll et al., 2014; Stucki et al., 2016
N1283 L4 L4.2.1 Ural (Coll et al., 2014; Stucki et al., 2016
Lineage 1 = L1; Lineage 2 = L2; Lineage 4 = L4. Mtb lineage designations defined as in Comas et al., 2010;
Gagneux, 2018.
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Figure 7.2: Growth profiles ofM. tuberculosis strains in cell growth assays under antibiotic free con-
ditions, with all OD600 values plotted (log2-transformed).
Genetic background of M. tuberculosis strain and its corresponding gyrA mutation are presented
above each respective plot. Coloured dots represent the measured log2OD600 values at a given time
(inminutes), with coloured lines connecting respective coloured dots. Different colours represent dif-
ferent replicates for each strain. For reference, black solid horizontal lines were plotted to denote non-
transformed OD600 values of either 0.05 (lower line) or 0.70 (upper line), while black dashed lines
denote OD600 values of either 0.03 (lower line) or 0.50 (upper line).
90
Table 7.2: Phylogenetic single nucleotide polymorphisms leading to missense DNA gyrase or DnaE
mutations that are present in the genomic data of the nine drug-susceptible M. tuberculosis strains
outlined in Supplementary Table 7.1
Gene Gene
Name
Amino
Acid Sub-
stitution
Strain Lineage
Rv0005 gyrB M291I N0069 L1
Rv0005 gyrB M291I N0072 L1
Rv0005 gyrB M291I N0157 L1
Rv0006 gyrA A384V N0069 L1
Rv0006 gyrA A384V N0072 L1
Rv0006 gyrA A384V N0157 L1
Rv0006 gyrA G247S N0136 L1
Rv0006 gyrA K224E N0072 L1
Rv0006 gyrA P154R N1216 L4
Rv1547 dnaE1 D316N* N0069 L1
Rv1547 dnaE1 S898L* N0052 L1
Rv3370c dnaE2 C313W* N0157 L1
Rv3370c dnaE2 P814S* N0052 L2
*These mutations do not occur in the polymerase and histidinol phosphatase-domain of DNA polymerase
dnaE, and therefore are not confirmed to confer a hypermutator phenotype in M. tuberculosis (Rock et al.,
2015; Baños-Mateos et al., 2017).
Table 7.3: Mutations present in the rpsL gene for 194 streptomycin-resistant colonies following fluc-
tuation analysis on 100 µg/mL of streptomycin
Mutation N0157 N1283 N0145
K43M 0 4 0
K43N 1 4 0
K43R 5 72 46
K43R, K10Q 0 1 0
K43T 9 13 13
K88E 0 3 0
K88R 0 5 0
nm 0 9 9
nm = streptomycin-resistant colonies with no mutations in rpsL.
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Figure 7.3: Growth profiles ofM. tuberculosis strains in cell growth assays under antibiotic free con-
ditions, with only measured OD600 values (log2-transformed) present after filtering for exponential
phase of growth.
Genetic background of M. tuberculosis strain and its corresponding gyrA mutation are presented
above each respective plot. Exponential growth phase was defined as a set consecutive time-points
where a linear relationship between log2OD600 (defined by a Pearson’s R2 value≥0.98) and time was
present. Coloured dots represent the measured log2OD600 values at a given time (in minutes), with
coloured lines connecting respective coloured dots. Different colours represent different replicates for
each strain. For reference, black solid horizontal lines were plotted to denote non-transformedOD600
values of either 0.05 (lower line) or 0.70 (upper line), while black dashed lines denote OD600 values
of either 0.03 (lower line) or 0.50 (upper line).
92
0.00
0.25
0.50
0.75
1.00
L1 L2 L3 L4 L5 L6
M. tuberculosis lineage
Pr
op
or
tio
n 
of
 g
yr
A
 m
ut
at
io
n 
pe
r l
in
ea
ge
gyrA  mutation
G88A G88C A90V S91P D94A D94G D94H D94N D94Y
n = 14 668 48 206 26
P = 3 × 10-6; Fisher’s exact test
Figure 7.4: Mutational profile for all (fixed and variable) fluoroquinolone-resistance gyrA mutations
is lineage-specific in clinical isolates ofM. tuberculosis.
An initial dataset of 3,450 genomeswith confirmedMDR-TBmutationswere surveyed. 854 genomes
were identified as fluoroquinolone-resistant, with 848 of these genomes containing gyrA mutations.
If genomic data from a single M. tuberculosis clinical isolate contained multiple fluoroquinolone-
resistance gyrAmutation, each mutation was counted once (n = 944). Number of genomes analyzed
per lineage is presented underneath each respective bar graph.Mtb lineage designations defined as in
Comas et al., 2010; Gagneux, 2018.
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Figure 7.5:Variation in the frequencyofmutation events per fluoroquinolone-resistance (FQ-R) gyrA
mutation amongst clinical isolates ofM. tuberculosis belonging to either L2 or L4 lineages.
Mutation events per FQ-R gyrAmutation were enumerated from an initial dataset of 3,450 genomes
with confirmed MDR-TB mutations. Genomes were defined as belonging to a given transmission
cluster by using a pairwise genetic distance threshold of 12 single nucleotide polymorphisms average
as a cut-off. Each unique and fixed FQ-R gyrA mutation present per transmission cluster, as well
as each fixed FQ-R gyrA mutation present in non-clustered genomes, were counted as independent
mutation events. The number of FQ-R gyrA mutation events per lineage is presented underneath
each respective bar graph.Mtb lineage designations defined as in Comas et al., 2010; Gagneux, 2018.
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Table 7.4: Mutations in the QRDR of gyrA for 680 ofloxacin-resistant colonies following fluctuation analysis on 4 µg/mL of ofloxacin
Strain G88C A90V S91P D94A D94G D94H D94N D94Y nm Strain Total
N0157 1 43 0 0 9 1 7 1 2 64
N0072 2 112 0 2 37 0 1 11 7 172
N0052 13 4 0 0 39 2 18 15 21 112
N0155 2 0 0 0 51 0 14 14 3 84
N1283 1 12 1 0 36 7 14 19 0 90
N0136 0 24 1 1 31 3 13 9 0 82
N1216 1 0 0 0 27 0 16 1 0 45
N0069 1 1 0 0 13 0 4 0 2 21
N0145 0 0 0 0 3 0 7 0 0 10
Mutation Total 21 196 2 3 246 13 94 70 35 680
nm = ofloxacin-resistant colonies with no mutations in the QRDR region of gyrA. Strains are ordered top to bottom based on their frequency of OFX-resistance at
4 µg/mLOFX as shown in Figure 3.1A.94
Table 7.5: Mutations in the QRDR of gyrB for 590 ofloxacin-resistant colonies following fluctuation
analysis on 4 µg/mL of ofloxacin
Strain E454K D461H nm Strain Total
N0157 0 1 41 22
N0072 0 0 155 155
N0052 1 0 101 102
N0155 0 0 66 7
N1283 0 0 69 46
N0136 0 0 81 69
N1216 0 0 46 81
N0069 0 0 22 42
N0145 0 0 7 66
Mutation Total 1 1 588 590
nm = ofloxacin-resistant colonies with no mutations in the QRDR region of gyrB. Strains are ordered top to
bottom based on their frequency of OFX-resistance at 4 µg/mLOFX as shown in Figure 3.1A.
Table 7.6: Ofloxacin MIC estimates for gyrA mutant strains and their respective parental strain
Strain gyrAMutation Genetic Background
(Parental Strain)
Ofloxacin MIC
(µg/mL)
Normalized
Ofloxacin MIC*
N0157 wt — 2.00 1.00
N3661 G88C N0157 31.60 15.80
N2034 A90V N0157 10.00 5.00
N2036 D94G N0157 20.00 10.00
N2035 D94N N0157 20.00 10.00
N1283 wt — 0.60 1.00
N2508 G88C N1283 12.60 21.00
N2505 A90V N1283 4.00 6.67
N3915 D94G N1283 12.60 21.00
N2507 D94N N1283 12.60 21.00
N0145 wt — 0.50 1.00
N3659 G88C N0145 39.80 79.60
N2847 A90V N0145 3.20 6.40
N1893 D94G N0145 10.00 20.00
N1895 D94N N0145 10.00 20.00
MIC estimates for Ofloxacin based on fitting of a Hill curve to the distribution of fluorescence in an Alamar
Blue assay (Franzblau et al., 1998). MIC is defined as the ofloxacin concentration where fittedHill curve showed
a ≥95% reduction in fluorescence. *Normalized Ofloxacin MIC is calculated by taking the ofloxacin MIC of
a givenM. tuberculosis strain and dividing it by the ofloxacin MIC of its respective wild-type parental strain;
Normalized Ofloxacin MICs for each wild-type parental strain are therefore equal to 1.00.
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Table 7.7: In vitro fitness ofM. tuberculosis strains based on cell growth assays in antibiotic-free conditions
Strain gyrAMutation Genetic Background
(Parental Strain)
Growth
Rate
(GR)
GR:
Lower
95%
GR:
Upper
95%
GenerationTime (in
hours)
Relative
Fitness
(RF)
RF:
Lower
95%
RF:
Upper
95%
P
N0157 wt — 0.045 0.044 0.047 22.22
N3661 G88C N0157 0.038 0.034 0.042 26.36 0.844 0.773 0.894 <0.001*
N2034 A90V N0157 0.052 0.048 0.057 19.23 1.156 1.091 1.213 <0.001*
N2036 D94G N0157 0.044 0.04 0.048 22.73 0.978 0.909 1.021 0.354
N2035 D94N N0157 0.042 0.038 0.046 23.81 0.933 0.864 0.979 0.009*
N1283 wt — 0.061 0.059 0.064 16.40
N2508 G88C N1283 0.042 0.037 0.047 23.81 0.689 0.627 0.734 <0.001*
N2505 A90V N1283 0.054 0.048 0.06 18.52 0.885 0.814 0.938 <0.001*
N3915 D94G N1283 0.062 0.056 0.068 16.13 1.016 0.949 1.062 0.638
N2507 D94N N1283 0.052 0.046 0.058 19.23 0.852 0.780 0.906 <0.001*
N0145 wt — 0.053 0.05 0.055 18.87
N3659 G88C N0145 0.044 0.038 0.05 22.73 0.830 0.760 0.909 <0.001*
N2847 A90V N0145 0.058 0.051 0.063 17.24 1.094 1.020 1.145 0.016*
N1893 D94G N0145 0.05 0.044 0.056 20.00 0.943 0.880 1.018 0.107
N1895 D94N N0145 0.051 0.044 0.056 19.61 0.962 0.880 1.018 0.206
The growth rate of a particularM. tuberculosis strain was defined as the slope during exponential phase of bacterial growth, with the exponential phase of bacterial
growth defined as where a log2-linear relationship existed between OD600 and time using a Pearson’s R2 value ≥ 0.98 as the threshold. Generation times were
calculated by taking the inverse of the calculated growth rate. The relative fitness of a given gyrA mutant was defined by taking its growth rate and dividing it by the
growth rate of its respective wild-type ancestor.
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Table 7.8: Number of publicly available genomes fromM. tuberculosis clinical isolates used to survey
the mutational profile for fluoroquinolone-resistance
Mtb lineage No. of MDR-TB
Genomes
No. of MDR-TB +
FQ-R Genomes
Lineage 1 109 13
Lineage 2 1,903 597
Lineage 3 151 44
Lineage 4 1,261 196
Lineage 5 18 2
Lineage 6 8 2
Total 3,450 854
Mtb=M. tuberculosis; MDR-TB=multidrug-resistant tuberculosis, defined asMtb genomes that have both an
isoniazid and a rifampicin-resistancemutation; FQ-R= fluoroquinolone-resistant, defined asMtb genomes that
have a fluoroquinolone-resistance mutation. Multiple drug-resistance mutations present in the genomic data
from a singleMtb clinical isolate is possible (classified as “variable,” and therefore not “fixed” for drug-resistance
mutations); if a genome contained multiple drug-resistance mutations, then the genome is simply counted as
MDR-TB or FQ-R once.Mtb lineage designations defined as in Comas et al., 2010; Gagneux, 2018.
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Table 7.9: Frequency of all (fixed and variable) fluoroquinolone-resistance mutations from sample set of 3,450MDR-TB genomes.
Mutation L1 L2 L3 L4 L5 L6 Mutation Total
gyrA G88A 0 4 0 2 0 0 6
gyrA G88C 0 10 0 1 0 0 11
gyrA A90V 6 160 14 73 2 2 257
gyrA S91P 0 40 4 9 0 0 53
gyrA D94A 1 84 0 33 0 0 118
gyrA D94G 7 263 22 51 2 0 345
gyrA D94H 0 16 0 10 0 0 26
gyrA D94N 0 64 1 7 0 0 72
gyrA D94Y 0 27 7 20 2 0 56
gyrBD461N 0 3 0 2 0 0 5
gyrBN499D 0 1 0 0 0 0 1
Lineage Total 14 672 48 208 6 2 950
If a genome was classified as “variable” for fluoroquinolone-resistance mutations, each gyrA or gyrBmutation present was counted once. Lineage 1 = L1, Lineage 2 =
L2, Lineage 3 = L3, Lineage 4 = L4, Lineage 6 = L5, Lineage 6 = L6. Mtb lineage designations defined as in Comas et al., 2010; Gagneux, 2018.
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Table 7.10: Frequency of fixed fluoroquinolone-resistance mutations from sample set of 3,450MDR-TB genomes.
Mutation L1 L2 L3 L4 L5 L6 Mutation Total
gyrA G88A 0 3 0 2 0 0 5
gyrA G88C 0 8 0 1 0 0 9
gyrA A90V 4 114 9 61 0 2 190
gyrA S91P 0 26 4 7 0 0 37
gyrA D94A 0 70 0 26 0 0 96
gyrA D94G 6 200 16 39 0 0 261
gyrA D94H 0 12 0 4 0 0 16
gyrA D94N 0 48 1 6 0 0 55
gyrA D94Y 0 19 5 17 0 0 41
gyrBD461N 0 3 0 2 0 0 5
gyrBN499D 0 1 0 0 0 0 1
Lineage Total 10 504 35 165 0 2 716
If a genome was classified as “variable” for fluoroquinolone-resistance mutations, each gyrA or gyrBmutation present was counted once. Lineage 1 = L1, Lineage 2 =
L2, Lineage 3 = L3, Lineage 4 = L4, Lineage 6 = L5, Lineage 6 = L6. Mtb lineage designations defined as in Comas et al., 2010; Gagneux, 2018.
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Table 7.11: Frequency of mutation events per fluoroquinolone-resistance gyrA mutation from an initial sample set of 3,450MDR-TB genomes.
Mutation L1 L2 L3 L4 L5 L6 Mutation Events To-
tal
gyrA G88A 0 3 0 2 0 0 5
gyrA G88C 0 6 0 1 0 0 7
gyrA A90V 4 79 9 33 0 2 127
gyrA S91P 0 22 3 4 0 0 29
gyrA D94A 0 45 0 17 0 0 62
gyrA D94G 3 153 15 30 0 0 201
gyrA D94H 0 11 0 4 0 0 15
gyrA D94N 0 33 1 6 0 0 40
gyrA D94Y 0 15 3 12 0 0 30
Lineage Total 7 367 31 109 0 2 516
Only “fixed” fluoroquinolone-resistance gyrAmutation events were enumerated here. Notably, no “fixed”mutations were observed in Lineage 5 (L5) strains. Lineage
1 = L1, Lineage 2 = L2, Lineage 3 = L3, Lineage 4 = L4, Lineage 6 = L6. Mtb lineage designations defined as in (Comas et al., 2010; Gagneux, 2018).
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